GPT-5.5
GPT-5.5 is OpenAI's newest frontier model for complex professional work, with strong performance in coding, reasoning, and tool-using workflows. It supports a 1,050,000 token context window, 128,000 max output tokens, configurable reasoning effort, image input, and a broad tool stack including web search, file search, code interpreter, hosted shell, apply patch, skills, MCP, tool search, and computer use.
structured-output
Fleet Telematics Bid Evaluation$0.134~44sReasoning
**Evaluating scheduling gaps**
I’m noticing that the schedule misses the mandatory date of November 15, and there’s only one facility available for 16 per day, even though the city has the capacity for 25 per day across two sites. The optional second crew isn’t priced in, which creates a significant material gap due to failing to meet the mandatory requirement. I wonder if this should be scored as a 1 or a 2 based on these criteria.{"vendor":"NorthStar Mobility Systems","procurement":"City of Redbrook hosted fleet telematics platform for 850 vehicles","executiveSummary":"NorthStar proposes RoadSight Cloud for all 850 vehicles and demonstrates several core functional capabilities, including 20-second moving-vehicle location updates, driver-safety alerts, maintenance alerts, reporting, role-based access, SAML 2.0, and a documented REST API. The three-year evaluated price is $1,126,400, which is $23,600 under the City's $1,150,000 not-to-exceed budget. However, the proposal fails multiple mandatory pass/fail requirements: the offered availability SLA is 99.5% rather than the required 99.9%; current cyber liability coverage is $2,000,000 rather than the required $5,000,000 at proposal submission; subcontractors with possible City-data access are not fully disclosed; and the baseline installation schedule completes after the required November 15, 2026 deadline. Under the RFP, material exceptions and missing mandatory evidence may not be cured after the proposal deadline. The recommended disposition is rejection as nonresponsive.","mandatoryGateReview":[{"requirementId":"M1","requirement":"Production data must be stored and processed exclusively in the United States.","status":"compliant","finding":"NorthStar states that the production application and primary database operate in AWS regions in Virginia and Oregon, encrypted backups remain in those regions, and production City data will not be transferred outside the United States.","evidenceCitations":["RFP 3.1 — Mandatory Compliance Gates, M1","Proposal C — Hosting and Security"],"materiality":"pass"},{"requirementId":"M2","requirement":"Vendor must provide a current SOC 2 Type II report covering the proposed production service.","status":"compliant","finding":"The proposal states Appendix D contains a SOC 2 Type II report for January 1 through December 31, 2025, issued February 20, 2026, covering RoadSight Cloud hosting, operations, access controls, and change management.","evidenceCitations":["RFP 3.1 — Mandatory Compliance Gates, M2","Proposal D — Assurance and Insurance"],"materiality":"pass"},{"requirementId":"M3","requirement":"Platform availability SLA must be at least 99.9% per calendar month.","status":"noncompliant","finding":"NorthStar offers a standard SLA guaranteeing 99.5% monthly availability, below the mandatory 99.9% monthly availability requirement.","evidenceCitations":["RFP 3.1 — Mandatory Compliance Gates, M3","Proposal G — Reliability and Support"],"materiality":"confirmed_rejection_basis"},{"requirementId":"M4","requirement":"Vendor must carry cyber liability insurance of at least $5,000,000 at proposal submission.","status":"noncompliant","finding":"NorthStar currently carries $2,000,000 in cyber liability coverage and states only that it can increase coverage to $5,000,000 before contract execution if selected. The RFP requires $5,000,000 at proposal submission.","evidenceCitations":["RFP 3.1 — Mandatory Compliance Gates, M4","Proposal D — Assurance and Insurance"],"materiality":"confirmed_rejection_basis"},{"requirementId":"M5","requirement":"Vendor must disclose all subcontractors that can access City data.","status":"noncompliant","finding":"NorthStar discloses AWS as hosting provider but also states that specialized support partners may occasionally assist with escalated cases. Those support partners are not named, and the proposal does not state whether their personnel can access City data. This is incomplete mandatory evidence for the subcontractor-access disclosure requirement.","evidenceCitations":["RFP 3.1 — Mandatory Compliance Gates, M5","Proposal E — Subcontractors"],"materiality":"confirmed_rejection_basis"},{"requirementId":"M6","requirement":"Installation of all 850 vehicles must be completed no later than November 15, 2026.","status":"noncompliant","finding":"NorthStar's baseline schedule installs all 850 vehicles by December 20, 2026, after the mandatory November 15, 2026 deadline. The second crew that might improve throughput is optional, subject to availability, and not included in the price proposal.","evidenceCitations":["RFP 3.1 — Mandatory Compliance Gates, M6","Proposal F — Implementation Plan","Proposal H — Pricing"],"materiality":"confirmed_rejection_basis"}],"criterionScores":[{"criterion":"Technical capability","weight":25,"score":4,"weightedPoints":20,"rationale":"The proposal substantially meets the stated functional requirements. NorthStar provides 20-second location reporting while vehicles are moving, live maps, geofences, speeding, harsh braking, idling alerts, mileage- and engine-hour-based maintenance alerts, CSV/PDF reports, role-based access, SAML 2.0, and a documented REST API. The main functional uncertainty is that standard online data retention is five years, while the City prefers seven years; older records can only be exported before expiration. API access also requires the Premium Integration Package, and custom development is excluded.","strengths":["20-second moving-vehicle location updates meet the 30-seconds-or-less requirement.","Includes configurable geofence, speeding, harsh braking, and idling alerts.","Includes mileage-based and engine-hour-based maintenance alerts.","Includes CSV/PDF reporting, role-based access, SAML 2.0, and documented REST API access."],"gaps":["Standard online historical data retention is five years, short of the City's preferred seven years.","REST API access is dependent on the Premium Integration Package, and custom development is excluded."],"evidenceCitations":["RFP 4.2 — Functional Requirements","Proposal A — Solution Overview","Proposal B — Integration"]},{"criterion":"Implementation plan","weight":20,"score":2,"weightedPoints":8,"rationale":"The proposal identifies staffing, dependencies, training activities, throughput, and a dated deployment plan, but the baseline plan is materially noncompliant with the required installation completion date. NorthStar proposes kickoff September 8, 2026, two technicians installing approximately 16 vehicles per weekday at one facility, and completion by December 20, 2026. The RFP states City fleet facilities can make 25 vehicles available per weekday across two sites beginning September 1, 2026, and mandatory completion is no later than November 15, 2026. The optional second crew is subject to availability and not priced.","strengths":["Provides a dated plan with kickoff and baseline completion date.","Identifies technician staffing, installation throughput, training sessions, and dependencies.","Includes administrator and driver-supervisor remote training."],"gaps":["Baseline completion date of December 20, 2026 misses the mandatory November 15, 2026 deadline.","Uses one City facility and 16 vehicles per weekday, despite the City's stated capacity of 25 vehicles per weekday across two sites.","Second installation crew is optional, subject to availability, and not included in the price proposal."],"evidenceCitations":["RFP 3.1 — Mandatory Compliance Gates, M6","RFP 4.3 — Implementation","Proposal F — Implementation Plan","Proposal H — Pricing"]},{"criterion":"Security and privacy","weight":20,"score":2,"weightedPoints":8,"rationale":"NorthStar provides evidence for U.S. hosting, encryption in transit and at rest, administrative MFA, access logging, vulnerability scanning, annual penetration testing, and a SOC 2 Type II report. However, material gaps remain: confirmed incident notification is within 48 hours rather than the required 24 hours; cyber liability insurance is only $2,000,000 at proposal submission; subcontractor governance and access disclosure are incomplete; and data deletion is limited to deletion within 90 days after termination upon written request rather than an unconditional contract-end process.","strengths":["Production application, database, and encrypted backups are stated to remain in AWS regions in Virginia and Oregon.","TLS 1.2 or later and AES-256 encryption are specified.","Administrative MFA and logging are specified.","Quarterly vulnerability scans and annual third-party penetration tests are specified.","SOC 2 Type II report is identified for RoadSight Cloud controls."],"gaps":["Incident notification is stated as without unreasonable delay and within 48 hours, not the required 24 hours for confirmed incidents affecting City data.","Cyber liability coverage at proposal submission is $2,000,000, below the mandatory $5,000,000.","Specialized support partners are not named, and their City-data access is not addressed.","Data deletion is described as occurring within 90 days after termination upon written request, leaving uncertainty against the RFP's data-deletion-at-contract-end requirement."],"evidenceCitations":["RFP 3.1 — Mandatory Compliance Gates, M1, M2, M4, M5","RFP 4.4 — Security and Privacy","Proposal C — Hosting and Security","Proposal D — Assurance and Insurance","Proposal E — Subcontractors"]},{"criterion":"Support and service levels","weight":15,"score":2,"weightedPoints":6,"rationale":"NorthStar meets several severity-one support requirements by offering North American 24/7 telephone support, a 30-minute target initial response, and an escalation path. However, its availability SLA is 99.5%, below the mandatory 99.9%, and service credits begin only below 99.5% with a 10% monthly subscription cap. This is a material gap in required service levels.","strengths":["Severity-one telephone support is staffed in the United States and Canada 24/7.","Severity-one initial response target is 30 minutes.","Escalation path is identified from support engineer to duty manager to vice president of operations."],"gaps":["Monthly availability SLA is 99.5%, below the required 99.9%.","Service credits begin only when monthly availability falls below 99.5%.","Service credits are capped at 10% of the affected month's subscription charge."],"evidenceCitations":["RFP 3.1 — Mandatory Compliance Gates, M3","RFP 4.5 — Support","Proposal G — Reliability and Support"]},{"criterion":"Three-year evaluated price","weight":20,"score":3,"weightedPoints":12,"rationale":"The disclosed three-year evaluated price is $1,126,400, which is below the $1,150,000 budget and includes implementation, hardware, baseline installation, subscription, cellular connectivity, standard support, required REST API access, and described remote training. However, the evaluated price is qualified because the baseline implementation schedule does not meet the mandatory installation deadline, and the optional second installation crew that may be needed to accelerate deployment is not priced.","strengths":["Evaluated price is $23,600 below the City's not-to-exceed budget.","Pricing includes the required Premium Integration Package for REST API access.","Training described in the implementation plan is included.","Taxes are excluded consistent with the RFP."],"gaps":["Optional second installation crew is not priced.","Baseline priced implementation completes after the mandatory installation deadline.","Pricing is firm for only 90 days; no longer price-validity commitment is evidenced in the excerpt."],"evidenceCitations":["RFP 2.1 — Contract and Budget","RFP 3.1 — Mandatory Compliance Gates, M6","Proposal F — Implementation Plan","Proposal H — Pricing"]}],"priceAnalysis":{"implementationCost":185000,"subscriptionCost":887400,"requiredApiCost":54000,"threeYearEvaluatedPrice":1126400,"budget":1150000,"budgetVariance":-23600,"methodology":"Implementation, hardware, and baseline installation: $185,000. Subscription: $29 per vehicle per month × 850 vehicles × 36 months = $887,400. Required REST API access through Premium Integration Package: $18,000 per year × 3 years = $54,000. Remote training is included; taxes are excluded. Three-year evaluated price = $185,000 + $887,400 + $54,000 = $1,126,400. Budget variance = $1,126,400 - $1,150,000 = -$23,600.","priceCompleteness":"qualified","pricingRisks":["The optional second installation crew is not priced, yet the baseline installation plan misses the mandatory completion deadline.","The evaluated price reflects a baseline implementation that is noncompliant with the required November 15, 2026 installation completion date.","Pricing is firm for 90 days only; the excerpt does not evidence pricing validity through award or contract execution."]},"totalWeightedScore":54,"materialRisks":[{"risk":"Proposal fails the mandatory 99.9% monthly availability SLA requirement by offering 99.5%.","severity":"critical","procurementImpact":"Confirmed mandatory gate failure and basis for rejection as nonresponsive under the RFP.","evidenceCitations":["RFP 3.1 — Mandatory Compliance Gates, MFinish reason:
lengthimport { createClient } from '@runware/sdk'
const client = await createClient({ apiKey: process.env.RUNWARE_API_KEY })
await client.connect()
const [result] = await client.run({
outputFormat: 'JSON',
model: 'openai:gpt@5.5',
settings: {
thinkingLevel: 'medium',
maxTokens: 4096
},
messages: [
{
role: 'user',
content: 'Act as the evaluation lead for a municipal technology procurement. Analyze the RFP requirements and vendor proposal excerpts below. Produce an evidence-based bid evaluation using the supplied JSON schema.\n\nApply these rules:\n- Evaluate only the information provided; do not assume unstated capabilities.\n- Treat a mandatory requirement as noncompliant when the proposal contradicts it or supplies no evidence.\n- Cite the relevant source section for every gate finding, criterion score, and material risk.\n- Use the scoring scale exactly: 5 = fully meets with clear evidence; 4 = substantially meets with minor uncertainty; 3 = partially meets; 2 = material gap; 1 = weak response; 0 = absent or directly noncompliant.\n- Calculate weighted points as weight multiplied by score divided by 5.\n- Calculate the three-year evaluated price from the disclosed quantities and charges. Show the arithmetic in the methodology field.\n- Distinguish confirmed facts from unresolved questions.\n- Mandatory conditions cannot be cured after the submission deadline unless the RFP expressly permits clarification.\n- Return JSON only.\n\nRFP EXCERPTS\n\n[RFP 1.2 — Scope]\nThe City of Redbrook seeks a hosted fleet telematics platform for 850 vehicles operated by Public Works, Water, Parks, and Building Inspection. Scope includes vehicle hardware, installation, cellular connectivity, live mapping, driver safety analytics, maintenance alerts, reporting, training, support, and an API for the City\'s asset-management system.\n\n[RFP 2.1 — Contract and Budget]\nThe evaluated term is 36 months. The City\'s not-to-exceed budget is $1,150,000 for implementation and all services required by this solicitation. Evaluated price must include hardware, installation, subscriptions, connectivity, required API access, training, and support. Taxes are excluded.\n\n[RFP 3.1 — Mandatory Compliance Gates]\nThe following requirements are mandatory and pass/fail. A bid that fails any item may be rejected as nonresponsive. Material exceptions and missing mandatory evidence may not be cured after the proposal deadline:\nM1. Production data must be stored and processed exclusively in the United States.\nM2. Vendor must provide a current SOC 2 Type II report covering the proposed production service.\nM3. Platform availability SLA must be at least 99.9% per calendar month.\nM4. Vendor must carry cyber liability insurance of at least $5,000,000 at proposal submission.\nM5. Vendor must disclose all subcontractors that can access City data.\nM6. Installation of all 850 vehicles must be completed no later than November 15, 2026.\n\n[RFP 4.2 — Functional Requirements]\nThe platform must provide vehicle locations at intervals of 30 seconds or less while vehicles are moving; configurable speeding, harsh braking, idling, and geofence alerts; preventive-maintenance schedules based on mileage and engine hours; downloadable reports; role-based access; SAML 2.0 single sign-on; and a documented REST API. The City prefers seven years of online historical data retention.\n\n[RFP 4.3 — Implementation]\nThe vendor must identify staffing, dependencies, installation throughput, training activities, and a dated deployment plan. City fleet facilities can make 25 vehicles available per weekday across two installation sites beginning September 1, 2026.\n\n[RFP 4.4 — Security and Privacy]\nThe response must address encryption in transit and at rest, privileged-access controls, security-event logging, incident notification, vulnerability management, annual penetration testing, data deletion at contract end, and subcontractor governance. Confirmed security incidents affecting City data must be reported within 24 hours.\n\n[RFP 4.5 — Support]\nThe City requires North American telephone support 24 hours a day, seven days a week for severity-one incidents. Severity-one incidents require a 30-minute response target. The proposal must identify escalation procedures and service-credit remedies.\n\n[RFP 5.1 — Evaluation Weights]\nTechnical capability: 25 points.\nImplementation plan: 20 points.\nSecurity and privacy: 20 points.\nSupport and service levels: 15 points.\nThree-year evaluated price: 20 points.\n\nVENDOR PROPOSAL EXCERPTS — NORTHSTAR MOBILITY SYSTEMS\n\n[Proposal A — Solution Overview]\nNorthStar proposes its RoadSight Cloud platform and NS-8 vehicle gateway for all 850 vehicles. Moving vehicles report location every 20 seconds. The platform includes live maps, geofences, speeding, harsh braking, excessive idling, mileage-based maintenance alerts, engine-hour maintenance alerts, CSV and PDF reports, and configurable role-based access. SAML 2.0 is included. Standard online data retention is five years; older records can be exported by the customer before expiration.\n\n[Proposal B — Integration]\nRoadSight offers a documented REST API. API access is provided through the Premium Integration Package. NorthStar expects the City to provide API credentials and technical documentation for its asset-management system. Up to 80 hours of remote integration consulting are included with the Premium Integration Package. Custom development is excluded.\n\n[Proposal C — Hosting and Security]\nThe production application and primary database operate in Amazon Web Services regions located in Virginia and Oregon. Encrypted backups remain in those regions. NorthStar states that production City data will not be transferred outside the United States. Data is encrypted using TLS 1.2 or later in transit and AES-256 at rest. Administrative access requires multifactor authentication and is logged. Quarterly vulnerability scans and annual third-party penetration tests are performed. NorthStar will notify the City of a confirmed incident without unreasonable delay and, in all cases, within 48 hours. Customer data is deleted within 90 days after contract termination upon written request.\n\n[Proposal D — Assurance and Insurance]\nAppendix D contains NorthStar\'s SOC 2 Type II report for the period January 1 through December 31, 2025, issued February 20, 2026, covering RoadSight Cloud hosting, operations, access controls, and change management. NorthStar currently carries $2,000,000 in cyber liability coverage and states that it can increase coverage to $5,000,000 before contract execution if selected.\n\n[Proposal E — Subcontractors]\nNorthStar identifies Amazon Web Services as its hosting provider. The proposal states that specialized support partners may occasionally assist with escalated cases under NorthStar supervision. No support partners are named, and the proposal does not state whether those personnel can access City data.\n\n[Proposal F — Implementation Plan]\nProject kickoff is proposed for September 8, 2026. Two NorthStar technicians would install approximately 16 vehicles per weekday at one City facility. A second two-person crew is listed as optional and subject to availability for an additional charge not included in the price proposal. The baseline schedule installs 850 vehicles by December 20, 2026. Administrator training consists of two remote four-hour sessions; driver-supervisor training consists of four remote two-hour sessions. Hardware shipment, vehicle rosters, and City facility access are listed as dependencies.\n\n[Proposal G — Reliability and Support]\nNorthStar\'s standard SLA guarantees 99.5% monthly availability. Severity-one telephone support is staffed in the United States and Canada 24/7, with a target initial response of 30 minutes. Escalations proceed from support engineer to duty manager to vice president of operations. Service credits begin when monthly availability falls below 99.5% and are capped at 10% of the affected month\'s subscription charge.\n\n[Proposal H — Pricing]\nOne-time implementation, hardware, and baseline installation: $185,000.\nRoadSight subscription, including cellular connectivity and standard support: $29 per vehicle per month for 850 vehicles over 36 months.\nPremium Integration Package required for REST API access: $18,000 per year.\nRemote training described in Proposal F: included.\nOptional second installation crew: not priced.\nTaxes: excluded.\nPricing is firm for 90 days.\n\nPrepare the final evaluation for the procurement record.'
}
],
jsonSchema: {
name: 'municipal_bid_evaluation',
strict: true,
schema: {
type: 'object',
properties: {
vendor: {
type: 'string'
},
procurement: {
type: 'string'
},
executiveSummary: {
type: 'string'
},
mandatoryGateReview: {
type: 'array',
items: {
type: 'object',
properties: {
requirementId: {
type: 'string'
},
requirement: {
type: 'string'
},
status: {
type: 'string',
enum: [
'compliant',
'noncompliant',
'not_evidenced'
]
},
finding: {
type: 'string'
},
evidenceCitations: {
type: 'array',
items: {
type: 'string'
}
},
materiality: {
type: 'string',
enum: [
'pass',
'potential_rejection_basis',
'confirmed_rejection_basis'
]
}
},
required: [
'requirementId',
'requirement',
'status',
'finding',
'evidenceCitations',
'materiality'
],
additionalProperties: false
}
},
criterionScores: {
type: 'array',
items: {
type: 'object',
properties: {
criterion: {
type: 'string'
},
weight: {
type: 'number'
},
score: {
type: 'integer',
minimum: 0,
maximum: 5
},
weightedPoints: {
type: 'number'
},
rationale: {
type: 'string'
},
strengths: {
type: 'array',
items: {
type: 'string'
}
},
gaps: {
type: 'array',
items: {
type: 'string'
}
},
evidenceCitations: {
type: 'array',
items: {
type: 'string'
}
}
},
required: [
'criterion',
'weight',
'score',
'weightedPoints',
'rationale',
'strengths',
'gaps',
'evidenceCitations'
],
additionalProperties: false
}
},
priceAnalysis: {
type: 'object',
properties: {
implementationCost: {
type: 'number'
},
subscriptionCost: {
type: 'number'
},
requiredApiCost: {
type: 'number'
},
threeYearEvaluatedPrice: {
type: 'number'
},
budget: {
type: 'number'
},
budgetVariance: {
type: 'number'
},
methodology: {
type: 'string'
},
priceCompleteness: {
type: 'string',
enum: [
'complete',
'qualified',
'incomplete'
]
},
pricingRisks: {
type: 'array',
items: {
type: 'string'
}
}
},
required: [
'implementationCost',
'subscriptionCost',
'requiredApiCost',
'threeYearEvaluatedPrice',
'budget',
'budgetVariance',
'methodology',
'priceCompleteness',
'pricingRisks'
],
additionalProperties: false
},
totalWeightedScore: {
type: 'number',
minimum: 0,
maximum: 100
},
materialRisks: {
type: 'array',
items: {
type: 'object',
properties: {
risk: {
type: 'string'
},
severity: {
type: 'string',
enum: [
'low',
'medium',
'high',
'critical'
]
},
procurementImpact: {
type: 'string'
},
evidenceCitations: {
type: 'array',
items: {
type: 'string'
}
}
},
required: [
'risk',
'severity',
'procurementImpact',
'evidenceCitations'
],
additionalProperties: false
}
},
clarificationQuestions: {
type: 'array',
items: {
type: 'object',
properties: {
question: {
type: 'string'
},
purpose: {
type: 'string'
},
curability: {
type: 'string',
enum: [
'clarification_only',
'potentially_curable_if_permitted',
'not_curable_after_deadline'
]
}
},
required: [
'question',
'purpose',
'curability'
],
additionalProperties: false
}
},
recommendation: {
type: 'object',
properties: {
disposition: {
type: 'string',
enum: [
'advance',
'advance_with_conditions',
'reject_as_nonresponsive'
]
},
rationale: {
type: 'string'
},
requiredProcurementAction: {
type: 'string'
}
},
required: [
'disposition',
'rationale',
'requiredProcurementAction'
],
additionalProperties: false
},
assumptionsAndLimitations: {
type: 'array',
items: {
type: 'string'
}
}
},
required: [
'vendor',
'procurement',
'executiveSummary',
'mandatoryGateReview',
'criterionScores',
'priceAnalysis',
'totalWeightedScore',
'materialRisks',
'clarificationQuestions',
'recommendation',
'assumptionsAndLimitations'
],
additionalProperties: false
},
type: 'object',
properties: {
summary: {
type: 'string'
},
keyPoints: {
type: 'array',
items: {
type: 'string'
}
},
confidence: {
type: 'number',
minimum: 0,
maximum: 1
}
},
required: [
'summary',
'keyPoints',
'confidence'
],
additionalProperties: false
}
})import asyncio
import os
from runware import Runware
async def main():
async with Runware(api_key=os.environ["RUNWARE_API_KEY"]) as client:
results = await client.run({
"outputFormat": "JSON",
"model": "openai:gpt@5.5",
"settings": {
"thinkingLevel": "medium",
"maxTokens": 4096
},
"messages": [
{
"role": "user",
"content": "Act as the evaluation lead for a municipal technology procurement. Analyze the RFP requirements and vendor proposal excerpts below. Produce an evidence-based bid evaluation using the supplied JSON schema.\n\nApply these rules:\n- Evaluate only the information provided; do not assume unstated capabilities.\n- Treat a mandatory requirement as noncompliant when the proposal contradicts it or supplies no evidence.\n- Cite the relevant source section for every gate finding, criterion score, and material risk.\n- Use the scoring scale exactly: 5 = fully meets with clear evidence; 4 = substantially meets with minor uncertainty; 3 = partially meets; 2 = material gap; 1 = weak response; 0 = absent or directly noncompliant.\n- Calculate weighted points as weight multiplied by score divided by 5.\n- Calculate the three-year evaluated price from the disclosed quantities and charges. Show the arithmetic in the methodology field.\n- Distinguish confirmed facts from unresolved questions.\n- Mandatory conditions cannot be cured after the submission deadline unless the RFP expressly permits clarification.\n- Return JSON only.\n\nRFP EXCERPTS\n\n[RFP 1.2 — Scope]\nThe City of Redbrook seeks a hosted fleet telematics platform for 850 vehicles operated by Public Works, Water, Parks, and Building Inspection. Scope includes vehicle hardware, installation, cellular connectivity, live mapping, driver safety analytics, maintenance alerts, reporting, training, support, and an API for the City's asset-management system.\n\n[RFP 2.1 — Contract and Budget]\nThe evaluated term is 36 months. The City's not-to-exceed budget is $1,150,000 for implementation and all services required by this solicitation. Evaluated price must include hardware, installation, subscriptions, connectivity, required API access, training, and support. Taxes are excluded.\n\n[RFP 3.1 — Mandatory Compliance Gates]\nThe following requirements are mandatory and pass/fail. A bid that fails any item may be rejected as nonresponsive. Material exceptions and missing mandatory evidence may not be cured after the proposal deadline:\nM1. Production data must be stored and processed exclusively in the United States.\nM2. Vendor must provide a current SOC 2 Type II report covering the proposed production service.\nM3. Platform availability SLA must be at least 99.9% per calendar month.\nM4. Vendor must carry cyber liability insurance of at least $5,000,000 at proposal submission.\nM5. Vendor must disclose all subcontractors that can access City data.\nM6. Installation of all 850 vehicles must be completed no later than November 15, 2026.\n\n[RFP 4.2 — Functional Requirements]\nThe platform must provide vehicle locations at intervals of 30 seconds or less while vehicles are moving; configurable speeding, harsh braking, idling, and geofence alerts; preventive-maintenance schedules based on mileage and engine hours; downloadable reports; role-based access; SAML 2.0 single sign-on; and a documented REST API. The City prefers seven years of online historical data retention.\n\n[RFP 4.3 — Implementation]\nThe vendor must identify staffing, dependencies, installation throughput, training activities, and a dated deployment plan. City fleet facilities can make 25 vehicles available per weekday across two installation sites beginning September 1, 2026.\n\n[RFP 4.4 — Security and Privacy]\nThe response must address encryption in transit and at rest, privileged-access controls, security-event logging, incident notification, vulnerability management, annual penetration testing, data deletion at contract end, and subcontractor governance. Confirmed security incidents affecting City data must be reported within 24 hours.\n\n[RFP 4.5 — Support]\nThe City requires North American telephone support 24 hours a day, seven days a week for severity-one incidents. Severity-one incidents require a 30-minute response target. The proposal must identify escalation procedures and service-credit remedies.\n\n[RFP 5.1 — Evaluation Weights]\nTechnical capability: 25 points.\nImplementation plan: 20 points.\nSecurity and privacy: 20 points.\nSupport and service levels: 15 points.\nThree-year evaluated price: 20 points.\n\nVENDOR PROPOSAL EXCERPTS — NORTHSTAR MOBILITY SYSTEMS\n\n[Proposal A — Solution Overview]\nNorthStar proposes its RoadSight Cloud platform and NS-8 vehicle gateway for all 850 vehicles. Moving vehicles report location every 20 seconds. The platform includes live maps, geofences, speeding, harsh braking, excessive idling, mileage-based maintenance alerts, engine-hour maintenance alerts, CSV and PDF reports, and configurable role-based access. SAML 2.0 is included. Standard online data retention is five years; older records can be exported by the customer before expiration.\n\n[Proposal B — Integration]\nRoadSight offers a documented REST API. API access is provided through the Premium Integration Package. NorthStar expects the City to provide API credentials and technical documentation for its asset-management system. Up to 80 hours of remote integration consulting are included with the Premium Integration Package. Custom development is excluded.\n\n[Proposal C — Hosting and Security]\nThe production application and primary database operate in Amazon Web Services regions located in Virginia and Oregon. Encrypted backups remain in those regions. NorthStar states that production City data will not be transferred outside the United States. Data is encrypted using TLS 1.2 or later in transit and AES-256 at rest. Administrative access requires multifactor authentication and is logged. Quarterly vulnerability scans and annual third-party penetration tests are performed. NorthStar will notify the City of a confirmed incident without unreasonable delay and, in all cases, within 48 hours. Customer data is deleted within 90 days after contract termination upon written request.\n\n[Proposal D — Assurance and Insurance]\nAppendix D contains NorthStar's SOC 2 Type II report for the period January 1 through December 31, 2025, issued February 20, 2026, covering RoadSight Cloud hosting, operations, access controls, and change management. NorthStar currently carries $2,000,000 in cyber liability coverage and states that it can increase coverage to $5,000,000 before contract execution if selected.\n\n[Proposal E — Subcontractors]\nNorthStar identifies Amazon Web Services as its hosting provider. The proposal states that specialized support partners may occasionally assist with escalated cases under NorthStar supervision. No support partners are named, and the proposal does not state whether those personnel can access City data.\n\n[Proposal F — Implementation Plan]\nProject kickoff is proposed for September 8, 2026. Two NorthStar technicians would install approximately 16 vehicles per weekday at one City facility. A second two-person crew is listed as optional and subject to availability for an additional charge not included in the price proposal. The baseline schedule installs 850 vehicles by December 20, 2026. Administrator training consists of two remote four-hour sessions; driver-supervisor training consists of four remote two-hour sessions. Hardware shipment, vehicle rosters, and City facility access are listed as dependencies.\n\n[Proposal G — Reliability and Support]\nNorthStar's standard SLA guarantees 99.5% monthly availability. Severity-one telephone support is staffed in the United States and Canada 24/7, with a target initial response of 30 minutes. Escalations proceed from support engineer to duty manager to vice president of operations. Service credits begin when monthly availability falls below 99.5% and are capped at 10% of the affected month's subscription charge.\n\n[Proposal H — Pricing]\nOne-time implementation, hardware, and baseline installation: $185,000.\nRoadSight subscription, including cellular connectivity and standard support: $29 per vehicle per month for 850 vehicles over 36 months.\nPremium Integration Package required for REST API access: $18,000 per year.\nRemote training described in Proposal F: included.\nOptional second installation crew: not priced.\nTaxes: excluded.\nPricing is firm for 90 days.\n\nPrepare the final evaluation for the procurement record."
}
],
"jsonSchema": {
"name": "municipal_bid_evaluation",
"strict": True,
"schema": {
"type": "object",
"properties": {
"vendor": {
"type": "string"
},
"procurement": {
"type": "string"
},
"executiveSummary": {
"type": "string"
},
"mandatoryGateReview": {
"type": "array",
"items": {
"type": "object",
"properties": {
"requirementId": {
"type": "string"
},
"requirement": {
"type": "string"
},
"status": {
"type": "string",
"enum": [
"compliant",
"noncompliant",
"not_evidenced"
]
},
"finding": {
"type": "string"
},
"evidenceCitations": {
"type": "array",
"items": {
"type": "string"
}
},
"materiality": {
"type": "string",
"enum": [
"pass",
"potential_rejection_basis",
"confirmed_rejection_basis"
]
}
},
"required": [
"requirementId",
"requirement",
"status",
"finding",
"evidenceCitations",
"materiality"
],
"additionalProperties": False
}
},
"criterionScores": {
"type": "array",
"items": {
"type": "object",
"properties": {
"criterion": {
"type": "string"
},
"weight": {
"type": "number"
},
"score": {
"type": "integer",
"minimum": 0,
"maximum": 5
},
"weightedPoints": {
"type": "number"
},
"rationale": {
"type": "string"
},
"strengths": {
"type": "array",
"items": {
"type": "string"
}
},
"gaps": {
"type": "array",
"items": {
"type": "string"
}
},
"evidenceCitations": {
"type": "array",
"items": {
"type": "string"
}
}
},
"required": [
"criterion",
"weight",
"score",
"weightedPoints",
"rationale",
"strengths",
"gaps",
"evidenceCitations"
],
"additionalProperties": False
}
},
"priceAnalysis": {
"type": "object",
"properties": {
"implementationCost": {
"type": "number"
},
"subscriptionCost": {
"type": "number"
},
"requiredApiCost": {
"type": "number"
},
"threeYearEvaluatedPrice": {
"type": "number"
},
"budget": {
"type": "number"
},
"budgetVariance": {
"type": "number"
},
"methodology": {
"type": "string"
},
"priceCompleteness": {
"type": "string",
"enum": [
"complete",
"qualified",
"incomplete"
]
},
"pricingRisks": {
"type": "array",
"items": {
"type": "string"
}
}
},
"required": [
"implementationCost",
"subscriptionCost",
"requiredApiCost",
"threeYearEvaluatedPrice",
"budget",
"budgetVariance",
"methodology",
"priceCompleteness",
"pricingRisks"
],
"additionalProperties": False
},
"totalWeightedScore": {
"type": "number",
"minimum": 0,
"maximum": 100
},
"materialRisks": {
"type": "array",
"items": {
"type": "object",
"properties": {
"risk": {
"type": "string"
},
"severity": {
"type": "string",
"enum": [
"low",
"medium",
"high",
"critical"
]
},
"procurementImpact": {
"type": "string"
},
"evidenceCitations": {
"type": "array",
"items": {
"type": "string"
}
}
},
"required": [
"risk",
"severity",
"procurementImpact",
"evidenceCitations"
],
"additionalProperties": False
}
},
"clarificationQuestions": {
"type": "array",
"items": {
"type": "object",
"properties": {
"question": {
"type": "string"
},
"purpose": {
"type": "string"
},
"curability": {
"type": "string",
"enum": [
"clarification_only",
"potentially_curable_if_permitted",
"not_curable_after_deadline"
]
}
},
"required": [
"question",
"purpose",
"curability"
],
"additionalProperties": False
}
},
"recommendation": {
"type": "object",
"properties": {
"disposition": {
"type": "string",
"enum": [
"advance",
"advance_with_conditions",
"reject_as_nonresponsive"
]
},
"rationale": {
"type": "string"
},
"requiredProcurementAction": {
"type": "string"
}
},
"required": [
"disposition",
"rationale",
"requiredProcurementAction"
],
"additionalProperties": False
},
"assumptionsAndLimitations": {
"type": "array",
"items": {
"type": "string"
}
}
},
"required": [
"vendor",
"procurement",
"executiveSummary",
"mandatoryGateReview",
"criterionScores",
"priceAnalysis",
"totalWeightedScore",
"materialRisks",
"clarificationQuestions",
"recommendation",
"assumptionsAndLimitations"
],
"additionalProperties": False
},
"type": "object",
"properties": {
"summary": {
"type": "string"
},
"keyPoints": {
"type": "array",
"items": {
"type": "string"
}
},
"confidence": {
"type": "number",
"minimum": 0,
"maximum": 1
}
},
"required": [
"summary",
"keyPoints",
"confidence"
],
"additionalProperties": False
}
})
asyncio.run(main())curl https://api.runware.ai/v1 \
-H "Authorization: Bearer $RUNWARE_API_KEY" \
-H "Content-Type: application/json" \
-d '[
{
"taskType": "textInference",
"taskUUID": "cc18fe96-2437-42ce-9c22-bd7d52bc580f",
"outputFormat": "JSON",
"model": "openai:gpt@5.5",
"settings": {
"thinkingLevel": "medium",
"maxTokens": 4096
},
"messages": [
{
"role": "user",
"content": "Act as the evaluation lead for a municipal technology procurement. Analyze the RFP requirements and vendor proposal excerpts below. Produce an evidence-based bid evaluation using the supplied JSON schema.\n\nApply these rules:\n- Evaluate only the information provided; do not assume unstated capabilities.\n- Treat a mandatory requirement as noncompliant when the proposal contradicts it or supplies no evidence.\n- Cite the relevant source section for every gate finding, criterion score, and material risk.\n- Use the scoring scale exactly: 5 = fully meets with clear evidence; 4 = substantially meets with minor uncertainty; 3 = partially meets; 2 = material gap; 1 = weak response; 0 = absent or directly noncompliant.\n- Calculate weighted points as weight multiplied by score divided by 5.\n- Calculate the three-year evaluated price from the disclosed quantities and charges. Show the arithmetic in the methodology field.\n- Distinguish confirmed facts from unresolved questions.\n- Mandatory conditions cannot be cured after the submission deadline unless the RFP expressly permits clarification.\n- Return JSON only.\n\nRFP EXCERPTS\n\n[RFP 1.2 — Scope]\nThe City of Redbrook seeks a hosted fleet telematics platform for 850 vehicles operated by Public Works, Water, Parks, and Building Inspection. Scope includes vehicle hardware, installation, cellular connectivity, live mapping, driver safety analytics, maintenance alerts, reporting, training, support, and an API for the City's asset-management system.\n\n[RFP 2.1 — Contract and Budget]\nThe evaluated term is 36 months. The City's not-to-exceed budget is $1,150,000 for implementation and all services required by this solicitation. Evaluated price must include hardware, installation, subscriptions, connectivity, required API access, training, and support. Taxes are excluded.\n\n[RFP 3.1 — Mandatory Compliance Gates]\nThe following requirements are mandatory and pass/fail. A bid that fails any item may be rejected as nonresponsive. Material exceptions and missing mandatory evidence may not be cured after the proposal deadline:\nM1. Production data must be stored and processed exclusively in the United States.\nM2. Vendor must provide a current SOC 2 Type II report covering the proposed production service.\nM3. Platform availability SLA must be at least 99.9% per calendar month.\nM4. Vendor must carry cyber liability insurance of at least $5,000,000 at proposal submission.\nM5. Vendor must disclose all subcontractors that can access City data.\nM6. Installation of all 850 vehicles must be completed no later than November 15, 2026.\n\n[RFP 4.2 — Functional Requirements]\nThe platform must provide vehicle locations at intervals of 30 seconds or less while vehicles are moving; configurable speeding, harsh braking, idling, and geofence alerts; preventive-maintenance schedules based on mileage and engine hours; downloadable reports; role-based access; SAML 2.0 single sign-on; and a documented REST API. The City prefers seven years of online historical data retention.\n\n[RFP 4.3 — Implementation]\nThe vendor must identify staffing, dependencies, installation throughput, training activities, and a dated deployment plan. City fleet facilities can make 25 vehicles available per weekday across two installation sites beginning September 1, 2026.\n\n[RFP 4.4 — Security and Privacy]\nThe response must address encryption in transit and at rest, privileged-access controls, security-event logging, incident notification, vulnerability management, annual penetration testing, data deletion at contract end, and subcontractor governance. Confirmed security incidents affecting City data must be reported within 24 hours.\n\n[RFP 4.5 — Support]\nThe City requires North American telephone support 24 hours a day, seven days a week for severity-one incidents. Severity-one incidents require a 30-minute response target. The proposal must identify escalation procedures and service-credit remedies.\n\n[RFP 5.1 — Evaluation Weights]\nTechnical capability: 25 points.\nImplementation plan: 20 points.\nSecurity and privacy: 20 points.\nSupport and service levels: 15 points.\nThree-year evaluated price: 20 points.\n\nVENDOR PROPOSAL EXCERPTS — NORTHSTAR MOBILITY SYSTEMS\n\n[Proposal A — Solution Overview]\nNorthStar proposes its RoadSight Cloud platform and NS-8 vehicle gateway for all 850 vehicles. Moving vehicles report location every 20 seconds. The platform includes live maps, geofences, speeding, harsh braking, excessive idling, mileage-based maintenance alerts, engine-hour maintenance alerts, CSV and PDF reports, and configurable role-based access. SAML 2.0 is included. Standard online data retention is five years; older records can be exported by the customer before expiration.\n\n[Proposal B — Integration]\nRoadSight offers a documented REST API. API access is provided through the Premium Integration Package. NorthStar expects the City to provide API credentials and technical documentation for its asset-management system. Up to 80 hours of remote integration consulting are included with the Premium Integration Package. Custom development is excluded.\n\n[Proposal C — Hosting and Security]\nThe production application and primary database operate in Amazon Web Services regions located in Virginia and Oregon. Encrypted backups remain in those regions. NorthStar states that production City data will not be transferred outside the United States. Data is encrypted using TLS 1.2 or later in transit and AES-256 at rest. Administrative access requires multifactor authentication and is logged. Quarterly vulnerability scans and annual third-party penetration tests are performed. NorthStar will notify the City of a confirmed incident without unreasonable delay and, in all cases, within 48 hours. Customer data is deleted within 90 days after contract termination upon written request.\n\n[Proposal D — Assurance and Insurance]\nAppendix D contains NorthStar's SOC 2 Type II report for the period January 1 through December 31, 2025, issued February 20, 2026, covering RoadSight Cloud hosting, operations, access controls, and change management. NorthStar currently carries $2,000,000 in cyber liability coverage and states that it can increase coverage to $5,000,000 before contract execution if selected.\n\n[Proposal E — Subcontractors]\nNorthStar identifies Amazon Web Services as its hosting provider. The proposal states that specialized support partners may occasionally assist with escalated cases under NorthStar supervision. No support partners are named, and the proposal does not state whether those personnel can access City data.\n\n[Proposal F — Implementation Plan]\nProject kickoff is proposed for September 8, 2026. Two NorthStar technicians would install approximately 16 vehicles per weekday at one City facility. A second two-person crew is listed as optional and subject to availability for an additional charge not included in the price proposal. The baseline schedule installs 850 vehicles by December 20, 2026. Administrator training consists of two remote four-hour sessions; driver-supervisor training consists of four remote two-hour sessions. Hardware shipment, vehicle rosters, and City facility access are listed as dependencies.\n\n[Proposal G — Reliability and Support]\nNorthStar's standard SLA guarantees 99.5% monthly availability. Severity-one telephone support is staffed in the United States and Canada 24/7, with a target initial response of 30 minutes. Escalations proceed from support engineer to duty manager to vice president of operations. Service credits begin when monthly availability falls below 99.5% and are capped at 10% of the affected month's subscription charge.\n\n[Proposal H — Pricing]\nOne-time implementation, hardware, and baseline installation: $185,000.\nRoadSight subscription, including cellular connectivity and standard support: $29 per vehicle per month for 850 vehicles over 36 months.\nPremium Integration Package required for REST API access: $18,000 per year.\nRemote training described in Proposal F: included.\nOptional second installation crew: not priced.\nTaxes: excluded.\nPricing is firm for 90 days.\n\nPrepare the final evaluation for the procurement record."
}
],
"jsonSchema": {
"name": "municipal_bid_evaluation",
"strict": true,
"schema": {
"type": "object",
"properties": {
"vendor": {
"type": "string"
},
"procurement": {
"type": "string"
},
"executiveSummary": {
"type": "string"
},
"mandatoryGateReview": {
"type": "array",
"items": {
"type": "object",
"properties": {
"requirementId": {
"type": "string"
},
"requirement": {
"type": "string"
},
"status": {
"type": "string",
"enum": [
"compliant",
"noncompliant",
"not_evidenced"
]
},
"finding": {
"type": "string"
},
"evidenceCitations": {
"type": "array",
"items": {
"type": "string"
}
},
"materiality": {
"type": "string",
"enum": [
"pass",
"potential_rejection_basis",
"confirmed_rejection_basis"
]
}
},
"required": [
"requirementId",
"requirement",
"status",
"finding",
"evidenceCitations",
"materiality"
],
"additionalProperties": false
}
},
"criterionScores": {
"type": "array",
"items": {
"type": "object",
"properties": {
"criterion": {
"type": "string"
},
"weight": {
"type": "number"
},
"score": {
"type": "integer",
"minimum": 0,
"maximum": 5
},
"weightedPoints": {
"type": "number"
},
"rationale": {
"type": "string"
},
"strengths": {
"type": "array",
"items": {
"type": "string"
}
},
"gaps": {
"type": "array",
"items": {
"type": "string"
}
},
"evidenceCitations": {
"type": "array",
"items": {
"type": "string"
}
}
},
"required": [
"criterion",
"weight",
"score",
"weightedPoints",
"rationale",
"strengths",
"gaps",
"evidenceCitations"
],
"additionalProperties": false
}
},
"priceAnalysis": {
"type": "object",
"properties": {
"implementationCost": {
"type": "number"
},
"subscriptionCost": {
"type": "number"
},
"requiredApiCost": {
"type": "number"
},
"threeYearEvaluatedPrice": {
"type": "number"
},
"budget": {
"type": "number"
},
"budgetVariance": {
"type": "number"
},
"methodology": {
"type": "string"
},
"priceCompleteness": {
"type": "string",
"enum": [
"complete",
"qualified",
"incomplete"
]
},
"pricingRisks": {
"type": "array",
"items": {
"type": "string"
}
}
},
"required": [
"implementationCost",
"subscriptionCost",
"requiredApiCost",
"threeYearEvaluatedPrice",
"budget",
"budgetVariance",
"methodology",
"priceCompleteness",
"pricingRisks"
],
"additionalProperties": false
},
"totalWeightedScore": {
"type": "number",
"minimum": 0,
"maximum": 100
},
"materialRisks": {
"type": "array",
"items": {
"type": "object",
"properties": {
"risk": {
"type": "string"
},
"severity": {
"type": "string",
"enum": [
"low",
"medium",
"high",
"critical"
]
},
"procurementImpact": {
"type": "string"
},
"evidenceCitations": {
"type": "array",
"items": {
"type": "string"
}
}
},
"required": [
"risk",
"severity",
"procurementImpact",
"evidenceCitations"
],
"additionalProperties": false
}
},
"clarificationQuestions": {
"type": "array",
"items": {
"type": "object",
"properties": {
"question": {
"type": "string"
},
"purpose": {
"type": "string"
},
"curability": {
"type": "string",
"enum": [
"clarification_only",
"potentially_curable_if_permitted",
"not_curable_after_deadline"
]
}
},
"required": [
"question",
"purpose",
"curability"
],
"additionalProperties": false
}
},
"recommendation": {
"type": "object",
"properties": {
"disposition": {
"type": "string",
"enum": [
"advance",
"advance_with_conditions",
"reject_as_nonresponsive"
]
},
"rationale": {
"type": "string"
},
"requiredProcurementAction": {
"type": "string"
}
},
"required": [
"disposition",
"rationale",
"requiredProcurementAction"
],
"additionalProperties": false
},
"assumptionsAndLimitations": {
"type": "array",
"items": {
"type": "string"
}
}
},
"required": [
"vendor",
"procurement",
"executiveSummary",
"mandatoryGateReview",
"criterionScores",
"priceAnalysis",
"totalWeightedScore",
"materialRisks",
"clarificationQuestions",
"recommendation",
"assumptionsAndLimitations"
],
"additionalProperties": false
},
"type": "object",
"properties": {
"summary": {
"type": "string"
},
"keyPoints": {
"type": "array",
"items": {
"type": "string"
}
},
"confidence": {
"type": "number",
"minimum": 0,
"maximum": 1
}
},
"required": [
"summary",
"keyPoints",
"confidence"
],
"additionalProperties": false
}
}
]'runware run openai:gpt@5.5 \
outputFormat=JSON \
settings.thinkingLevel=medium \
settings.maxTokens=4096 \
messages.0.role=user \
messages.0.content="Act as the evaluation lead for a municipal technology procurement. Analyze the RFP requirements and vendor proposal excerpts below. Produce an evidence-based bid evaluation using the supplied JSON schema.
Apply these rules:
- Evaluate only the information provided; do not assume unstated capabilities.
- Treat a mandatory requirement as noncompliant when the proposal contradicts it or supplies no evidence.
- Cite the relevant source section for every gate finding, criterion score, and material risk.
- Use the scoring scale exactly: 5 = fully meets with clear evidence; 4 = substantially meets with minor uncertainty; 3 = partially meets; 2 = material gap; 1 = weak response; 0 = absent or directly noncompliant.
- Calculate weighted points as weight multiplied by score divided by 5.
- Calculate the three-year evaluated price from the disclosed quantities and charges. Show the arithmetic in the methodology field.
- Distinguish confirmed facts from unresolved questions.
- Mandatory conditions cannot be cured after the submission deadline unless the RFP expressly permits clarification.
- Return JSON only.
RFP EXCERPTS
[RFP 1.2 — Scope]
The City of Redbrook seeks a hosted fleet telematics platform for 850 vehicles operated by Public Works, Water, Parks, and Building Inspection. Scope includes vehicle hardware, installation, cellular connectivity, live mapping, driver safety analytics, maintenance alerts, reporting, training, support, and an API for the City's asset-management system.
[RFP 2.1 — Contract and Budget]
The evaluated term is 36 months. The City's not-to-exceed budget is \$1,150,000 for implementation and all services required by this solicitation. Evaluated price must include hardware, installation, subscriptions, connectivity, required API access, training, and support. Taxes are excluded.
[RFP 3.1 — Mandatory Compliance Gates]
The following requirements are mandatory and pass/fail. A bid that fails any item may be rejected as nonresponsive. Material exceptions and missing mandatory evidence may not be cured after the proposal deadline:
M1. Production data must be stored and processed exclusively in the United States.
M2. Vendor must provide a current SOC 2 Type II report covering the proposed production service.
M3. Platform availability SLA must be at least 99.9% per calendar month.
M4. Vendor must carry cyber liability insurance of at least \$5,000,000 at proposal submission.
M5. Vendor must disclose all subcontractors that can access City data.
M6. Installation of all 850 vehicles must be completed no later than November 15, 2026.
[RFP 4.2 — Functional Requirements]
The platform must provide vehicle locations at intervals of 30 seconds or less while vehicles are moving; configurable speeding, harsh braking, idling, and geofence alerts; preventive-maintenance schedules based on mileage and engine hours; downloadable reports; role-based access; SAML 2.0 single sign-on; and a documented REST API. The City prefers seven years of online historical data retention.
[RFP 4.3 — Implementation]
The vendor must identify staffing, dependencies, installation throughput, training activities, and a dated deployment plan. City fleet facilities can make 25 vehicles available per weekday across two installation sites beginning September 1, 2026.
[RFP 4.4 — Security and Privacy]
The response must address encryption in transit and at rest, privileged-access controls, security-event logging, incident notification, vulnerability management, annual penetration testing, data deletion at contract end, and subcontractor governance. Confirmed security incidents affecting City data must be reported within 24 hours.
[RFP 4.5 — Support]
The City requires North American telephone support 24 hours a day, seven days a week for severity-one incidents. Severity-one incidents require a 30-minute response target. The proposal must identify escalation procedures and service-credit remedies.
[RFP 5.1 — Evaluation Weights]
Technical capability: 25 points.
Implementation plan: 20 points.
Security and privacy: 20 points.
Support and service levels: 15 points.
Three-year evaluated price: 20 points.
VENDOR PROPOSAL EXCERPTS — NORTHSTAR MOBILITY SYSTEMS
[Proposal A — Solution Overview]
NorthStar proposes its RoadSight Cloud platform and NS-8 vehicle gateway for all 850 vehicles. Moving vehicles report location every 20 seconds. The platform includes live maps, geofences, speeding, harsh braking, excessive idling, mileage-based maintenance alerts, engine-hour maintenance alerts, CSV and PDF reports, and configurable role-based access. SAML 2.0 is included. Standard online data retention is five years; older records can be exported by the customer before expiration.
[Proposal B — Integration]
RoadSight offers a documented REST API. API access is provided through the Premium Integration Package. NorthStar expects the City to provide API credentials and technical documentation for its asset-management system. Up to 80 hours of remote integration consulting are included with the Premium Integration Package. Custom development is excluded.
[Proposal C — Hosting and Security]
The production application and primary database operate in Amazon Web Services regions located in Virginia and Oregon. Encrypted backups remain in those regions. NorthStar states that production City data will not be transferred outside the United States. Data is encrypted using TLS 1.2 or later in transit and AES-256 at rest. Administrative access requires multifactor authentication and is logged. Quarterly vulnerability scans and annual third-party penetration tests are performed. NorthStar will notify the City of a confirmed incident without unreasonable delay and, in all cases, within 48 hours. Customer data is deleted within 90 days after contract termination upon written request.
[Proposal D — Assurance and Insurance]
Appendix D contains NorthStar's SOC 2 Type II report for the period January 1 through December 31, 2025, issued February 20, 2026, covering RoadSight Cloud hosting, operations, access controls, and change management. NorthStar currently carries \$2,000,000 in cyber liability coverage and states that it can increase coverage to \$5,000,000 before contract execution if selected.
[Proposal E — Subcontractors]
NorthStar identifies Amazon Web Services as its hosting provider. The proposal states that specialized support partners may occasionally assist with escalated cases under NorthStar supervision. No support partners are named, and the proposal does not state whether those personnel can access City data.
[Proposal F — Implementation Plan]
Project kickoff is proposed for September 8, 2026. Two NorthStar technicians would install approximately 16 vehicles per weekday at one City facility. A second two-person crew is listed as optional and subject to availability for an additional charge not included in the price proposal. The baseline schedule installs 850 vehicles by December 20, 2026. Administrator training consists of two remote four-hour sessions; driver-supervisor training consists of four remote two-hour sessions. Hardware shipment, vehicle rosters, and City facility access are listed as dependencies.
[Proposal G — Reliability and Support]
NorthStar's standard SLA guarantees 99.5% monthly availability. Severity-one telephone support is staffed in the United States and Canada 24/7, with a target initial response of 30 minutes. Escalations proceed from support engineer to duty manager to vice president of operations. Service credits begin when monthly availability falls below 99.5% and are capped at 10% of the affected month's subscription charge.
[Proposal H — Pricing]
One-time implementation, hardware, and baseline installation: \$185,000.
RoadSight subscription, including cellular connectivity and standard support: \$29 per vehicle per month for 850 vehicles over 36 months.
Premium Integration Package required for REST API access: \$18,000 per year.
Remote training described in Proposal F: included.
Optional second installation crew: not priced.
Taxes: excluded.
Pricing is firm for 90 days.
Prepare the final evaluation for the procurement record." \
jsonSchema.name=municipal_bid_evaluation \
jsonSchema.strict=true \
jsonSchema.schema.type=object \
jsonSchema.schema.properties.vendor.type=string \
jsonSchema.schema.properties.procurement.type=string \
jsonSchema.schema.properties.executiveSummary.type=string \
jsonSchema.schema.properties.mandatoryGateReview.type=array \
jsonSchema.schema.properties.mandatoryGateReview.items.type=object \
jsonSchema.schema.properties.mandatoryGateReview.items.properties.requirementId.type=string \
jsonSchema.schema.properties.mandatoryGateReview.items.properties.requirement.type=string \
jsonSchema.schema.properties.mandatoryGateReview.items.properties.status.type=string \
jsonSchema.schema.properties.mandatoryGateReview.items.properties.status.enum.0=compliant \
jsonSchema.schema.properties.mandatoryGateReview.items.properties.status.enum.1=noncompliant \
jsonSchema.schema.properties.mandatoryGateReview.items.properties.status.enum.2=not_evidenced \
jsonSchema.schema.properties.mandatoryGateReview.items.properties.finding.type=string \
jsonSchema.schema.properties.mandatoryGateReview.items.properties.evidenceCitations.type=array \
jsonSchema.schema.properties.mandatoryGateReview.items.properties.evidenceCitations.items.type=string \
jsonSchema.schema.properties.mandatoryGateReview.items.properties.materiality.type=string \
jsonSchema.schema.properties.mandatoryGateReview.items.properties.materiality.enum.0=pass \
jsonSchema.schema.properties.mandatoryGateReview.items.properties.materiality.enum.1=potential_rejection_basis \
jsonSchema.schema.properties.mandatoryGateReview.items.properties.materiality.enum.2=confirmed_rejection_basis \
jsonSchema.schema.properties.mandatoryGateReview.items.required.0=requirementId \
jsonSchema.schema.properties.mandatoryGateReview.items.required.1=requirement \
jsonSchema.schema.properties.mandatoryGateReview.items.required.2=status \
jsonSchema.schema.properties.mandatoryGateReview.items.required.3=finding \
jsonSchema.schema.properties.mandatoryGateReview.items.required.4=evidenceCitations \
jsonSchema.schema.properties.mandatoryGateReview.items.required.5=materiality \
jsonSchema.schema.properties.mandatoryGateReview.items.additionalProperties=false \
jsonSchema.schema.properties.criterionScores.type=array \
jsonSchema.schema.properties.criterionScores.items.type=object \
jsonSchema.schema.properties.criterionScores.items.properties.criterion.type=string \
jsonSchema.schema.properties.criterionScores.items.properties.weight.type=number \
jsonSchema.schema.properties.criterionScores.items.properties.score.type=integer \
jsonSchema.schema.properties.criterionScores.items.properties.score.minimum=0 \
jsonSchema.schema.properties.criterionScores.items.properties.score.maximum=5 \
jsonSchema.schema.properties.criterionScores.items.properties.weightedPoints.type=number \
jsonSchema.schema.properties.criterionScores.items.properties.rationale.type=string \
jsonSchema.schema.properties.criterionScores.items.properties.strengths.type=array \
jsonSchema.schema.properties.criterionScores.items.properties.strengths.items.type=string \
jsonSchema.schema.properties.criterionScores.items.properties.gaps.type=array \
jsonSchema.schema.properties.criterionScores.items.properties.gaps.items.type=string \
jsonSchema.schema.properties.criterionScores.items.properties.evidenceCitations.type=array \
jsonSchema.schema.properties.criterionScores.items.properties.evidenceCitations.items.type=string \
jsonSchema.schema.properties.criterionScores.items.required.0=criterion \
jsonSchema.schema.properties.criterionScores.items.required.1=weight \
jsonSchema.schema.properties.criterionScores.items.required.2=score \
jsonSchema.schema.properties.criterionScores.items.required.3=weightedPoints \
jsonSchema.schema.properties.criterionScores.items.required.4=rationale \
jsonSchema.schema.properties.criterionScores.items.required.5=strengths \
jsonSchema.schema.properties.criterionScores.items.required.6=gaps \
jsonSchema.schema.properties.criterionScores.items.required.7=evidenceCitations \
jsonSchema.schema.properties.criterionScores.items.additionalProperties=false \
jsonSchema.schema.properties.priceAnalysis.type=object \
jsonSchema.schema.properties.priceAnalysis.properties.implementationCost.type=number \
jsonSchema.schema.properties.priceAnalysis.properties.subscriptionCost.type=number \
jsonSchema.schema.properties.priceAnalysis.properties.requiredApiCost.type=number \
jsonSchema.schema.properties.priceAnalysis.properties.threeYearEvaluatedPrice.type=number \
jsonSchema.schema.properties.priceAnalysis.properties.budget.type=number \
jsonSchema.schema.properties.priceAnalysis.properties.budgetVariance.type=number \
jsonSchema.schema.properties.priceAnalysis.properties.methodology.type=string \
jsonSchema.schema.properties.priceAnalysis.properties.priceCompleteness.type=string \
jsonSchema.schema.properties.priceAnalysis.properties.priceCompleteness.enum.0=complete \
jsonSchema.schema.properties.priceAnalysis.properties.priceCompleteness.enum.1=qualified \
jsonSchema.schema.properties.priceAnalysis.properties.priceCompleteness.enum.2=incomplete \
jsonSchema.schema.properties.priceAnalysis.properties.pricingRisks.type=array \
jsonSchema.schema.properties.priceAnalysis.properties.pricingRisks.items.type=string \
jsonSchema.schema.properties.priceAnalysis.required.0=implementationCost \
jsonSchema.schema.properties.priceAnalysis.required.1=subscriptionCost \
jsonSchema.schema.properties.priceAnalysis.required.2=requiredApiCost \
jsonSchema.schema.properties.priceAnalysis.required.3=threeYearEvaluatedPrice \
jsonSchema.schema.properties.priceAnalysis.required.4=budget \
jsonSchema.schema.properties.priceAnalysis.required.5=budgetVariance \
jsonSchema.schema.properties.priceAnalysis.required.6=methodology \
jsonSchema.schema.properties.priceAnalysis.required.7=priceCompleteness \
jsonSchema.schema.properties.priceAnalysis.required.8=pricingRisks \
jsonSchema.schema.properties.priceAnalysis.additionalProperties=false \
jsonSchema.schema.properties.totalWeightedScore.type=number \
jsonSchema.schema.properties.totalWeightedScore.minimum=0 \
jsonSchema.schema.properties.totalWeightedScore.maximum=100 \
jsonSchema.schema.properties.materialRisks.type=array \
jsonSchema.schema.properties.materialRisks.items.type=object \
jsonSchema.schema.properties.materialRisks.items.properties.risk.type=string \
jsonSchema.schema.properties.materialRisks.items.properties.severity.type=string \
jsonSchema.schema.properties.materialRisks.items.properties.severity.enum.0=low \
jsonSchema.schema.properties.materialRisks.items.properties.severity.enum.1=medium \
jsonSchema.schema.properties.materialRisks.items.properties.severity.enum.2=high \
jsonSchema.schema.properties.materialRisks.items.properties.severity.enum.3=critical \
jsonSchema.schema.properties.materialRisks.items.properties.procurementImpact.type=string \
jsonSchema.schema.properties.materialRisks.items.properties.evidenceCitations.type=array \
jsonSchema.schema.properties.materialRisks.items.properties.evidenceCitations.items.type=string \
jsonSchema.schema.properties.materialRisks.items.required.0=risk \
jsonSchema.schema.properties.materialRisks.items.required.1=severity \
jsonSchema.schema.properties.materialRisks.items.required.2=procurementImpact \
jsonSchema.schema.properties.materialRisks.items.required.3=evidenceCitations \
jsonSchema.schema.properties.materialRisks.items.additionalProperties=false \
jsonSchema.schema.properties.clarificationQuestions.type=array \
jsonSchema.schema.properties.clarificationQuestions.items.type=object \
jsonSchema.schema.properties.clarificationQuestions.items.properties.question.type=string \
jsonSchema.schema.properties.clarificationQuestions.items.properties.purpose.type=string \
jsonSchema.schema.properties.clarificationQuestions.items.properties.curability.type=string \
jsonSchema.schema.properties.clarificationQuestions.items.properties.curability.enum.0=clarification_only \
jsonSchema.schema.properties.clarificationQuestions.items.properties.curability.enum.1=potentially_curable_if_permitted \
jsonSchema.schema.properties.clarificationQuestions.items.properties.curability.enum.2=not_curable_after_deadline \
jsonSchema.schema.properties.clarificationQuestions.items.required.0=question \
jsonSchema.schema.properties.clarificationQuestions.items.required.1=purpose \
jsonSchema.schema.properties.clarificationQuestions.items.required.2=curability \
jsonSchema.schema.properties.clarificationQuestions.items.additionalProperties=false \
jsonSchema.schema.properties.recommendation.type=object \
jsonSchema.schema.properties.recommendation.properties.disposition.type=string \
jsonSchema.schema.properties.recommendation.properties.disposition.enum.0=advance \
jsonSchema.schema.properties.recommendation.properties.disposition.enum.1=advance_with_conditions \
jsonSchema.schema.properties.recommendation.properties.disposition.enum.2=reject_as_nonresponsive \
jsonSchema.schema.properties.recommendation.properties.rationale.type=string \
jsonSchema.schema.properties.recommendation.properties.requiredProcurementAction.type=string \
jsonSchema.schema.properties.recommendation.required.0=disposition \
jsonSchema.schema.properties.recommendation.required.1=rationale \
jsonSchema.schema.properties.recommendation.required.2=requiredProcurementAction \
jsonSchema.schema.properties.recommendation.additionalProperties=false \
jsonSchema.schema.properties.assumptionsAndLimitations.type=array \
jsonSchema.schema.properties.assumptionsAndLimitations.items.type=string \
jsonSchema.schema.required.0=vendor \
jsonSchema.schema.required.1=procurement \
jsonSchema.schema.required.2=executiveSummary \
jsonSchema.schema.required.3=mandatoryGateReview \
jsonSchema.schema.required.4=criterionScores \
jsonSchema.schema.required.5=priceAnalysis \
jsonSchema.schema.required.6=totalWeightedScore \
jsonSchema.schema.required.7=materialRisks \
jsonSchema.schema.required.8=clarificationQuestions \
jsonSchema.schema.required.9=recommendation \
jsonSchema.schema.required.10=assumptionsAndLimitations \
jsonSchema.schema.additionalProperties=false \
jsonSchema.type=object \
jsonSchema.properties.summary.type=string \
jsonSchema.properties.keyPoints.type=array \
jsonSchema.properties.keyPoints.items.type=string \
jsonSchema.properties.confidence.type=number \
jsonSchema.properties.confidence.minimum=0 \
jsonSchema.properties.confidence.maximum=1 \
jsonSchema.required.0=summary \
jsonSchema.required.1=keyPoints \
jsonSchema.required.2=confidence \
jsonSchema.additionalProperties=false{
"taskType": "textInference",
"taskUUID": "cc18fe96-2437-42ce-9c22-bd7d52bc580f",
"outputFormat": "JSON",
"model": "openai:gpt@5.5",
"settings": {
"thinkingLevel": "medium",
"maxTokens": 4096
},
"messages": [
{
"role": "user",
"content": "Act as the evaluation lead for a municipal technology procurement. Analyze the RFP requirements and vendor proposal excerpts below. Produce an evidence-based bid evaluation using the supplied JSON schema.\n\nApply these rules:\n- Evaluate only the information provided; do not assume unstated capabilities.\n- Treat a mandatory requirement as noncompliant when the proposal contradicts it or supplies no evidence.\n- Cite the relevant source section for every gate finding, criterion score, and material risk.\n- Use the scoring scale exactly: 5 = fully meets with clear evidence; 4 = substantially meets with minor uncertainty; 3 = partially meets; 2 = material gap; 1 = weak response; 0 = absent or directly noncompliant.\n- Calculate weighted points as weight multiplied by score divided by 5.\n- Calculate the three-year evaluated price from the disclosed quantities and charges. Show the arithmetic in the methodology field.\n- Distinguish confirmed facts from unresolved questions.\n- Mandatory conditions cannot be cured after the submission deadline unless the RFP expressly permits clarification.\n- Return JSON only.\n\nRFP EXCERPTS\n\n[RFP 1.2 — Scope]\nThe City of Redbrook seeks a hosted fleet telematics platform for 850 vehicles operated by Public Works, Water, Parks, and Building Inspection. Scope includes vehicle hardware, installation, cellular connectivity, live mapping, driver safety analytics, maintenance alerts, reporting, training, support, and an API for the City's asset-management system.\n\n[RFP 2.1 — Contract and Budget]\nThe evaluated term is 36 months. The City's not-to-exceed budget is $1,150,000 for implementation and all services required by this solicitation. Evaluated price must include hardware, installation, subscriptions, connectivity, required API access, training, and support. Taxes are excluded.\n\n[RFP 3.1 — Mandatory Compliance Gates]\nThe following requirements are mandatory and pass/fail. A bid that fails any item may be rejected as nonresponsive. Material exceptions and missing mandatory evidence may not be cured after the proposal deadline:\nM1. Production data must be stored and processed exclusively in the United States.\nM2. Vendor must provide a current SOC 2 Type II report covering the proposed production service.\nM3. Platform availability SLA must be at least 99.9% per calendar month.\nM4. Vendor must carry cyber liability insurance of at least $5,000,000 at proposal submission.\nM5. Vendor must disclose all subcontractors that can access City data.\nM6. Installation of all 850 vehicles must be completed no later than November 15, 2026.\n\n[RFP 4.2 — Functional Requirements]\nThe platform must provide vehicle locations at intervals of 30 seconds or less while vehicles are moving; configurable speeding, harsh braking, idling, and geofence alerts; preventive-maintenance schedules based on mileage and engine hours; downloadable reports; role-based access; SAML 2.0 single sign-on; and a documented REST API. The City prefers seven years of online historical data retention.\n\n[RFP 4.3 — Implementation]\nThe vendor must identify staffing, dependencies, installation throughput, training activities, and a dated deployment plan. City fleet facilities can make 25 vehicles available per weekday across two installation sites beginning September 1, 2026.\n\n[RFP 4.4 — Security and Privacy]\nThe response must address encryption in transit and at rest, privileged-access controls, security-event logging, incident notification, vulnerability management, annual penetration testing, data deletion at contract end, and subcontractor governance. Confirmed security incidents affecting City data must be reported within 24 hours.\n\n[RFP 4.5 — Support]\nThe City requires North American telephone support 24 hours a day, seven days a week for severity-one incidents. Severity-one incidents require a 30-minute response target. The proposal must identify escalation procedures and service-credit remedies.\n\n[RFP 5.1 — Evaluation Weights]\nTechnical capability: 25 points.\nImplementation plan: 20 points.\nSecurity and privacy: 20 points.\nSupport and service levels: 15 points.\nThree-year evaluated price: 20 points.\n\nVENDOR PROPOSAL EXCERPTS — NORTHSTAR MOBILITY SYSTEMS\n\n[Proposal A — Solution Overview]\nNorthStar proposes its RoadSight Cloud platform and NS-8 vehicle gateway for all 850 vehicles. Moving vehicles report location every 20 seconds. The platform includes live maps, geofences, speeding, harsh braking, excessive idling, mileage-based maintenance alerts, engine-hour maintenance alerts, CSV and PDF reports, and configurable role-based access. SAML 2.0 is included. Standard online data retention is five years; older records can be exported by the customer before expiration.\n\n[Proposal B — Integration]\nRoadSight offers a documented REST API. API access is provided through the Premium Integration Package. NorthStar expects the City to provide API credentials and technical documentation for its asset-management system. Up to 80 hours of remote integration consulting are included with the Premium Integration Package. Custom development is excluded.\n\n[Proposal C — Hosting and Security]\nThe production application and primary database operate in Amazon Web Services regions located in Virginia and Oregon. Encrypted backups remain in those regions. NorthStar states that production City data will not be transferred outside the United States. Data is encrypted using TLS 1.2 or later in transit and AES-256 at rest. Administrative access requires multifactor authentication and is logged. Quarterly vulnerability scans and annual third-party penetration tests are performed. NorthStar will notify the City of a confirmed incident without unreasonable delay and, in all cases, within 48 hours. Customer data is deleted within 90 days after contract termination upon written request.\n\n[Proposal D — Assurance and Insurance]\nAppendix D contains NorthStar's SOC 2 Type II report for the period January 1 through December 31, 2025, issued February 20, 2026, covering RoadSight Cloud hosting, operations, access controls, and change management. NorthStar currently carries $2,000,000 in cyber liability coverage and states that it can increase coverage to $5,000,000 before contract execution if selected.\n\n[Proposal E — Subcontractors]\nNorthStar identifies Amazon Web Services as its hosting provider. The proposal states that specialized support partners may occasionally assist with escalated cases under NorthStar supervision. No support partners are named, and the proposal does not state whether those personnel can access City data.\n\n[Proposal F — Implementation Plan]\nProject kickoff is proposed for September 8, 2026. Two NorthStar technicians would install approximately 16 vehicles per weekday at one City facility. A second two-person crew is listed as optional and subject to availability for an additional charge not included in the price proposal. The baseline schedule installs 850 vehicles by December 20, 2026. Administrator training consists of two remote four-hour sessions; driver-supervisor training consists of four remote two-hour sessions. Hardware shipment, vehicle rosters, and City facility access are listed as dependencies.\n\n[Proposal G — Reliability and Support]\nNorthStar's standard SLA guarantees 99.5% monthly availability. Severity-one telephone support is staffed in the United States and Canada 24/7, with a target initial response of 30 minutes. Escalations proceed from support engineer to duty manager to vice president of operations. Service credits begin when monthly availability falls below 99.5% and are capped at 10% of the affected month's subscription charge.\n\n[Proposal H — Pricing]\nOne-time implementation, hardware, and baseline installation: $185,000.\nRoadSight subscription, including cellular connectivity and standard support: $29 per vehicle per month for 850 vehicles over 36 months.\nPremium Integration Package required for REST API access: $18,000 per year.\nRemote training described in Proposal F: included.\nOptional second installation crew: not priced.\nTaxes: excluded.\nPricing is firm for 90 days.\n\nPrepare the final evaluation for the procurement record."
}
],
"jsonSchema": {
"name": "municipal_bid_evaluation",
"strict": true,
"schema": {
"type": "object",
"properties": {
"vendor": {
"type": "string"
},
"procurement": {
"type": "string"
},
"executiveSummary": {
"type": "string"
},
"mandatoryGateReview": {
"type": "array",
"items": {
"type": "object",
"properties": {
"requirementId": {
"type": "string"
},
"requirement": {
"type": "string"
},
"status": {
"type": "string",
"enum": [
"compliant",
"noncompliant",
"not_evidenced"
]
},
"finding": {
"type": "string"
},
"evidenceCitations": {
"type": "array",
"items": {
"type": "string"
}
},
"materiality": {
"type": "string",
"enum": [
"pass",
"potential_rejection_basis",
"confirmed_rejection_basis"
]
}
},
"required": [
"requirementId",
"requirement",
"status",
"finding",
"evidenceCitations",
"materiality"
],
"additionalProperties": false
}
},
"criterionScores": {
"type": "array",
"items": {
"type": "object",
"properties": {
"criterion": {
"type": "string"
},
"weight": {
"type": "number"
},
"score": {
"type": "integer",
"minimum": 0,
"maximum": 5
},
"weightedPoints": {
"type": "number"
},
"rationale": {
"type": "string"
},
"strengths": {
"type": "array",
"items": {
"type": "string"
}
},
"gaps": {
"type": "array",
"items": {
"type": "string"
}
},
"evidenceCitations": {
"type": "array",
"items": {
"type": "string"
}
}
},
"required": [
"criterion",
"weight",
"score",
"weightedPoints",
"rationale",
"strengths",
"gaps",
"evidenceCitations"
],
"additionalProperties": false
}
},
"priceAnalysis": {
"type": "object",
"properties": {
"implementationCost": {
"type": "number"
},
"subscriptionCost": {
"type": "number"
},
"requiredApiCost": {
"type": "number"
},
"threeYearEvaluatedPrice": {
"type": "number"
},
"budget": {
"type": "number"
},
"budgetVariance": {
"type": "number"
},
"methodology": {
"type": "string"
},
"priceCompleteness": {
"type": "string",
"enum": [
"complete",
"qualified",
"incomplete"
]
},
"pricingRisks": {
"type": "array",
"items": {
"type": "string"
}
}
},
"required": [
"implementationCost",
"subscriptionCost",
"requiredApiCost",
"threeYearEvaluatedPrice",
"budget",
"budgetVariance",
"methodology",
"priceCompleteness",
"pricingRisks"
],
"additionalProperties": false
},
"totalWeightedScore": {
"type": "number",
"minimum": 0,
"maximum": 100
},
"materialRisks": {
"type": "array",
"items": {
"type": "object",
"properties": {
"risk": {
"type": "string"
},
"severity": {
"type": "string",
"enum": [
"low",
"medium",
"high",
"critical"
]
},
"procurementImpact": {
"type": "string"
},
"evidenceCitations": {
"type": "array",
"items": {
"type": "string"
}
}
},
"required": [
"risk",
"severity",
"procurementImpact",
"evidenceCitations"
],
"additionalProperties": false
}
},
"clarificationQuestions": {
"type": "array",
"items": {
"type": "object",
"properties": {
"question": {
"type": "string"
},
"purpose": {
"type": "string"
},
"curability": {
"type": "string",
"enum": [
"clarification_only",
"potentially_curable_if_permitted",
"not_curable_after_deadline"
]
}
},
"required": [
"question",
"purpose",
"curability"
],
"additionalProperties": false
}
},
"recommendation": {
"type": "object",
"properties": {
"disposition": {
"type": "string",
"enum": [
"advance",
"advance_with_conditions",
"reject_as_nonresponsive"
]
},
"rationale": {
"type": "string"
},
"requiredProcurementAction": {
"type": "string"
}
},
"required": [
"disposition",
"rationale",
"requiredProcurementAction"
],
"additionalProperties": false
},
"assumptionsAndLimitations": {
"type": "array",
"items": {
"type": "string"
}
}
},
"required": [
"vendor",
"procurement",
"executiveSummary",
"mandatoryGateReview",
"criterionScores",
"priceAnalysis",
"totalWeightedScore",
"materialRisks",
"clarificationQuestions",
"recommendation",
"assumptionsAndLimitations"
],
"additionalProperties": false
},
"type": "object",
"properties": {
"summary": {
"type": "string"
},
"keyPoints": {
"type": "array",
"items": {
"type": "string"
}
},
"confidence": {
"type": "number",
"minimum": 0,
"maximum": 1
}
},
"required": [
"summary",
"keyPoints",
"confidence"
],
"additionalProperties": false
}
}Response
{
"taskType": "textInference",
"taskUUID": "cc18fe96-2437-42ce-9c22-bd7d52bc580f",
"text": "{\"vendor\":\"NorthStar Mobility Systems\",\"procurement\":\"City of Redbrook hosted fleet telematics platform for 850 vehicles\",\"executiveSummary\":\"NorthStar proposes RoadSight Cloud for all 850 vehicles and demonstrates several core functional capabilities, including 20-second moving-vehicle location updates, driver-safety alerts, maintenance alerts, reporting, role-based access, SAML 2.0, and a documented REST API. The three-year evaluated price is $1,126,400, which is $23,600 under the City's $1,150,000 not-to-exceed budget. However, the proposal fails multiple mandatory pass/fail requirements: the offered availability SLA is 99.5% rather than the required 99.9%; current cyber liability coverage is $2,000,000 rather than the required $5,000,000 at proposal submission; subcontractors with possible City-data access are not fully disclosed; and the baseline installation schedule completes after the required November 15, 2026 deadline. Under the RFP, material exceptions and missing mandatory evidence may not be cured after the proposal deadline. The recommended disposition is rejection as nonresponsive.\",\"mandatoryGateReview\":[{\"requirementId\":\"M1\",\"requirement\":\"Production data must be stored and processed exclusively in the United States.\",\"status\":\"compliant\",\"finding\":\"NorthStar states that the production application and primary database operate in AWS regions in Virginia and Oregon, encrypted backups remain in those regions, and production City data will not be transferred outside the United States.\",\"evidenceCitations\":[\"RFP 3.1 — Mandatory Compliance Gates, M1\",\"Proposal C — Hosting and Security\"],\"materiality\":\"pass\"},{\"requirementId\":\"M2\",\"requirement\":\"Vendor must provide a current SOC 2 Type II report covering the proposed production service.\",\"status\":\"compliant\",\"finding\":\"The proposal states Appendix D contains a SOC 2 Type II report for January 1 through December 31, 2025, issued February 20, 2026, covering RoadSight Cloud hosting, operations, access controls, and change management.\",\"evidenceCitations\":[\"RFP 3.1 — Mandatory Compliance Gates, M2\",\"Proposal D — Assurance and Insurance\"],\"materiality\":\"pass\"},{\"requirementId\":\"M3\",\"requirement\":\"Platform availability SLA must be at least 99.9% per calendar month.\",\"status\":\"noncompliant\",\"finding\":\"NorthStar offers a standard SLA guaranteeing 99.5% monthly availability, below the mandatory 99.9% monthly availability requirement.\",\"evidenceCitations\":[\"RFP 3.1 — Mandatory Compliance Gates, M3\",\"Proposal G — Reliability and Support\"],\"materiality\":\"confirmed_rejection_basis\"},{\"requirementId\":\"M4\",\"requirement\":\"Vendor must carry cyber liability insurance of at least $5,000,000 at proposal submission.\",\"status\":\"noncompliant\",\"finding\":\"NorthStar currently carries $2,000,000 in cyber liability coverage and states only that it can increase coverage to $5,000,000 before contract execution if selected. The RFP requires $5,000,000 at proposal submission.\",\"evidenceCitations\":[\"RFP 3.1 — Mandatory Compliance Gates, M4\",\"Proposal D — Assurance and Insurance\"],\"materiality\":\"confirmed_rejection_basis\"},{\"requirementId\":\"M5\",\"requirement\":\"Vendor must disclose all subcontractors that can access City data.\",\"status\":\"noncompliant\",\"finding\":\"NorthStar discloses AWS as hosting provider but also states that specialized support partners may occasionally assist with escalated cases. Those support partners are not named, and the proposal does not state whether their personnel can access City data. This is incomplete mandatory evidence for the subcontractor-access disclosure requirement.\",\"evidenceCitations\":[\"RFP 3.1 — Mandatory Compliance Gates, M5\",\"Proposal E — Subcontractors\"],\"materiality\":\"confirmed_rejection_basis\"},{\"requirementId\":\"M6\",\"requirement\":\"Installation of all 850 vehicles must be completed no later than November 15, 2026.\",\"status\":\"noncompliant\",\"finding\":\"NorthStar's baseline schedule installs all 850 vehicles by December 20, 2026, after the mandatory November 15, 2026 deadline. The second crew that might improve throughput is optional, subject to availability, and not included in the price proposal.\",\"evidenceCitations\":[\"RFP 3.1 — Mandatory Compliance Gates, M6\",\"Proposal F — Implementation Plan\",\"Proposal H — Pricing\"],\"materiality\":\"confirmed_rejection_basis\"}],\"criterionScores\":[{\"criterion\":\"Technical capability\",\"weight\":25,\"score\":4,\"weightedPoints\":20,\"rationale\":\"The proposal substantially meets the stated functional requirements. NorthStar provides 20-second location reporting while vehicles are moving, live maps, geofences, speeding, harsh braking, idling alerts, mileage- and engine-hour-based maintenance alerts, CSV/PDF reports, role-based access, SAML 2.0, and a documented REST API. The main functional uncertainty is that standard online data retention is five years, while the City prefers seven years; older records can only be exported before expiration. API access also requires the Premium Integration Package, and custom development is excluded.\",\"strengths\":[\"20-second moving-vehicle location updates meet the 30-seconds-or-less requirement.\",\"Includes configurable geofence, speeding, harsh braking, and idling alerts.\",\"Includes mileage-based and engine-hour-based maintenance alerts.\",\"Includes CSV/PDF reporting, role-based access, SAML 2.0, and documented REST API access.\"],\"gaps\":[\"Standard online historical data retention is five years, short of the City's preferred seven years.\",\"REST API access is dependent on the Premium Integration Package, and custom development is excluded.\"],\"evidenceCitations\":[\"RFP 4.2 — Functional Requirements\",\"Proposal A — Solution Overview\",\"Proposal B — Integration\"]},{\"criterion\":\"Implementation plan\",\"weight\":20,\"score\":2,\"weightedPoints\":8,\"rationale\":\"The proposal identifies staffing, dependencies, training activities, throughput, and a dated deployment plan, but the baseline plan is materially noncompliant with the required installation completion date. NorthStar proposes kickoff September 8, 2026, two technicians installing approximately 16 vehicles per weekday at one facility, and completion by December 20, 2026. The RFP states City fleet facilities can make 25 vehicles available per weekday across two sites beginning September 1, 2026, and mandatory completion is no later than November 15, 2026. The optional second crew is subject to availability and not priced.\",\"strengths\":[\"Provides a dated plan with kickoff and baseline completion date.\",\"Identifies technician staffing, installation throughput, training sessions, and dependencies.\",\"Includes administrator and driver-supervisor remote training.\"],\"gaps\":[\"Baseline completion date of December 20, 2026 misses the mandatory November 15, 2026 deadline.\",\"Uses one City facility and 16 vehicles per weekday, despite the City's stated capacity of 25 vehicles per weekday across two sites.\",\"Second installation crew is optional, subject to availability, and not included in the price proposal.\"],\"evidenceCitations\":[\"RFP 3.1 — Mandatory Compliance Gates, M6\",\"RFP 4.3 — Implementation\",\"Proposal F — Implementation Plan\",\"Proposal H — Pricing\"]},{\"criterion\":\"Security and privacy\",\"weight\":20,\"score\":2,\"weightedPoints\":8,\"rationale\":\"NorthStar provides evidence for U.S. hosting, encryption in transit and at rest, administrative MFA, access logging, vulnerability scanning, annual penetration testing, and a SOC 2 Type II report. However, material gaps remain: confirmed incident notification is within 48 hours rather than the required 24 hours; cyber liability insurance is only $2,000,000 at proposal submission; subcontractor governance and access disclosure are incomplete; and data deletion is limited to deletion within 90 days after termination upon written request rather than an unconditional contract-end process.\",\"strengths\":[\"Production application, database, and encrypted backups are stated to remain in AWS regions in Virginia and Oregon.\",\"TLS 1.2 or later and AES-256 encryption are specified.\",\"Administrative MFA and logging are specified.\",\"Quarterly vulnerability scans and annual third-party penetration tests are specified.\",\"SOC 2 Type II report is identified for RoadSight Cloud controls.\"],\"gaps\":[\"Incident notification is stated as without unreasonable delay and within 48 hours, not the required 24 hours for confirmed incidents affecting City data.\",\"Cyber liability coverage at proposal submission is $2,000,000, below the mandatory $5,000,000.\",\"Specialized support partners are not named, and their City-data access is not addressed.\",\"Data deletion is described as occurring within 90 days after termination upon written request, leaving uncertainty against the RFP's data-deletion-at-contract-end requirement.\"],\"evidenceCitations\":[\"RFP 3.1 — Mandatory Compliance Gates, M1, M2, M4, M5\",\"RFP 4.4 — Security and Privacy\",\"Proposal C — Hosting and Security\",\"Proposal D — Assurance and Insurance\",\"Proposal E — Subcontractors\"]},{\"criterion\":\"Support and service levels\",\"weight\":15,\"score\":2,\"weightedPoints\":6,\"rationale\":\"NorthStar meets several severity-one support requirements by offering North American 24/7 telephone support, a 30-minute target initial response, and an escalation path. However, its availability SLA is 99.5%, below the mandatory 99.9%, and service credits begin only below 99.5% with a 10% monthly subscription cap. This is a material gap in required service levels.\",\"strengths\":[\"Severity-one telephone support is staffed in the United States and Canada 24/7.\",\"Severity-one initial response target is 30 minutes.\",\"Escalation path is identified from support engineer to duty manager to vice president of operations.\"],\"gaps\":[\"Monthly availability SLA is 99.5%, below the required 99.9%.\",\"Service credits begin only when monthly availability falls below 99.5%.\",\"Service credits are capped at 10% of the affected month's subscription charge.\"],\"evidenceCitations\":[\"RFP 3.1 — Mandatory Compliance Gates, M3\",\"RFP 4.5 — Support\",\"Proposal G — Reliability and Support\"]},{\"criterion\":\"Three-year evaluated price\",\"weight\":20,\"score\":3,\"weightedPoints\":12,\"rationale\":\"The disclosed three-year evaluated price is $1,126,400, which is below the $1,150,000 budget and includes implementation, hardware, baseline installation, subscription, cellular connectivity, standard support, required REST API access, and described remote training. However, the evaluated price is qualified because the baseline implementation schedule does not meet the mandatory installation deadline, and the optional second installation crew that may be needed to accelerate deployment is not priced.\",\"strengths\":[\"Evaluated price is $23,600 below the City's not-to-exceed budget.\",\"Pricing includes the required Premium Integration Package for REST API access.\",\"Training described in the implementation plan is included.\",\"Taxes are excluded consistent with the RFP.\"],\"gaps\":[\"Optional second installation crew is not priced.\",\"Baseline priced implementation completes after the mandatory installation deadline.\",\"Pricing is firm for only 90 days; no longer price-validity commitment is evidenced in the excerpt.\"],\"evidenceCitations\":[\"RFP 2.1 — Contract and Budget\",\"RFP 3.1 — Mandatory Compliance Gates, M6\",\"Proposal F — Implementation Plan\",\"Proposal H — Pricing\"]}],\"priceAnalysis\":{\"implementationCost\":185000,\"subscriptionCost\":887400,\"requiredApiCost\":54000,\"threeYearEvaluatedPrice\":1126400,\"budget\":1150000,\"budgetVariance\":-23600,\"methodology\":\"Implementation, hardware, and baseline installation: $185,000. Subscription: $29 per vehicle per month × 850 vehicles × 36 months = $887,400. Required REST API access through Premium Integration Package: $18,000 per year × 3 years = $54,000. Remote training is included; taxes are excluded. Three-year evaluated price = $185,000 + $887,400 + $54,000 = $1,126,400. Budget variance = $1,126,400 - $1,150,000 = -$23,600.\",\"priceCompleteness\":\"qualified\",\"pricingRisks\":[\"The optional second installation crew is not priced, yet the baseline installation plan misses the mandatory completion deadline.\",\"The evaluated price reflects a baseline implementation that is noncompliant with the required November 15, 2026 installation completion date.\",\"Pricing is firm for 90 days only; the excerpt does not evidence pricing validity through award or contract execution.\"]},\"totalWeightedScore\":54,\"materialRisks\":[{\"risk\":\"Proposal fails the mandatory 99.9% monthly availability SLA requirement by offering 99.5%.\",\"severity\":\"critical\",\"procurementImpact\":\"Confirmed mandatory gate failure and basis for rejection as nonresponsive under the RFP.\",\"evidenceCitations\":[\"RFP 3.1 — Mandatory Compliance Gates, M",
"cost": 0.13368,
"finishReason": "length",
"reasoningContent": [
"**Evaluating scheduling gaps**\n\nI’m noticing that the schedule misses the mandatory date of November 15, and there’s only one facility available for 16 per day, even though the city has the capacity for 25 per day across two sites. The optional second crew isn’t priced in, which creates a significant material gap due to failing to meet the mandatory requirement. I wonder if this should be scored as a 1 or a 2 based on these criteria."
]
}text-generation
Biotech Licensing Decision Memo$0.808~5m 35sReasoning
**Calculating cash flows**
I need to create a board memo with calculations regarding cash flows. The valuation date is September 30, 2026, and I need to discount annual cash flows at year-end. If signing occurs at that valuation date, it seems like there's likely no discount. Should I consider payments in 2027 discounted to year-end 2027? It looks like I should discount annual cash flows as if received at each year-end. I'll also determine milestones for each year, starting with the signing cash at date zero.
**Calculating screening analysis**
I need to assess the screening at the end of each calendar year, possibly using t=1 for 2027. Since the valuation date is September 30, 2026, I should consider fractional years. I need to show discount factors while remembering to ignore time value within milestone years. For Q1 and Q4 2027, I’ll use year-end 2027. Signing is at t=0, and the 2028 Q4 milestone would approximately be 2.25 years. I’ll also calculate probabilities sequentially—advancing to filing at 35%, filing to approval at 80%, and commercial launch success at 95%.
**Applying sales probabilities**
I need to calculate the probability of approval at 28% and the sales milestones or royalties at 26.6%. Now, I'm wondering if I should apply scenario weights based on the likelihood of the launch. It seems important to use the cumulative launch probability along with the scenario weights. This could help me estimate the most likely sales scenarios if the launch goes ahead. I want to ensure I’m accurately reflecting these conditions in my calculations.
**Calculating discount factors**
I need to calculate royalties using a 12% annual discount rate. The formula uses the discount factor (DF) that I need to compute for each year, starting from September 30. For year-end cash flows, I note that the factors for 2027 to 2038 will be about 1.25 to 12.25, respectively. I’ve calculated DFs for each year, from 2026 to 2038, using the formula DF = 1/(1.12^t). I want to ensure I have these values accurate.
**Considering milestone adjustments**
I see that if the alternative year index changes values by 2.9%, I should mention that. I also need to adjust the headlines to the nearest 0.1. So, it’s time to compute this. For Milestones Offer A, I have a signing value of 42.0, which is immediate. I’ll make sure to keep everything accurate and clear as I finalize these calculations and considerations. It’s important to get these details right!
**Evaluating Offers and Cash Flow**
I’m thinking about the cash proceeds from the offers. For example, Offer B has an estimated rPV that’s $1.2M higher than Offer A when looking at licenses alone. But, including financing, B is $21.2M higher. However, I need to consider the dilution costs associated with the equity in Offer B. Offer A is non-dilutive with upfront cash differing significantly. By Q1 2027, B may showcase greater overall cash, but I have to think about the burn rate and runway.
**Evaluating strategic decisions**
I’m considering the final authority of NordVale if execution is strong, while Asterion might not hold up if their infrastructure is weaker than the protections. I need to weigh the preferred economic outcome against the preferred risk-adjusted strategic outcome. The values are B cash plus rPV at 130.2 versus A at 109.0. B seems to offer more near-term cash and better contractual protection, making it a likely choice for the strategic outcome. But I’m pondering if pure non-dilutive license economics could be preferred.
**Weighing options for economic outcomes**
I’m looking at A’s $42 non-dilutive upfront payment and supply. The “preferred economic outcome” might lean towards B when considering equity. If the difference for a "license-only" option is minimal, A could be better due to its non-dilutive upfront and manufacturing benefits. My recommendation is to pursue Offer B as the preferred risk-adjusted strategic outcome but negotiate for three must-haves. If improvements aren’t made, I’d sign with B unless Asterion’s execution is insufficient. Economic-wise, B is superior by about $21.2 million rPV and provides more certain cash. In terms of strategic advantages, B offers better control and lower manufacturing burdens.
**Formulating negotiation strategies**
I’m proposing to focus on Offer B as my recommendation, while also keeping A as a fallback option. I need to identify three must-have changes, along with three that are negotiable, and a walk-away option. Since I'm advocating for B, I should direct the mandate towards Asterion, using A as my Best Alternative To a Negotiated Agreement (BATNA).
For the must-haves, I’m considering converting equity into a non-dilutive upfront payment or placing limits on ownership and ensuring no voting rights or standstill agreements. I wonder if this could be packaged as a change.
**Analyzing commercial PV components**
I'm evaluating commercial PV components and looking at sales milestones and royalties. For Company A, total revenue from sales milestones and royalties seems to be around 25.1 at the launch price. Meanwhile, Company B shows a bit lower at 26.5. When considering total pre-commercial values, A comes in at 109.0 and B at around 130.227. I'm wondering how the differences between them might impact sales, especially with A potentially benefiting from higher sales in the supply tier.
**Evaluating sales sensitivity**
I’m looking into how sensitivity to sales affects economic values. If equity has no value, sales scenarios could change outcomes significantly. I want to quantify sales sensitivity variations, maybe at ±20%, and see how that might affect projected values.
I need to calculate sales projections based on different scenarios, including upside and downside. This also involves considering milestone timings and royalties. So, I’ll be comparing these metrics to ensure it's credible and relevant. I’ll dive into those calculations now.
**Calculating sales milestones**
I have total sales milestones at 4.156. Now, I need to create a formula for the royalties plus supply conditional. For scenarios where sales are below 100, the total royalty is 19%. If sales reach 100, I can maintain that total.
Looking at higher sales, for 120 and 128, I'll use the formula: royalty of 15 + 0.18(S-100) + supply 4S. It simplifies to 0.22S - 3. For sales at 120, the total is 23.4, and for 128, it’s 25.16.
**Analyzing royalty advantages**
I'm considering the royalty advantages and how they play out under different sales scenarios. For sales above 150, I'm calculating cash flows as A = 0.25S - 7.5 and B = 0.19S, which gives a difference of A - B = 0.06S - 7.5. This shows a positive difference when sales exceed 125. Between 100 and 150, the difference is A - B = 0.03S - 3, remaining positive above 100. I'm curious how this affects sales milestones.
**Analyzing project success probabilities**
I'm considering the probability of success in Phase 2, estimating it at around 35%. It's important to compare milestones for A and B, where B has larger milestones but may have lower probabilities. I notice that cash flow is significant for B, and without equity, A shows a better outcome. If the P filing is low, breakeven analysis becomes crucial. How do I ensure the right assumptions in this analysis?
**Calculating milestone valuations**
I'm working on milestone valuation tables for a project with various scenarios concerning signing probabilities and financial projections. I’ll summarize expected payments and their present values (PV) based on different scenarios, like "down," "base," and "up." I’m focusing on expected sales milestones and calculating PVs accordingly, aiming for clarity. It seems that I can derive total outcome values while considering weights and probabilities—like the 0.266 multiplier—across different years for more accurate assessments.
**Condensing royalties table**
I'm considering a way to condense the royalties table, focusing on expected or conditional launch figures. I want to set up columns for each year, including base sales, weighted cash for scenarios A and B before the launch, along with discount factors (DF). Additionally, I’ll calculate the risk-adjusted present values (PV) for both A and B. This organization should help in analyzing potential outcomes more clearly and efficiently while retaining important details about revenue projections.
**Evaluating Offer B**
I'm thinking about "Offer B equity investment at a 25% premium." I should treat it as financing proceeds, where existing shareholders issue fewer shares than at the volume-weighted average price (VWAP). The premium might provide some economic benefit compared to the market value. However, it’s essential to note that there's no economic value above cash, which raises concerns about potential dilution for the shareholders. It seems like a complex situation to navigate!# Decision memo: HX-217 Europe/UK licensing offers
**To:** Board of Directors, Helixor Therapeutics
**As of:** 30 September 2026
**Currency:** USD millions unless noted
**Prepared as:** Screening corporate-development analysis; not legal, tax, accounting, or investment advice.
---
## 1. Executive recommendation
**Recommendation:** Proceed to negotiate with **Asterion Oncology / Offer B** as the preferred transaction, subject to confirmatory diligence and targeted improvements. Do not sign until the equity terms are clean, Asterion’s development/manufacturing execution capability is validated, and enforceable diligence/reversion protections are documented.
**Preferred economic outcome:**
- On a company cash-proceeds rPV basis, **Offer B is superior: $130.2M vs. $109.0M for Offer A**, primarily because of the $20M equity investment and larger near-term and regulatory milestones.
- **Excluding the $20M equity proceeds**, Offer B’s license-only rPV is **$110.2M**, effectively tied with Offer A’s **$109.0M**. Therefore, the economic superiority of Offer B depends materially on treating the equity proceeds as useful financing cash, while recognizing dilution.
**Preferred risk-adjusted strategic outcome:**
- **Offer B is also strategically preferable** because it provides stronger Helixor consent rights over material development/regulatory changes, a specified development plan and $22M minimum spend commitment through EMA filing, better pre-approval sublicensing control, and avoids Helixor’s European manufacturing burden.
- Offer A’s 4% supply margin is valuable, but modest in PV terms and comes with CMC, quality, capacity, and working-capital obligations. Offer A’s weaker diligence covenant and unrestricted sublicensing are meaningful strategic negatives.
**Financing conclusion:** Both offers fund the $18M pivotal-readiness workstream and materially reduce financing risk before Q4 2028. Offer B provides more certain pre-readout cash by Q1 2027: **$73M nominal vs. $60M under Offer A**, though $20M of Offer B is dilutive equity rather than license consideration.
---
## 2. Decision snapshot
| Metric | Offer A: NordVale | Offer B: Asterion | Comment |
|---|---:|---:|---|
| Signing cash | $42M | $28M license cash + $20M equity | B has more total cash, but only $28M is non-dilutive license cash |
| Certain cash by Q1 2027 | $60M | $73M | Includes first-patient milestone; B includes equity |
| rPV including all instructed proceeds | **$109.0M** | **$130.2M** | B higher by $21.2M |
| License-only rPV, excluding B equity | $109.0M | **$110.2M** | Essentially tied; B higher by $1.2M |
| Commercial rPV component | $25.1M | $26.5M | Similar; B sales milestones offset A supply margin/tiered upside |
| Royalty / supply economics | Tiered 15% / 18% / 21% + 4% supply margin | Flat 19%; no supply margin | A has higher upside economics above $100M sales |
| Governance | NordVale final EU authority after consultation | Helixor consent for material TPP, endpoints, regulatory strategy | B better preserves asset integrity |
| Diligence | CRE only; no minimum spend | Annual plans + $22M minimum spend through EMA filing | B materially stronger |
| Manufacturing | Helixor retains; 4% margin | Asterion controls; no Helixor margin | A adds value but operational burden |
| Sublicensing | No consent; 15% of non-royalty consideration | Pre-approval consent; 25% of non-royalty consideration | B better |
| Recommendation | Fallback / leverage | **Preferred** | Subject to diligence and must-have changes |
---
## 3. Valuation methodology and results
### Core probability calculations
Management’s probabilities are treated as sequential:
| Event | Calculation | Cumulative probability |
|---|---:|---:|
| Advance from current stage to filing | Given | **35.0%** |
| Approval | 35% × 80% | **28.0%** |
| Successful commercial launch | 35% × 80% × 95% | **26.6%** |
**Judgment on probability mapping:**
- First-patient-dosed milestones are treated as **certain if the deal signs**, per instruction.
- Positive Phase 2 top-line milestones are mapped to the **35% probability of advancing to filing**, per instruction, even though positive top-line and actual filing are not identical events.
- EMA filing milestones use **35%** cumulative filing probability.
- Approval milestones use **28%** cumulative approval probability.
- Sales milestones, royalties, and Offer A supply margin use **26.6%** cumulative launch probability, with downside/base/upside sales scenarios weighted **25% / 50% / 25% conditional on launch**.
### Discounting assumptions
- Valuation date: **30 September 2026**.
- Discount rate: **12% annually**.
- Signing cash is treated as immediate.
- Annual cash flows and milestones are discounted as if received at calendar year-end.
- Time value within milestone years is ignored; therefore Q1 2027 and Q4 2027 items would receive the same year-end treatment if applicable. This is conservative for the Q1 2027 first-patient milestones and approximately neutral for Q4 events.
### Headline rPV results
| Component | Offer A rPV | Offer B rPV including equity | Offer B license-only rPV excluding equity |
|---|---:|---:|---:|
| Signing / equity / certain first-patient cash | $57.6 | $69.7 | $49.7 |
| Positive Phase 2 top-line milestone | $9.5 | $12.2 | $12.2 |
| EMA filing milestone | $7.3 | $9.7 | $9.7 |
| First approval milestone | $9.5 | $12.1 | $12.1 |
| Sales milestones | $7.0 | $9.3 | $9.3 |
| Royalties and supply margin | $18.2 | $17.2 | $17.2 |
| **Total rPV** | **$109.0** | **$130.2** | **$110.2** |
**Interpretation:**
- Offer B is clearly superior on total company cash proceeds because of the $20M equity investment.
- On license-only economics, the offers are essentially equivalent. Offer B is only $1.2M ahead, which is within normal screening-model noise.
- Therefore, the board should not view Offer B as economically superior unless the equity proceeds are strategically useful and the dilution/ownership terms are acceptable.
---
## 4. Financing and runway
### Current cash position
| Item | Amount |
|---|---:|
| Cash at 30 September 2026 | $68M |
| Current burn | $8.5M per quarter |
| Existing runway at current burn | Through Q3 2028 |
| Additional pivotal-readiness workstream | $18M during 2027–2028 |
| No-deal funding gap through Q3 2028 including workstream | Approximately $18M |
Helixor’s stated cash runway funds existing operations through Q3 2028 but **does not fund the additional $18M pivotal-readiness workstream**. Without a transaction or financing, Helixor would need to defer the workstream, reduce spend, or raise capital before the Phase 2 top-line readout.
### Nominal cash available before Q4 2028, excluding contingent positive-data milestones
| Item | Offer A | Offer B |
|---|---:|---:|
| Current cash | $68M | $68M |
| Signing cash / equity proceeds | $42M | $48M |
| First-patient milestone, Q1 2027 | $18M | $25M |
| **Total resources before Q4 2028 positive-data milestone** | **$128M** | **$141M** |
| Baseline burn through Q3 2028, 8 quarters | $(68M)$ | $(68M)$ |
| Additional workstream | $(18M)$ | $(18M)$ |
| **Estimated cushion through Q3 2028** | **$42M** | **$55M** |
If Helixor also must fund Q4 2028 before receiving any positive-data milestone, the additional burn is approximately $8.5M, leaving estimated cushions of **$33.5M under Offer A** and **$46.5M under Offer B**, before transaction costs or unplanned spend.
### Financing conclusion
Both offers appear to fund the $18M workstream and materially reduce financing risk before Q4 2028. Offer B provides the larger cushion, but part of that cushion is dilutive equity.
**Important limitation:** This assumes the $18M workstream remains a Helixor obligation funded from transaction proceeds. If the final license requires the European partner to assume some or all of this workstream, runway improves. Conversely, if the workstream is U.S./global and expands beyond $18M, runway shortens.
---
## 5. Strategic and contractual assessment
### Control and governance
**Offer A — NordVale**
- Equal JDC, but NordVale has final authority for Europe after consultation.
- This is customary for a regional license but leaves Helixor exposed to decisions that could affect global development strategy, regulatory positioning, label, publications, and future U.S./ROW value.
- Lack of Helixor consent over material TPP, endpoint, or regulatory changes is a concern.
**Offer B — Asterion**
- Equal JDC plus Helixor consent rights for material changes to target product profile, trial endpoints, or regulatory strategy, not to be unreasonably withheld.
- This better protects asset integrity and global optionality.
- The board should ensure “material changes” is defined tightly enough to avoid disputes.
**Advantage:** Offer B.
### Diligence protection
**Offer A**
- Commercially reasonable efforts only; no minimum development-spend commitment.
- This creates deprioritization risk, especially if NordVale’s portfolio priorities shift.
**Offer B**
- Annual development plans and $22M aggregate minimum development-spend commitment through EMA filing.
- Stronger protection, though Helixor should negotiate remedies for missed spend or timeline slippage.
**Advantage:** Offer B.
### Manufacturing economics and operational burden
**Offer A**
- Helixor retains manufacturing rights and expects a 4% supply margin on European net sales.
- PV of the 4% supply margin is approximately **$3.6M** in this screen.
- However, Helixor retains operational obligations: CMC management, GMP compliance, batch release, quality systems, capacity planning, potential working capital, and supply failure risk.
**Offer B**
- Asterion controls manufacturing.
- Helixor loses supply margin but avoids European manufacturing operational burden.
- Must ensure tech-transfer, quality, audit, supply continuity, and step-in protections do not impair Helixor’s U.S./ROW rights.
**Economic advantage:** Offer A.
**Risk-adjusted operational advantage:** Offer B, unless Helixor has a strategic reason to retain EU manufacturing.
### Sublicensing
**Offer A**
- NordVale may sublicense without Helixor consent.
- Helixor receives 15% of non-royalty sublicense consideration.
- This is weak; NordVale could shift execution to a sublicensee without meaningful Helixor control.
**Offer B**
- Asterion needs Helixor consent to sublicense before approval, not to be unreasonably withheld.
- Helixor receives 25% of non-royalty sublicense consideration.
- Better economics and better pre-approval control.
**Advantage:** Offer B.
### Equity investment implications
Offer B’s $20M equity investment is useful financing cash but should not be treated as license consideration. Key implications:
- It dilutes existing shareholders, though the 25% premium reduces dilution relative to issuing at VWAP.
- Per-share impact depends on Helixor’s share count, VWAP, and final investment documents.
- Equity ownership may create information, voting, standstill, lock-up, registration-rights, MNPI, and future M&A signaling issues.
- If the equity investor receives governance rights, vetoes, board observation, or restrictive covenants, the strategic cost could outweigh some financing benefit.
**Board view:** Acceptable only if “clean” equity: no board seat or observer, no restrictive vetoes, appropriate standstill/lock-up, customary registration rights only, and no rights that impair future financing or M&A.
### Counterparty execution risk
No facts were provided on either counterparty’s balance sheet, EMA track record, cholangiocarcinoma or rare oncology commercial capabilities, CMC infrastructure, or portfolio priorities. Therefore, the analysis treats execution risk as unproven for both.
**Judgment:** Offer B has better contractual protections on paper. That does not substitute for diligence confirming Asterion can execute.
---
## 6. Sensitivities and reversal conditions
### Quantified sensitivity 1: clinical probability to filing
Holding filing-to-approval at 80% and approval-to-launch at 95%, varying the cumulative probability of filing:
| Cumulative probability of filing | Offer A rPV | Offer B rPV incl. equity | Offer B license-only rPV excl. equity |
|---:|---:|---:|---:|
| 25% | $94.3 | $112.9 | $92.9 |
| 35% base | $109.0 | $130.2 | $110.2 |
| 45% | $123.7 | $147.5 | $127.5 |
**Implication:** Including equity, Offer B remains ahead. Excluding equity, Offer A becomes economically better if the filing probability falls below approximately **30%**.
### Quantified sensitivity 2: discount rate
| Discount rate | Offer A rPV | Offer B rPV incl. equity | Offer B license-only rPV excl. equity |
|---:|---:|---:|---:|
| 10% | $115.1 | $137.0 | $117.0 |
| 12% base | $109.0 | $130.2 | $110.2 |
| 15% | $101.4 | $121.6 | $101.6 |
**Implication:** The total-proceeds preference for Offer B is robust. License-only economics remain essentially tied, especially at higher discount rates.
### Quantified sensitivity 3: sales scale
Assuming all downside/base/upside sales are shifted by the same percentage:
| Sales case | Offer A rPV | Offer B rPV incl. equity | Offer B license-only rPV excl. equity |
|---|---:|---:|---:|
| 20% lower sales | $102.2 | $125.1 | $105.1 |
| Base sales | $109.0 | $130.2 | $110.2 |
| 20% higher sales | $114.5 | $137.6 | $117.6 |
**Implication:** Offer B remains ahead in these ranges. At very high sales levels, Offer A’s all-in marginal economics above $150M — 21% royalty plus 4% supply margin, or 25% total — could outperform Offer B’s 19% flat royalty on a license-only basis. However, the current forecast does not create that result.
### Five assumptions most capable of reversing the recommendation
1. **Value and acceptability of Offer B equity.** If the board excludes the $20M equity proceeds or views the equity as strategically costly, Offer B’s economic advantage largely disappears.
2. **Asterion execution capability.** If diligence shows Asterion lacks EMA, oncology, launch, or manufacturing capability, Offer B’s contractual protections may not compensate.
3. **Clinical probability.** If probability of reaching filing is materially below 35%, Offer A’s larger non-dilutive upfront becomes more attractive on a license-only basis.
4. **Manufacturing burden and margin realization.** Offer A includes approximately $3.6M PV from the 4% supply margin. If required capex, CMC staffing, working capital, or quality risk consumes that margin, Offer A’s value declines. Conversely, if Helixor highly values manufacturing control, Offer A improves strategically.
5. **Sales upside / threshold timing.** Major upside above forecast could favor Offer A’s tiered royalty plus supply margin. Conversely, if sales underperform or fail to cross strict thresholds, both offers lose commercial value, but Offer B’s larger near-term milestones and equity become more important.
---
## 7. Negotiation mandate
### Three must-have changes / conditions
1. **Clean equity package for Offer B.**
The $20M equity investment must have no board seat or observer, no unusual veto rights, no anti-dilution beyond customary securities terms, no MFN on future financings, appropriate standstill and lock-up provisions, and registration rights that do not impair future financings.
2. **Enforceable diligence and reversion protections.**
Preserve Asterion’s $22M minimum development-spend commitment, add quarterly reporting, define eligible spend, require catch-up for missed spend, and include meaningful remedies for material failure: cure rights, step-in rights, or reversion/termination for uncured deprioritization.
3. **Global asset-protection covenants.**
Helixor must retain access to EU clinical, regulatory, safety, and CMC data for U.S./ROW use. Asterion’s manufacturing control must be subject to tech-transfer, quality, audit, supply continuity, and step-in protections. Helixor’s consent rights over material TPP, endpoints, and regulatory strategy must not be diluted through affiliates or sublicenses.
### Three tradable points
1. **Milestone mix versus upfront certainty.**
Helixor can trade a portion of later sales milestones for more upfront or earlier non-contingent cash, especially if it improves runway and reduces equity reliance.
2. **Post-approval sublicensing flexibility.**
Helixor can allow broader post-approval sublicensing if Asterion remains liable for sublicensee performance and Helixor retains economics and audit rights.
3. **Routine commercialization control.**
Helixor can accept Asterion final say over routine EU pricing, reimbursement sequencing, medical affairs, and commercialization tactics, provided material label, TPP, regulatory, and safety matters remain protected.
### Walk-away position
Helixor should not accept a final deal that has any of the following:
- Less than approximately **$60M of certain pre-readout cash** without a credible alternative financing plan.
- No enforceable development-spend or timeline remedy.
- Loss of Helixor consent over material TPP, trial endpoint, or regulatory-strategy changes.
- Equity terms that create governance overhang, block future financings, or impair M&A optionality.
- Counterparty diligence showing inadequate financial capacity, EMA execution ability, manufacturing infrastructure, or commitment to HX-217.
If Asterion cannot meet these conditions, Helixor should use Offer B as leverage to improve Offer A, specifically seeking NordVale minimum development-spend commitments, pre-approval sublicense consent, and Helixor consent rights over material regulatory changes. If neither party improves, Helixor should consider a short, targeted process extension or bridge financing rather than locking HX-217 into a weak regional deal.
---
## 8. Key diligence questions
### Counterparty execution
1. What is each counterparty’s recent EMA oncology approval track record, especially in rare tumors or biomarker-defined indications?
2. Does either party have cholangiocarcinoma, IDH-mutant, hepatobiliary, or rare oncology launch experience in Europe/UK?
3. What internal budget approval has been obtained for HX-217, including post-Phase 2 readiness and EMA filing activities?
4. How will each party staff regulatory, clinical operations, pharmacovigilance, market access, and medical affairs?
### Development and regulatory plan
5. What is the proposed EMA pathway for a 120-patient single-arm Phase 2 data package?
6. What endpoints, response durability assumptions, follow-up duration, and comparator context are expected to support filing?
7. What are the specific annual development plans and decision gates through Q4 2028 and Q4 2029?
8. What happens if Phase 2 response rate is positive but durability, safety, or subgroup data are mixed?
### Manufacturing / CMC
9. Under Offer A, what capex, staffing, quality, and working-capital commitments would Helixor need to support EU supply?
10. Under Offer B, what tech-transfer obligations, CMC data rights, supply continuity obligations, and step-in rights will Helixor have?
11. Will either structure interfere with Helixor’s U.S./ROW manufacturing, regulatory filings, or supply chain?
### Equity and financing
12. What percentage ownership would Asterion receive from the $20M equity investment?
13. What are the standstill, lock-up, voting, registration, information, and anti-dilution terms?
14. Would Asterion’s equity stake deter other partners, investors, or acquirers?
### Commercial assumptions
15. What pricing, reimbursement timing, country launch sequence, and patient-population assumptions support the $45M–$160M base sales forecast?
16. What competitive threats could affect second-line IDH1-mutant cholangiocarcinoma by 2031–2038?
17. How are strict sales milestone thresholds calculated, audited, and treated in partial launch years?
### Sublicensing and termination
18. How is non-royalty sublicense consideration allocated if a broader asset package is sublicensed?
19. Are affiliate sublicenses treated differently from third-party sublicenses?
20. What are the consequences of termination for convenience, patent challenge, safety failure, or deprioritization?
---
## 9. Appendix of calculations
### A. Discount factors used
Annual discount rate: 12%. Signing treated as immediate.
| Year-end | Discount factor |
|---:|---:|
| 2027 | 0.8679 |
| 2028 | 0.7749 |
| 2029 | 0.6919 |
| 2030 | 0.6178 |
| 2031 | 0.5516 |
| 2032 | 0.4925 |
| 2033 | 0.4397 |
| 2034 | 0.3926 |
| 2035 | 0.3505 |
| 2036 | 0.3130 |
| 2037 | 0.2795 |
| 2038 | 0.2495 |
Minor rounding differences may occur.
---
### B. Development and regulatory milestone PV
#### Offer A
| Payment | Nominal | Year | Probability | DF | rPV |
|---|---:|---:|---:|---:|---:|
| Signing | $42 | 2026 | 100% | 1.0000 | $42.0 |
| First Phase 2 patient dosed | $18 | 2027 | 100% | 0.8679 | $15.6 |
| Positive Phase 2 top-line | $35 | 2028 | 35% | 0.7749 | $9.5 |
| EMA filing | $30 | 2029 | 35% | 0.6919 | $7.3 |
| First European approval | $55 | 2030 | 28% | 0.6178 | $9.5 |
| **Subtotal** | | | | | **$83.9** |
#### Offer B
| Payment | Nominal | Year | Probability | DF | rPV |
|---|---:|---:|---:|---:|---:|
| Signing cash | $28 | 2026 | 100% | 1.0000 | $28.0 |
| Equity proceeds | $20 | 2026 | 100% | 1.0000 | $20.0 |
| First Phase 2 patient dosed | $25 | 2027 | 100% | 0.8679 | $21.7 |
| Positive Phase 2 top-line | $45 | 2028 | 35% | 0.7749 | $12.2 |
| EMA filing | $40 | 2029 | 35% | 0.6919 | $9.7 |
| First European approval | $70 | 2030 | 28% | 0.6178 | $12.1 |
| **Subtotal including equity** | | | | | **$103.7** |
| **Subtotal excluding equity** | | | | | **$83.7** |
---
### C. Sales milestone timing by scenario
Sales thresholds are earned only when annual net sales are **strictly greater than** the threshold.
#### Offer A
| Milestone | Downside timing | Base timing | Upside timing | rPV |
|---|---:|---:|---:|---:|
| $35M when sales first exceed $100M | Never | 2033 | 2032 | $3.2 |
| $50M when sales first exceed $150M | Never | 2035 | 2033 | $3.8 |
| **Total** | | | | **$7.0** |
#### Offer B
| Milestone | Downside timing | Base timing | Upside timing | rPV |
|---|---:|---:|---:|---:|
| $30M when sales first exceed $75M | 2034 | 2032 | 2032 | $3.7 |
| $45M when sales first exceed $125M | Never | 2034 | 2033 | $3.7 |
| $65M when sales first exceed $175M | Never | Never | 2033 | $1.9 |
| **Total** | | | | **$9.3** |
---
### D. Royalty and supply calculations
#### Offer A royalty formula
For annual sales **S**:
- 15% on sales up to and including $100M.
- 18% on the portion above $100M up to and including $150M.
- 21% on the portion above $150M.
- Plus 4% supply margin on net sales.
Examples:
- At $125M sales: royalty = 15% × $100M + 18% × $25M = $19.5M; supply margin = 4% × $125M = $5.0M; total = $24.5M.
- At $160M sales: royalty = $15.0M + $9.0M + 21% × $10M = $26.1M; supply margin = $6.4M; total = $32.5M.
#### Royalty / supply rPV by year
Amounts below are scenario-weighted conditional cash flows assuming launch, then risk-adjusted by 26.6% launch probability.
| Year | Base sales | Offer A scenario-weighted royalty + supply before launch probability | Offer B scenario-weighted royalty before launch probability | Offer A risk-adjusted PV | Offer B risk-adjusted PV |
|---:|---:|---:|---:|---:|---:|
| 2031 | $45 | $8.6 | $8.6 | $1.3 | $1.3 |
| 2032 | $85 | $16.3 | $16.2 | $2.1 | $2.1 |
| 2033 | $125 | $25.0 | $23.8 | $2.9 | $2.8 |
| 2034 | $150 | $30.6 | $28.5 | $3.2 | $3.0 |
| 2035 | $160 | $33.1 | $30.4 | $3.1 | $2.8 |
| 2036 | $150 | $30.6 | $28.5 | $2.6 | $2.4 |
| 2037 | $125 | $25.0 | $23.8 | $1.9 | $1.8 |
| 2038 | $90 | $17.3 | $17.1 | $1.2 | $1.1 |
| **Total rPV** | | | | **$18.2** | **$17.2** |
---
### E. Limitations of this screening analysis
This analysis intentionally simplifies several material items:
1. **Taxes ignored.** After-tax value may be materially lower, and withholding taxes could differ by jurisdiction and structure.
2. **Foreign exchange ignored.** European/UK revenues would likely be earned in EUR/GBP, while valuation is in USD.
3. **COGS and operating costs ignored.** Offer A’s 4% supply margin is treated as net margin, but real manufacturing may require capex, working capital, QA/QC, and supply-chain investment.
4. **Time value within milestone years ignored.** Q1 2027 payments are conservatively discounted to year-end; Q4 payments are roughly aligned.
5. **No country-by-country reimbursement delay modeled.** Sales are treated as annual year-end cash flows, not phased by pricing and reimbursement timing.
6. **No probability assigned to sublicensing proceeds.** Sublicense economics are assessed qualitatively because no sublicense probability or consideration forecast was provided.
7. **No dilution or per-share valuation model.** Offer B’s equity is included as $20M cash proceeds only; per-share impact depends on VWAP, shares issued, and final securities terms.
8. **No counterparty-specific execution adjustment.** Both parties are assumed equally capable until diligence proves otherwise.Finish reason:
stopimport { createClient } from '@runware/sdk'
const client = await createClient({ apiKey: process.env.RUNWARE_API_KEY })
await client.connect()
const [result] = await client.run({
model: 'openai:gpt@5.5',
settings: {
thinkingLevel: 'high'
},
messages: [
{
role: 'user',
content: 'Act as a senior biotech corporate-development advisor. Prepare a decision memo for the board of Helixor Therapeutics, a cash-constrained US biotech considering two offers to license HX-217, its wholly owned oral inhibitor for second-line IDH1-mutant cholangiocarcinoma, in Europe and the United Kingdom.\n\nSituation as of 30 September 2026:\n- HX-217 is entering a 120-patient, single-arm Phase 2 study. Top-line data are expected in Q4 2028.\n- Phase 1 showed a 31% objective response rate in 29 evaluable patients, but the confidence interval is wide and follow-up is immature.\n- Management estimates the probabilities of advancing from the current stage to filing, filing to approval, and successful commercial launch at 35%, 80%, and 95%, respectively. Treat these as sequential probabilities.\n- If successful, launch is expected at the start of 2031. Base-case annual European net sales are projected at $45M, $85M, $125M, $150M, $160M, $150M, $125M, and $90M from 2031 through 2038.\n- Downside sales are 55% of base case; upside sales are 145% of base case. Use scenario weights of 25% downside, 50% base, and 25% upside.\n- Helixor has $68M in cash, burns $8.5M per quarter, has no debt, and expects its existing cash to fund operations through Q3 2028. A pivotal-readiness workstream not included in current burn will require $18M during 2027–2028.\n- Use a 12% annual discount rate and 30 September 2026 as the valuation date. For this screening analysis, discount annual cash flows as if received at each year-end. Ignore taxes, foreign exchange, cost of goods, and time value within milestone years. State the limitations this creates.\n\nOffer A — NordVale Pharma:\n- $42M cash at signing.\n- Development milestones: $18M at first Phase 2 patient dosed, expected Q1 2027; $35M upon positive Phase 2 top-line results, expected Q4 2028; $30M upon EMA filing, expected Q4 2029.\n- Regulatory milestone: $55M upon first European approval, expected Q4 2030.\n- Sales milestones: $35M when annual net sales first exceed $100M and $50M when they first exceed $150M. Apply the probability of commercial launch and determine milestone timing separately in each sales scenario; a threshold is earned only when sales are strictly greater than it.\n- Tiered royalties on annual net sales: 15% up to and including $100M, 18% on the portion above $100M up to and including $150M, and 21% on the portion above $150M.\n- NordVale funds all European development, regulatory, and commercialization costs after signing.\n- Governance: joint development committee with equal representation, but NordVale has final authority for Europe after good-faith consultation.\n- Diligence: commercially reasonable efforts, with no minimum development-spend commitment.\n- Helixor retains manufacturing rights and expects a 4% supply margin on net sales, in addition to royalties.\n- NordVale may sublicense without consent; Helixor receives 15% of non-royalty sublicense consideration.\n\nOffer B — Asterion Oncology:\n- $28M cash at signing plus a $20M equity investment at a 25% premium to Helixor’s 20-day VWAP. Treat the investment as financing proceeds, not license consideration or economic value above its cash amount; flag dilution and valuation considerations qualitatively.\n- Development milestones: $25M at first Phase 2 patient dosed, expected Q1 2027; $45M upon positive Phase 2 top-line results, expected Q4 2028; $40M upon EMA filing, expected Q4 2029.\n- Regulatory milestone: $70M upon first European approval, expected Q4 2030.\n- Sales milestones: $30M when annual net sales first exceed $75M, $45M when they first exceed $125M, and $65M when they first exceed $175M. Apply the probability of commercial launch and determine timing separately by scenario; thresholds must be strictly exceeded.\n- Flat 19% royalty on annual net sales.\n- Asterion funds all European development, regulatory, and commercialization costs after signing.\n- Governance: equal joint development committee; Helixor consent is required for material changes to the target product profile, trial endpoints, or regulatory strategy, not to be unreasonably withheld.\n- Diligence: specified annual development plans and a $22M aggregate minimum development-spend commitment through EMA filing, subject to customary force-majeure exceptions.\n- Asterion controls manufacturing. Helixor receives no supply margin.\n- Asterion needs Helixor’s consent to sublicense before approval; consent may not be unreasonably withheld. Helixor receives 25% of non-royalty sublicense consideration.\n\nAnalytical instructions:\n1. Calculate the cumulative probability of filing, approval, and launch from the current stage.\n2. Estimate each offer’s risk-adjusted present value to Helixor. Include signing cash, the Offer B equity proceeds, development and regulatory milestones, scenario-specific sales milestones, royalties, and Offer A’s supply margin. Probability-adjust contingent payments consistently: the first-patient milestone is assumed certain if the deal signs; positive-data milestones use the probability of advancing to filing; filing, approval, and commercial payments use the appropriate cumulative probabilities. Explain any judgment required to map a payment to a probability.\n3. Show enough intermediate calculations for a finance team to reproduce the result, including milestone timing by sales scenario and the treatment of tiered royalties.\n4. Assess financing runway. Explain whether each offer funds the additional $18M workstream and meaningfully reduces financing risk before Q4 2028, without assuming that milestone receipts arrive earlier than stated.\n5. Compare non-economic terms: control, diligence protection, manufacturing economics and operational burden, sublicensing, counterparty execution risk, and the implications of the equity investment.\n6. Identify the five assumptions most capable of reversing the recommendation. Include at least two quantified sensitivities, such as changing launch probability, discount rate, or peak sales.\n7. Recommend one offer, or recommend delaying or seeking improved terms. Separate the preferred economic outcome from the preferred risk-adjusted strategic outcome.\n8. Provide a negotiation plan with three must-have changes, three tradable points, and a walk-away position. Do not invent facts about either counterparty; identify diligence questions where evidence is missing.\n\nWrite a self-contained, board-ready memo with these sections: Executive recommendation; Decision snapshot; Valuation methodology and results; Financing and runway; Strategic and contractual assessment; Sensitivities and reversal conditions; Negotiation mandate; Key diligence questions; and Appendix of calculations. Use concise prose, tables where helpful, explicit units, and clearly labeled assumptions. Distinguish facts, calculations, and judgment. Round headline values to the nearest $0.1M, note minor rounding differences, and do not present the analysis as legal, tax, accounting, or investment advice.'
}
]
})import asyncio
import os
from runware import Runware
async def main():
async with Runware(api_key=os.environ["RUNWARE_API_KEY"]) as client:
results = await client.run({
"model": "openai:gpt@5.5",
"settings": {
"thinkingLevel": "high"
},
"messages": [
{
"role": "user",
"content": "Act as a senior biotech corporate-development advisor. Prepare a decision memo for the board of Helixor Therapeutics, a cash-constrained US biotech considering two offers to license HX-217, its wholly owned oral inhibitor for second-line IDH1-mutant cholangiocarcinoma, in Europe and the United Kingdom.\n\nSituation as of 30 September 2026:\n- HX-217 is entering a 120-patient, single-arm Phase 2 study. Top-line data are expected in Q4 2028.\n- Phase 1 showed a 31% objective response rate in 29 evaluable patients, but the confidence interval is wide and follow-up is immature.\n- Management estimates the probabilities of advancing from the current stage to filing, filing to approval, and successful commercial launch at 35%, 80%, and 95%, respectively. Treat these as sequential probabilities.\n- If successful, launch is expected at the start of 2031. Base-case annual European net sales are projected at $45M, $85M, $125M, $150M, $160M, $150M, $125M, and $90M from 2031 through 2038.\n- Downside sales are 55% of base case; upside sales are 145% of base case. Use scenario weights of 25% downside, 50% base, and 25% upside.\n- Helixor has $68M in cash, burns $8.5M per quarter, has no debt, and expects its existing cash to fund operations through Q3 2028. A pivotal-readiness workstream not included in current burn will require $18M during 2027–2028.\n- Use a 12% annual discount rate and 30 September 2026 as the valuation date. For this screening analysis, discount annual cash flows as if received at each year-end. Ignore taxes, foreign exchange, cost of goods, and time value within milestone years. State the limitations this creates.\n\nOffer A — NordVale Pharma:\n- $42M cash at signing.\n- Development milestones: $18M at first Phase 2 patient dosed, expected Q1 2027; $35M upon positive Phase 2 top-line results, expected Q4 2028; $30M upon EMA filing, expected Q4 2029.\n- Regulatory milestone: $55M upon first European approval, expected Q4 2030.\n- Sales milestones: $35M when annual net sales first exceed $100M and $50M when they first exceed $150M. Apply the probability of commercial launch and determine milestone timing separately in each sales scenario; a threshold is earned only when sales are strictly greater than it.\n- Tiered royalties on annual net sales: 15% up to and including $100M, 18% on the portion above $100M up to and including $150M, and 21% on the portion above $150M.\n- NordVale funds all European development, regulatory, and commercialization costs after signing.\n- Governance: joint development committee with equal representation, but NordVale has final authority for Europe after good-faith consultation.\n- Diligence: commercially reasonable efforts, with no minimum development-spend commitment.\n- Helixor retains manufacturing rights and expects a 4% supply margin on net sales, in addition to royalties.\n- NordVale may sublicense without consent; Helixor receives 15% of non-royalty sublicense consideration.\n\nOffer B — Asterion Oncology:\n- $28M cash at signing plus a $20M equity investment at a 25% premium to Helixor’s 20-day VWAP. Treat the investment as financing proceeds, not license consideration or economic value above its cash amount; flag dilution and valuation considerations qualitatively.\n- Development milestones: $25M at first Phase 2 patient dosed, expected Q1 2027; $45M upon positive Phase 2 top-line results, expected Q4 2028; $40M upon EMA filing, expected Q4 2029.\n- Regulatory milestone: $70M upon first European approval, expected Q4 2030.\n- Sales milestones: $30M when annual net sales first exceed $75M, $45M when they first exceed $125M, and $65M when they first exceed $175M. Apply the probability of commercial launch and determine timing separately by scenario; thresholds must be strictly exceeded.\n- Flat 19% royalty on annual net sales.\n- Asterion funds all European development, regulatory, and commercialization costs after signing.\n- Governance: equal joint development committee; Helixor consent is required for material changes to the target product profile, trial endpoints, or regulatory strategy, not to be unreasonably withheld.\n- Diligence: specified annual development plans and a $22M aggregate minimum development-spend commitment through EMA filing, subject to customary force-majeure exceptions.\n- Asterion controls manufacturing. Helixor receives no supply margin.\n- Asterion needs Helixor’s consent to sublicense before approval; consent may not be unreasonably withheld. Helixor receives 25% of non-royalty sublicense consideration.\n\nAnalytical instructions:\n1. Calculate the cumulative probability of filing, approval, and launch from the current stage.\n2. Estimate each offer’s risk-adjusted present value to Helixor. Include signing cash, the Offer B equity proceeds, development and regulatory milestones, scenario-specific sales milestones, royalties, and Offer A’s supply margin. Probability-adjust contingent payments consistently: the first-patient milestone is assumed certain if the deal signs; positive-data milestones use the probability of advancing to filing; filing, approval, and commercial payments use the appropriate cumulative probabilities. Explain any judgment required to map a payment to a probability.\n3. Show enough intermediate calculations for a finance team to reproduce the result, including milestone timing by sales scenario and the treatment of tiered royalties.\n4. Assess financing runway. Explain whether each offer funds the additional $18M workstream and meaningfully reduces financing risk before Q4 2028, without assuming that milestone receipts arrive earlier than stated.\n5. Compare non-economic terms: control, diligence protection, manufacturing economics and operational burden, sublicensing, counterparty execution risk, and the implications of the equity investment.\n6. Identify the five assumptions most capable of reversing the recommendation. Include at least two quantified sensitivities, such as changing launch probability, discount rate, or peak sales.\n7. Recommend one offer, or recommend delaying or seeking improved terms. Separate the preferred economic outcome from the preferred risk-adjusted strategic outcome.\n8. Provide a negotiation plan with three must-have changes, three tradable points, and a walk-away position. Do not invent facts about either counterparty; identify diligence questions where evidence is missing.\n\nWrite a self-contained, board-ready memo with these sections: Executive recommendation; Decision snapshot; Valuation methodology and results; Financing and runway; Strategic and contractual assessment; Sensitivities and reversal conditions; Negotiation mandate; Key diligence questions; and Appendix of calculations. Use concise prose, tables where helpful, explicit units, and clearly labeled assumptions. Distinguish facts, calculations, and judgment. Round headline values to the nearest $0.1M, note minor rounding differences, and do not present the analysis as legal, tax, accounting, or investment advice."
}
]
})
asyncio.run(main())curl https://api.runware.ai/v1 \
-H "Authorization: Bearer $RUNWARE_API_KEY" \
-H "Content-Type: application/json" \
-d '[
{
"taskType": "textInference",
"taskUUID": "4675dfbe-af29-4178-b486-58d54c2e4378",
"model": "openai:gpt@5.5",
"settings": {
"thinkingLevel": "high"
},
"messages": [
{
"role": "user",
"content": "Act as a senior biotech corporate-development advisor. Prepare a decision memo for the board of Helixor Therapeutics, a cash-constrained US biotech considering two offers to license HX-217, its wholly owned oral inhibitor for second-line IDH1-mutant cholangiocarcinoma, in Europe and the United Kingdom.\n\nSituation as of 30 September 2026:\n- HX-217 is entering a 120-patient, single-arm Phase 2 study. Top-line data are expected in Q4 2028.\n- Phase 1 showed a 31% objective response rate in 29 evaluable patients, but the confidence interval is wide and follow-up is immature.\n- Management estimates the probabilities of advancing from the current stage to filing, filing to approval, and successful commercial launch at 35%, 80%, and 95%, respectively. Treat these as sequential probabilities.\n- If successful, launch is expected at the start of 2031. Base-case annual European net sales are projected at $45M, $85M, $125M, $150M, $160M, $150M, $125M, and $90M from 2031 through 2038.\n- Downside sales are 55% of base case; upside sales are 145% of base case. Use scenario weights of 25% downside, 50% base, and 25% upside.\n- Helixor has $68M in cash, burns $8.5M per quarter, has no debt, and expects its existing cash to fund operations through Q3 2028. A pivotal-readiness workstream not included in current burn will require $18M during 2027–2028.\n- Use a 12% annual discount rate and 30 September 2026 as the valuation date. For this screening analysis, discount annual cash flows as if received at each year-end. Ignore taxes, foreign exchange, cost of goods, and time value within milestone years. State the limitations this creates.\n\nOffer A — NordVale Pharma:\n- $42M cash at signing.\n- Development milestones: $18M at first Phase 2 patient dosed, expected Q1 2027; $35M upon positive Phase 2 top-line results, expected Q4 2028; $30M upon EMA filing, expected Q4 2029.\n- Regulatory milestone: $55M upon first European approval, expected Q4 2030.\n- Sales milestones: $35M when annual net sales first exceed $100M and $50M when they first exceed $150M. Apply the probability of commercial launch and determine milestone timing separately in each sales scenario; a threshold is earned only when sales are strictly greater than it.\n- Tiered royalties on annual net sales: 15% up to and including $100M, 18% on the portion above $100M up to and including $150M, and 21% on the portion above $150M.\n- NordVale funds all European development, regulatory, and commercialization costs after signing.\n- Governance: joint development committee with equal representation, but NordVale has final authority for Europe after good-faith consultation.\n- Diligence: commercially reasonable efforts, with no minimum development-spend commitment.\n- Helixor retains manufacturing rights and expects a 4% supply margin on net sales, in addition to royalties.\n- NordVale may sublicense without consent; Helixor receives 15% of non-royalty sublicense consideration.\n\nOffer B — Asterion Oncology:\n- $28M cash at signing plus a $20M equity investment at a 25% premium to Helixor’s 20-day VWAP. Treat the investment as financing proceeds, not license consideration or economic value above its cash amount; flag dilution and valuation considerations qualitatively.\n- Development milestones: $25M at first Phase 2 patient dosed, expected Q1 2027; $45M upon positive Phase 2 top-line results, expected Q4 2028; $40M upon EMA filing, expected Q4 2029.\n- Regulatory milestone: $70M upon first European approval, expected Q4 2030.\n- Sales milestones: $30M when annual net sales first exceed $75M, $45M when they first exceed $125M, and $65M when they first exceed $175M. Apply the probability of commercial launch and determine timing separately by scenario; thresholds must be strictly exceeded.\n- Flat 19% royalty on annual net sales.\n- Asterion funds all European development, regulatory, and commercialization costs after signing.\n- Governance: equal joint development committee; Helixor consent is required for material changes to the target product profile, trial endpoints, or regulatory strategy, not to be unreasonably withheld.\n- Diligence: specified annual development plans and a $22M aggregate minimum development-spend commitment through EMA filing, subject to customary force-majeure exceptions.\n- Asterion controls manufacturing. Helixor receives no supply margin.\n- Asterion needs Helixor’s consent to sublicense before approval; consent may not be unreasonably withheld. Helixor receives 25% of non-royalty sublicense consideration.\n\nAnalytical instructions:\n1. Calculate the cumulative probability of filing, approval, and launch from the current stage.\n2. Estimate each offer’s risk-adjusted present value to Helixor. Include signing cash, the Offer B equity proceeds, development and regulatory milestones, scenario-specific sales milestones, royalties, and Offer A’s supply margin. Probability-adjust contingent payments consistently: the first-patient milestone is assumed certain if the deal signs; positive-data milestones use the probability of advancing to filing; filing, approval, and commercial payments use the appropriate cumulative probabilities. Explain any judgment required to map a payment to a probability.\n3. Show enough intermediate calculations for a finance team to reproduce the result, including milestone timing by sales scenario and the treatment of tiered royalties.\n4. Assess financing runway. Explain whether each offer funds the additional $18M workstream and meaningfully reduces financing risk before Q4 2028, without assuming that milestone receipts arrive earlier than stated.\n5. Compare non-economic terms: control, diligence protection, manufacturing economics and operational burden, sublicensing, counterparty execution risk, and the implications of the equity investment.\n6. Identify the five assumptions most capable of reversing the recommendation. Include at least two quantified sensitivities, such as changing launch probability, discount rate, or peak sales.\n7. Recommend one offer, or recommend delaying or seeking improved terms. Separate the preferred economic outcome from the preferred risk-adjusted strategic outcome.\n8. Provide a negotiation plan with three must-have changes, three tradable points, and a walk-away position. Do not invent facts about either counterparty; identify diligence questions where evidence is missing.\n\nWrite a self-contained, board-ready memo with these sections: Executive recommendation; Decision snapshot; Valuation methodology and results; Financing and runway; Strategic and contractual assessment; Sensitivities and reversal conditions; Negotiation mandate; Key diligence questions; and Appendix of calculations. Use concise prose, tables where helpful, explicit units, and clearly labeled assumptions. Distinguish facts, calculations, and judgment. Round headline values to the nearest $0.1M, note minor rounding differences, and do not present the analysis as legal, tax, accounting, or investment advice."
}
]
}
]'runware run openai:gpt@5.5 \
settings.thinkingLevel=high \
messages.0.role=user \
messages.0.content="Act as a senior biotech corporate-development advisor. Prepare a decision memo for the board of Helixor Therapeutics, a cash-constrained US biotech considering two offers to license HX-217, its wholly owned oral inhibitor for second-line IDH1-mutant cholangiocarcinoma, in Europe and the United Kingdom.
Situation as of 30 September 2026:
- HX-217 is entering a 120-patient, single-arm Phase 2 study. Top-line data are expected in Q4 2028.
- Phase 1 showed a 31% objective response rate in 29 evaluable patients, but the confidence interval is wide and follow-up is immature.
- Management estimates the probabilities of advancing from the current stage to filing, filing to approval, and successful commercial launch at 35%, 80%, and 95%, respectively. Treat these as sequential probabilities.
- If successful, launch is expected at the start of 2031. Base-case annual European net sales are projected at \$45M, \$85M, \$125M, \$150M, \$160M, \$150M, \$125M, and \$90M from 2031 through 2038.
- Downside sales are 55% of base case; upside sales are 145% of base case. Use scenario weights of 25% downside, 50% base, and 25% upside.
- Helixor has \$68M in cash, burns \$8.5M per quarter, has no debt, and expects its existing cash to fund operations through Q3 2028. A pivotal-readiness workstream not included in current burn will require \$18M during 2027–2028.
- Use a 12% annual discount rate and 30 September 2026 as the valuation date. For this screening analysis, discount annual cash flows as if received at each year-end. Ignore taxes, foreign exchange, cost of goods, and time value within milestone years. State the limitations this creates.
Offer A — NordVale Pharma:
- \$42M cash at signing.
- Development milestones: \$18M at first Phase 2 patient dosed, expected Q1 2027; \$35M upon positive Phase 2 top-line results, expected Q4 2028; \$30M upon EMA filing, expected Q4 2029.
- Regulatory milestone: \$55M upon first European approval, expected Q4 2030.
- Sales milestones: \$35M when annual net sales first exceed \$100M and \$50M when they first exceed \$150M. Apply the probability of commercial launch and determine milestone timing separately in each sales scenario; a threshold is earned only when sales are strictly greater than it.
- Tiered royalties on annual net sales: 15% up to and including \$100M, 18% on the portion above \$100M up to and including \$150M, and 21% on the portion above \$150M.
- NordVale funds all European development, regulatory, and commercialization costs after signing.
- Governance: joint development committee with equal representation, but NordVale has final authority for Europe after good-faith consultation.
- Diligence: commercially reasonable efforts, with no minimum development-spend commitment.
- Helixor retains manufacturing rights and expects a 4% supply margin on net sales, in addition to royalties.
- NordVale may sublicense without consent; Helixor receives 15% of non-royalty sublicense consideration.
Offer B — Asterion Oncology:
- \$28M cash at signing plus a \$20M equity investment at a 25% premium to Helixor’s 20-day VWAP. Treat the investment as financing proceeds, not license consideration or economic value above its cash amount; flag dilution and valuation considerations qualitatively.
- Development milestones: \$25M at first Phase 2 patient dosed, expected Q1 2027; \$45M upon positive Phase 2 top-line results, expected Q4 2028; \$40M upon EMA filing, expected Q4 2029.
- Regulatory milestone: \$70M upon first European approval, expected Q4 2030.
- Sales milestones: \$30M when annual net sales first exceed \$75M, \$45M when they first exceed \$125M, and \$65M when they first exceed \$175M. Apply the probability of commercial launch and determine timing separately by scenario; thresholds must be strictly exceeded.
- Flat 19% royalty on annual net sales.
- Asterion funds all European development, regulatory, and commercialization costs after signing.
- Governance: equal joint development committee; Helixor consent is required for material changes to the target product profile, trial endpoints, or regulatory strategy, not to be unreasonably withheld.
- Diligence: specified annual development plans and a \$22M aggregate minimum development-spend commitment through EMA filing, subject to customary force-majeure exceptions.
- Asterion controls manufacturing. Helixor receives no supply margin.
- Asterion needs Helixor’s consent to sublicense before approval; consent may not be unreasonably withheld. Helixor receives 25% of non-royalty sublicense consideration.
Analytical instructions:
1. Calculate the cumulative probability of filing, approval, and launch from the current stage.
2. Estimate each offer’s risk-adjusted present value to Helixor. Include signing cash, the Offer B equity proceeds, development and regulatory milestones, scenario-specific sales milestones, royalties, and Offer A’s supply margin. Probability-adjust contingent payments consistently: the first-patient milestone is assumed certain if the deal signs; positive-data milestones use the probability of advancing to filing; filing, approval, and commercial payments use the appropriate cumulative probabilities. Explain any judgment required to map a payment to a probability.
3. Show enough intermediate calculations for a finance team to reproduce the result, including milestone timing by sales scenario and the treatment of tiered royalties.
4. Assess financing runway. Explain whether each offer funds the additional \$18M workstream and meaningfully reduces financing risk before Q4 2028, without assuming that milestone receipts arrive earlier than stated.
5. Compare non-economic terms: control, diligence protection, manufacturing economics and operational burden, sublicensing, counterparty execution risk, and the implications of the equity investment.
6. Identify the five assumptions most capable of reversing the recommendation. Include at least two quantified sensitivities, such as changing launch probability, discount rate, or peak sales.
7. Recommend one offer, or recommend delaying or seeking improved terms. Separate the preferred economic outcome from the preferred risk-adjusted strategic outcome.
8. Provide a negotiation plan with three must-have changes, three tradable points, and a walk-away position. Do not invent facts about either counterparty; identify diligence questions where evidence is missing.
Write a self-contained, board-ready memo with these sections: Executive recommendation; Decision snapshot; Valuation methodology and results; Financing and runway; Strategic and contractual assessment; Sensitivities and reversal conditions; Negotiation mandate; Key diligence questions; and Appendix of calculations. Use concise prose, tables where helpful, explicit units, and clearly labeled assumptions. Distinguish facts, calculations, and judgment. Round headline values to the nearest \$0.1M, note minor rounding differences, and do not present the analysis as legal, tax, accounting, or investment advice."{
"taskType": "textInference",
"taskUUID": "4675dfbe-af29-4178-b486-58d54c2e4378",
"model": "openai:gpt@5.5",
"settings": {
"thinkingLevel": "high"
},
"messages": [
{
"role": "user",
"content": "Act as a senior biotech corporate-development advisor. Prepare a decision memo for the board of Helixor Therapeutics, a cash-constrained US biotech considering two offers to license HX-217, its wholly owned oral inhibitor for second-line IDH1-mutant cholangiocarcinoma, in Europe and the United Kingdom.\n\nSituation as of 30 September 2026:\n- HX-217 is entering a 120-patient, single-arm Phase 2 study. Top-line data are expected in Q4 2028.\n- Phase 1 showed a 31% objective response rate in 29 evaluable patients, but the confidence interval is wide and follow-up is immature.\n- Management estimates the probabilities of advancing from the current stage to filing, filing to approval, and successful commercial launch at 35%, 80%, and 95%, respectively. Treat these as sequential probabilities.\n- If successful, launch is expected at the start of 2031. Base-case annual European net sales are projected at $45M, $85M, $125M, $150M, $160M, $150M, $125M, and $90M from 2031 through 2038.\n- Downside sales are 55% of base case; upside sales are 145% of base case. Use scenario weights of 25% downside, 50% base, and 25% upside.\n- Helixor has $68M in cash, burns $8.5M per quarter, has no debt, and expects its existing cash to fund operations through Q3 2028. A pivotal-readiness workstream not included in current burn will require $18M during 2027–2028.\n- Use a 12% annual discount rate and 30 September 2026 as the valuation date. For this screening analysis, discount annual cash flows as if received at each year-end. Ignore taxes, foreign exchange, cost of goods, and time value within milestone years. State the limitations this creates.\n\nOffer A — NordVale Pharma:\n- $42M cash at signing.\n- Development milestones: $18M at first Phase 2 patient dosed, expected Q1 2027; $35M upon positive Phase 2 top-line results, expected Q4 2028; $30M upon EMA filing, expected Q4 2029.\n- Regulatory milestone: $55M upon first European approval, expected Q4 2030.\n- Sales milestones: $35M when annual net sales first exceed $100M and $50M when they first exceed $150M. Apply the probability of commercial launch and determine milestone timing separately in each sales scenario; a threshold is earned only when sales are strictly greater than it.\n- Tiered royalties on annual net sales: 15% up to and including $100M, 18% on the portion above $100M up to and including $150M, and 21% on the portion above $150M.\n- NordVale funds all European development, regulatory, and commercialization costs after signing.\n- Governance: joint development committee with equal representation, but NordVale has final authority for Europe after good-faith consultation.\n- Diligence: commercially reasonable efforts, with no minimum development-spend commitment.\n- Helixor retains manufacturing rights and expects a 4% supply margin on net sales, in addition to royalties.\n- NordVale may sublicense without consent; Helixor receives 15% of non-royalty sublicense consideration.\n\nOffer B — Asterion Oncology:\n- $28M cash at signing plus a $20M equity investment at a 25% premium to Helixor’s 20-day VWAP. Treat the investment as financing proceeds, not license consideration or economic value above its cash amount; flag dilution and valuation considerations qualitatively.\n- Development milestones: $25M at first Phase 2 patient dosed, expected Q1 2027; $45M upon positive Phase 2 top-line results, expected Q4 2028; $40M upon EMA filing, expected Q4 2029.\n- Regulatory milestone: $70M upon first European approval, expected Q4 2030.\n- Sales milestones: $30M when annual net sales first exceed $75M, $45M when they first exceed $125M, and $65M when they first exceed $175M. Apply the probability of commercial launch and determine timing separately by scenario; thresholds must be strictly exceeded.\n- Flat 19% royalty on annual net sales.\n- Asterion funds all European development, regulatory, and commercialization costs after signing.\n- Governance: equal joint development committee; Helixor consent is required for material changes to the target product profile, trial endpoints, or regulatory strategy, not to be unreasonably withheld.\n- Diligence: specified annual development plans and a $22M aggregate minimum development-spend commitment through EMA filing, subject to customary force-majeure exceptions.\n- Asterion controls manufacturing. Helixor receives no supply margin.\n- Asterion needs Helixor’s consent to sublicense before approval; consent may not be unreasonably withheld. Helixor receives 25% of non-royalty sublicense consideration.\n\nAnalytical instructions:\n1. Calculate the cumulative probability of filing, approval, and launch from the current stage.\n2. Estimate each offer’s risk-adjusted present value to Helixor. Include signing cash, the Offer B equity proceeds, development and regulatory milestones, scenario-specific sales milestones, royalties, and Offer A’s supply margin. Probability-adjust contingent payments consistently: the first-patient milestone is assumed certain if the deal signs; positive-data milestones use the probability of advancing to filing; filing, approval, and commercial payments use the appropriate cumulative probabilities. Explain any judgment required to map a payment to a probability.\n3. Show enough intermediate calculations for a finance team to reproduce the result, including milestone timing by sales scenario and the treatment of tiered royalties.\n4. Assess financing runway. Explain whether each offer funds the additional $18M workstream and meaningfully reduces financing risk before Q4 2028, without assuming that milestone receipts arrive earlier than stated.\n5. Compare non-economic terms: control, diligence protection, manufacturing economics and operational burden, sublicensing, counterparty execution risk, and the implications of the equity investment.\n6. Identify the five assumptions most capable of reversing the recommendation. Include at least two quantified sensitivities, such as changing launch probability, discount rate, or peak sales.\n7. Recommend one offer, or recommend delaying or seeking improved terms. Separate the preferred economic outcome from the preferred risk-adjusted strategic outcome.\n8. Provide a negotiation plan with three must-have changes, three tradable points, and a walk-away position. Do not invent facts about either counterparty; identify diligence questions where evidence is missing.\n\nWrite a self-contained, board-ready memo with these sections: Executive recommendation; Decision snapshot; Valuation methodology and results; Financing and runway; Strategic and contractual assessment; Sensitivities and reversal conditions; Negotiation mandate; Key diligence questions; and Appendix of calculations. Use concise prose, tables where helpful, explicit units, and clearly labeled assumptions. Distinguish facts, calculations, and judgment. Round headline values to the nearest $0.1M, note minor rounding differences, and do not present the analysis as legal, tax, accounting, or investment advice."
}
]
}Response
{
"taskType": "textInference",
"taskUUID": "4675dfbe-af29-4178-b486-58d54c2e4378",
"text": "# Decision memo: HX-217 Europe/UK licensing offers \n**To:** Board of Directors, Helixor Therapeutics \n**As of:** 30 September 2026 \n**Currency:** USD millions unless noted \n**Prepared as:** Screening corporate-development analysis; not legal, tax, accounting, or investment advice.\n\n---\n\n## 1. Executive recommendation\n\n**Recommendation:** Proceed to negotiate with **Asterion Oncology / Offer B** as the preferred transaction, subject to confirmatory diligence and targeted improvements. Do not sign until the equity terms are clean, Asterion’s development/manufacturing execution capability is validated, and enforceable diligence/reversion protections are documented.\n\n**Preferred economic outcome:** \n- On a company cash-proceeds rPV basis, **Offer B is superior: $130.2M vs. $109.0M for Offer A**, primarily because of the $20M equity investment and larger near-term and regulatory milestones. \n- **Excluding the $20M equity proceeds**, Offer B’s license-only rPV is **$110.2M**, effectively tied with Offer A’s **$109.0M**. Therefore, the economic superiority of Offer B depends materially on treating the equity proceeds as useful financing cash, while recognizing dilution.\n\n**Preferred risk-adjusted strategic outcome:** \n- **Offer B is also strategically preferable** because it provides stronger Helixor consent rights over material development/regulatory changes, a specified development plan and $22M minimum spend commitment through EMA filing, better pre-approval sublicensing control, and avoids Helixor’s European manufacturing burden. \n- Offer A’s 4% supply margin is valuable, but modest in PV terms and comes with CMC, quality, capacity, and working-capital obligations. Offer A’s weaker diligence covenant and unrestricted sublicensing are meaningful strategic negatives.\n\n**Financing conclusion:** Both offers fund the $18M pivotal-readiness workstream and materially reduce financing risk before Q4 2028. Offer B provides more certain pre-readout cash by Q1 2027: **$73M nominal vs. $60M under Offer A**, though $20M of Offer B is dilutive equity rather than license consideration.\n\n---\n\n## 2. Decision snapshot\n\n| Metric | Offer A: NordVale | Offer B: Asterion | Comment |\n|---|---:|---:|---|\n| Signing cash | $42M | $28M license cash + $20M equity | B has more total cash, but only $28M is non-dilutive license cash |\n| Certain cash by Q1 2027 | $60M | $73M | Includes first-patient milestone; B includes equity |\n| rPV including all instructed proceeds | **$109.0M** | **$130.2M** | B higher by $21.2M |\n| License-only rPV, excluding B equity | $109.0M | **$110.2M** | Essentially tied; B higher by $1.2M |\n| Commercial rPV component | $25.1M | $26.5M | Similar; B sales milestones offset A supply margin/tiered upside |\n| Royalty / supply economics | Tiered 15% / 18% / 21% + 4% supply margin | Flat 19%; no supply margin | A has higher upside economics above $100M sales |\n| Governance | NordVale final EU authority after consultation | Helixor consent for material TPP, endpoints, regulatory strategy | B better preserves asset integrity |\n| Diligence | CRE only; no minimum spend | Annual plans + $22M minimum spend through EMA filing | B materially stronger |\n| Manufacturing | Helixor retains; 4% margin | Asterion controls; no Helixor margin | A adds value but operational burden |\n| Sublicensing | No consent; 15% of non-royalty consideration | Pre-approval consent; 25% of non-royalty consideration | B better |\n| Recommendation | Fallback / leverage | **Preferred** | Subject to diligence and must-have changes |\n\n---\n\n## 3. Valuation methodology and results\n\n### Core probability calculations\n\nManagement’s probabilities are treated as sequential:\n\n| Event | Calculation | Cumulative probability |\n|---|---:|---:|\n| Advance from current stage to filing | Given | **35.0%** |\n| Approval | 35% × 80% | **28.0%** |\n| Successful commercial launch | 35% × 80% × 95% | **26.6%** |\n\n**Judgment on probability mapping:** \n- First-patient-dosed milestones are treated as **certain if the deal signs**, per instruction. \n- Positive Phase 2 top-line milestones are mapped to the **35% probability of advancing to filing**, per instruction, even though positive top-line and actual filing are not identical events. \n- EMA filing milestones use **35%** cumulative filing probability. \n- Approval milestones use **28%** cumulative approval probability. \n- Sales milestones, royalties, and Offer A supply margin use **26.6%** cumulative launch probability, with downside/base/upside sales scenarios weighted **25% / 50% / 25% conditional on launch**.\n\n### Discounting assumptions\n\n- Valuation date: **30 September 2026**. \n- Discount rate: **12% annually**. \n- Signing cash is treated as immediate. \n- Annual cash flows and milestones are discounted as if received at calendar year-end. \n- Time value within milestone years is ignored; therefore Q1 2027 and Q4 2027 items would receive the same year-end treatment if applicable. This is conservative for the Q1 2027 first-patient milestones and approximately neutral for Q4 events.\n\n### Headline rPV results\n\n| Component | Offer A rPV | Offer B rPV including equity | Offer B license-only rPV excluding equity |\n|---|---:|---:|---:|\n| Signing / equity / certain first-patient cash | $57.6 | $69.7 | $49.7 |\n| Positive Phase 2 top-line milestone | $9.5 | $12.2 | $12.2 |\n| EMA filing milestone | $7.3 | $9.7 | $9.7 |\n| First approval milestone | $9.5 | $12.1 | $12.1 |\n| Sales milestones | $7.0 | $9.3 | $9.3 |\n| Royalties and supply margin | $18.2 | $17.2 | $17.2 |\n| **Total rPV** | **$109.0** | **$130.2** | **$110.2** |\n\n**Interpretation:** \n- Offer B is clearly superior on total company cash proceeds because of the $20M equity investment. \n- On license-only economics, the offers are essentially equivalent. Offer B is only $1.2M ahead, which is within normal screening-model noise. \n- Therefore, the board should not view Offer B as economically superior unless the equity proceeds are strategically useful and the dilution/ownership terms are acceptable.\n\n---\n\n## 4. Financing and runway\n\n### Current cash position\n\n| Item | Amount |\n|---|---:|\n| Cash at 30 September 2026 | $68M |\n| Current burn | $8.5M per quarter |\n| Existing runway at current burn | Through Q3 2028 |\n| Additional pivotal-readiness workstream | $18M during 2027–2028 |\n| No-deal funding gap through Q3 2028 including workstream | Approximately $18M |\n\nHelixor’s stated cash runway funds existing operations through Q3 2028 but **does not fund the additional $18M pivotal-readiness workstream**. Without a transaction or financing, Helixor would need to defer the workstream, reduce spend, or raise capital before the Phase 2 top-line readout.\n\n### Nominal cash available before Q4 2028, excluding contingent positive-data milestones\n\n| Item | Offer A | Offer B |\n|---|---:|---:|\n| Current cash | $68M | $68M |\n| Signing cash / equity proceeds | $42M | $48M |\n| First-patient milestone, Q1 2027 | $18M | $25M |\n| **Total resources before Q4 2028 positive-data milestone** | **$128M** | **$141M** |\n| Baseline burn through Q3 2028, 8 quarters | $(68M)$ | $(68M)$ |\n| Additional workstream | $(18M)$ | $(18M)$ |\n| **Estimated cushion through Q3 2028** | **$42M** | **$55M** |\n\nIf Helixor also must fund Q4 2028 before receiving any positive-data milestone, the additional burn is approximately $8.5M, leaving estimated cushions of **$33.5M under Offer A** and **$46.5M under Offer B**, before transaction costs or unplanned spend.\n\n### Financing conclusion\n\nBoth offers appear to fund the $18M workstream and materially reduce financing risk before Q4 2028. Offer B provides the larger cushion, but part of that cushion is dilutive equity.\n\n**Important limitation:** This assumes the $18M workstream remains a Helixor obligation funded from transaction proceeds. If the final license requires the European partner to assume some or all of this workstream, runway improves. Conversely, if the workstream is U.S./global and expands beyond $18M, runway shortens.\n\n---\n\n## 5. Strategic and contractual assessment\n\n### Control and governance\n\n**Offer A — NordVale** \n- Equal JDC, but NordVale has final authority for Europe after consultation. \n- This is customary for a regional license but leaves Helixor exposed to decisions that could affect global development strategy, regulatory positioning, label, publications, and future U.S./ROW value. \n- Lack of Helixor consent over material TPP, endpoint, or regulatory changes is a concern.\n\n**Offer B — Asterion** \n- Equal JDC plus Helixor consent rights for material changes to target product profile, trial endpoints, or regulatory strategy, not to be unreasonably withheld. \n- This better protects asset integrity and global optionality. \n- The board should ensure “material changes” is defined tightly enough to avoid disputes.\n\n**Advantage:** Offer B.\n\n### Diligence protection\n\n**Offer A** \n- Commercially reasonable efforts only; no minimum development-spend commitment. \n- This creates deprioritization risk, especially if NordVale’s portfolio priorities shift.\n\n**Offer B** \n- Annual development plans and $22M aggregate minimum development-spend commitment through EMA filing. \n- Stronger protection, though Helixor should negotiate remedies for missed spend or timeline slippage.\n\n**Advantage:** Offer B.\n\n### Manufacturing economics and operational burden\n\n**Offer A** \n- Helixor retains manufacturing rights and expects a 4% supply margin on European net sales. \n- PV of the 4% supply margin is approximately **$3.6M** in this screen. \n- However, Helixor retains operational obligations: CMC management, GMP compliance, batch release, quality systems, capacity planning, potential working capital, and supply failure risk.\n\n**Offer B** \n- Asterion controls manufacturing. \n- Helixor loses supply margin but avoids European manufacturing operational burden. \n- Must ensure tech-transfer, quality, audit, supply continuity, and step-in protections do not impair Helixor’s U.S./ROW rights.\n\n**Economic advantage:** Offer A. \n**Risk-adjusted operational advantage:** Offer B, unless Helixor has a strategic reason to retain EU manufacturing.\n\n### Sublicensing\n\n**Offer A** \n- NordVale may sublicense without Helixor consent. \n- Helixor receives 15% of non-royalty sublicense consideration. \n- This is weak; NordVale could shift execution to a sublicensee without meaningful Helixor control.\n\n**Offer B** \n- Asterion needs Helixor consent to sublicense before approval, not to be unreasonably withheld. \n- Helixor receives 25% of non-royalty sublicense consideration. \n- Better economics and better pre-approval control.\n\n**Advantage:** Offer B.\n\n### Equity investment implications\n\nOffer B’s $20M equity investment is useful financing cash but should not be treated as license consideration. Key implications:\n\n- It dilutes existing shareholders, though the 25% premium reduces dilution relative to issuing at VWAP. \n- Per-share impact depends on Helixor’s share count, VWAP, and final investment documents. \n- Equity ownership may create information, voting, standstill, lock-up, registration-rights, MNPI, and future M&A signaling issues. \n- If the equity investor receives governance rights, vetoes, board observation, or restrictive covenants, the strategic cost could outweigh some financing benefit.\n\n**Board view:** Acceptable only if “clean” equity: no board seat or observer, no restrictive vetoes, appropriate standstill/lock-up, customary registration rights only, and no rights that impair future financing or M&A.\n\n### Counterparty execution risk\n\nNo facts were provided on either counterparty’s balance sheet, EMA track record, cholangiocarcinoma or rare oncology commercial capabilities, CMC infrastructure, or portfolio priorities. Therefore, the analysis treats execution risk as unproven for both.\n\n**Judgment:** Offer B has better contractual protections on paper. That does not substitute for diligence confirming Asterion can execute.\n\n---\n\n## 6. Sensitivities and reversal conditions\n\n### Quantified sensitivity 1: clinical probability to filing\n\nHolding filing-to-approval at 80% and approval-to-launch at 95%, varying the cumulative probability of filing:\n\n| Cumulative probability of filing | Offer A rPV | Offer B rPV incl. equity | Offer B license-only rPV excl. equity |\n|---:|---:|---:|---:|\n| 25% | $94.3 | $112.9 | $92.9 |\n| 35% base | $109.0 | $130.2 | $110.2 |\n| 45% | $123.7 | $147.5 | $127.5 |\n\n**Implication:** Including equity, Offer B remains ahead. Excluding equity, Offer A becomes economically better if the filing probability falls below approximately **30%**.\n\n### Quantified sensitivity 2: discount rate\n\n| Discount rate | Offer A rPV | Offer B rPV incl. equity | Offer B license-only rPV excl. equity |\n|---:|---:|---:|---:|\n| 10% | $115.1 | $137.0 | $117.0 |\n| 12% base | $109.0 | $130.2 | $110.2 |\n| 15% | $101.4 | $121.6 | $101.6 |\n\n**Implication:** The total-proceeds preference for Offer B is robust. License-only economics remain essentially tied, especially at higher discount rates.\n\n### Quantified sensitivity 3: sales scale\n\nAssuming all downside/base/upside sales are shifted by the same percentage:\n\n| Sales case | Offer A rPV | Offer B rPV incl. equity | Offer B license-only rPV excl. equity |\n|---|---:|---:|---:|\n| 20% lower sales | $102.2 | $125.1 | $105.1 |\n| Base sales | $109.0 | $130.2 | $110.2 |\n| 20% higher sales | $114.5 | $137.6 | $117.6 |\n\n**Implication:** Offer B remains ahead in these ranges. At very high sales levels, Offer A’s all-in marginal economics above $150M — 21% royalty plus 4% supply margin, or 25% total — could outperform Offer B’s 19% flat royalty on a license-only basis. However, the current forecast does not create that result.\n\n### Five assumptions most capable of reversing the recommendation\n\n1. **Value and acceptability of Offer B equity.** If the board excludes the $20M equity proceeds or views the equity as strategically costly, Offer B’s economic advantage largely disappears. \n2. **Asterion execution capability.** If diligence shows Asterion lacks EMA, oncology, launch, or manufacturing capability, Offer B’s contractual protections may not compensate. \n3. **Clinical probability.** If probability of reaching filing is materially below 35%, Offer A’s larger non-dilutive upfront becomes more attractive on a license-only basis. \n4. **Manufacturing burden and margin realization.** Offer A includes approximately $3.6M PV from the 4% supply margin. If required capex, CMC staffing, working capital, or quality risk consumes that margin, Offer A’s value declines. Conversely, if Helixor highly values manufacturing control, Offer A improves strategically. \n5. **Sales upside / threshold timing.** Major upside above forecast could favor Offer A’s tiered royalty plus supply margin. Conversely, if sales underperform or fail to cross strict thresholds, both offers lose commercial value, but Offer B’s larger near-term milestones and equity become more important.\n\n---\n\n## 7. Negotiation mandate\n\n### Three must-have changes / conditions\n\n1. **Clean equity package for Offer B.** \n The $20M equity investment must have no board seat or observer, no unusual veto rights, no anti-dilution beyond customary securities terms, no MFN on future financings, appropriate standstill and lock-up provisions, and registration rights that do not impair future financings.\n\n2. **Enforceable diligence and reversion protections.** \n Preserve Asterion’s $22M minimum development-spend commitment, add quarterly reporting, define eligible spend, require catch-up for missed spend, and include meaningful remedies for material failure: cure rights, step-in rights, or reversion/termination for uncured deprioritization.\n\n3. **Global asset-protection covenants.** \n Helixor must retain access to EU clinical, regulatory, safety, and CMC data for U.S./ROW use. Asterion’s manufacturing control must be subject to tech-transfer, quality, audit, supply continuity, and step-in protections. Helixor’s consent rights over material TPP, endpoints, and regulatory strategy must not be diluted through affiliates or sublicenses.\n\n### Three tradable points\n\n1. **Milestone mix versus upfront certainty.** \n Helixor can trade a portion of later sales milestones for more upfront or earlier non-contingent cash, especially if it improves runway and reduces equity reliance.\n\n2. **Post-approval sublicensing flexibility.** \n Helixor can allow broader post-approval sublicensing if Asterion remains liable for sublicensee performance and Helixor retains economics and audit rights.\n\n3. **Routine commercialization control.** \n Helixor can accept Asterion final say over routine EU pricing, reimbursement sequencing, medical affairs, and commercialization tactics, provided material label, TPP, regulatory, and safety matters remain protected.\n\n### Walk-away position\n\nHelixor should not accept a final deal that has any of the following:\n\n- Less than approximately **$60M of certain pre-readout cash** without a credible alternative financing plan. \n- No enforceable development-spend or timeline remedy. \n- Loss of Helixor consent over material TPP, trial endpoint, or regulatory-strategy changes. \n- Equity terms that create governance overhang, block future financings, or impair M&A optionality. \n- Counterparty diligence showing inadequate financial capacity, EMA execution ability, manufacturing infrastructure, or commitment to HX-217.\n\nIf Asterion cannot meet these conditions, Helixor should use Offer B as leverage to improve Offer A, specifically seeking NordVale minimum development-spend commitments, pre-approval sublicense consent, and Helixor consent rights over material regulatory changes. If neither party improves, Helixor should consider a short, targeted process extension or bridge financing rather than locking HX-217 into a weak regional deal.\n\n---\n\n## 8. Key diligence questions\n\n### Counterparty execution\n\n1. What is each counterparty’s recent EMA oncology approval track record, especially in rare tumors or biomarker-defined indications? \n2. Does either party have cholangiocarcinoma, IDH-mutant, hepatobiliary, or rare oncology launch experience in Europe/UK? \n3. What internal budget approval has been obtained for HX-217, including post-Phase 2 readiness and EMA filing activities? \n4. How will each party staff regulatory, clinical operations, pharmacovigilance, market access, and medical affairs?\n\n### Development and regulatory plan\n\n5. What is the proposed EMA pathway for a 120-patient single-arm Phase 2 data package? \n6. What endpoints, response durability assumptions, follow-up duration, and comparator context are expected to support filing? \n7. What are the specific annual development plans and decision gates through Q4 2028 and Q4 2029? \n8. What happens if Phase 2 response rate is positive but durability, safety, or subgroup data are mixed?\n\n### Manufacturing / CMC\n\n9. Under Offer A, what capex, staffing, quality, and working-capital commitments would Helixor need to support EU supply? \n10. Under Offer B, what tech-transfer obligations, CMC data rights, supply continuity obligations, and step-in rights will Helixor have? \n11. Will either structure interfere with Helixor’s U.S./ROW manufacturing, regulatory filings, or supply chain?\n\n### Equity and financing\n\n12. What percentage ownership would Asterion receive from the $20M equity investment? \n13. What are the standstill, lock-up, voting, registration, information, and anti-dilution terms? \n14. Would Asterion’s equity stake deter other partners, investors, or acquirers?\n\n### Commercial assumptions\n\n15. What pricing, reimbursement timing, country launch sequence, and patient-population assumptions support the $45M–$160M base sales forecast? \n16. What competitive threats could affect second-line IDH1-mutant cholangiocarcinoma by 2031–2038? \n17. How are strict sales milestone thresholds calculated, audited, and treated in partial launch years?\n\n### Sublicensing and termination\n\n18. How is non-royalty sublicense consideration allocated if a broader asset package is sublicensed? \n19. Are affiliate sublicenses treated differently from third-party sublicenses? \n20. What are the consequences of termination for convenience, patent challenge, safety failure, or deprioritization?\n\n---\n\n## 9. Appendix of calculations\n\n### A. Discount factors used\n\nAnnual discount rate: 12%. Signing treated as immediate.\n\n| Year-end | Discount factor |\n|---:|---:|\n| 2027 | 0.8679 |\n| 2028 | 0.7749 |\n| 2029 | 0.6919 |\n| 2030 | 0.6178 |\n| 2031 | 0.5516 |\n| 2032 | 0.4925 |\n| 2033 | 0.4397 |\n| 2034 | 0.3926 |\n| 2035 | 0.3505 |\n| 2036 | 0.3130 |\n| 2037 | 0.2795 |\n| 2038 | 0.2495 |\n\nMinor rounding differences may occur.\n\n---\n\n### B. Development and regulatory milestone PV\n\n#### Offer A\n\n| Payment | Nominal | Year | Probability | DF | rPV |\n|---|---:|---:|---:|---:|---:|\n| Signing | $42 | 2026 | 100% | 1.0000 | $42.0 |\n| First Phase 2 patient dosed | $18 | 2027 | 100% | 0.8679 | $15.6 |\n| Positive Phase 2 top-line | $35 | 2028 | 35% | 0.7749 | $9.5 |\n| EMA filing | $30 | 2029 | 35% | 0.6919 | $7.3 |\n| First European approval | $55 | 2030 | 28% | 0.6178 | $9.5 |\n| **Subtotal** | | | | | **$83.9** |\n\n#### Offer B\n\n| Payment | Nominal | Year | Probability | DF | rPV |\n|---|---:|---:|---:|---:|---:|\n| Signing cash | $28 | 2026 | 100% | 1.0000 | $28.0 |\n| Equity proceeds | $20 | 2026 | 100% | 1.0000 | $20.0 |\n| First Phase 2 patient dosed | $25 | 2027 | 100% | 0.8679 | $21.7 |\n| Positive Phase 2 top-line | $45 | 2028 | 35% | 0.7749 | $12.2 |\n| EMA filing | $40 | 2029 | 35% | 0.6919 | $9.7 |\n| First European approval | $70 | 2030 | 28% | 0.6178 | $12.1 |\n| **Subtotal including equity** | | | | | **$103.7** |\n| **Subtotal excluding equity** | | | | | **$83.7** |\n\n---\n\n### C. Sales milestone timing by scenario\n\nSales thresholds are earned only when annual net sales are **strictly greater than** the threshold.\n\n#### Offer A\n\n| Milestone | Downside timing | Base timing | Upside timing | rPV |\n|---|---:|---:|---:|---:|\n| $35M when sales first exceed $100M | Never | 2033 | 2032 | $3.2 |\n| $50M when sales first exceed $150M | Never | 2035 | 2033 | $3.8 |\n| **Total** | | | | **$7.0** |\n\n#### Offer B\n\n| Milestone | Downside timing | Base timing | Upside timing | rPV |\n|---|---:|---:|---:|---:|\n| $30M when sales first exceed $75M | 2034 | 2032 | 2032 | $3.7 |\n| $45M when sales first exceed $125M | Never | 2034 | 2033 | $3.7 |\n| $65M when sales first exceed $175M | Never | Never | 2033 | $1.9 |\n| **Total** | | | | **$9.3** |\n\n---\n\n### D. Royalty and supply calculations\n\n#### Offer A royalty formula\n\nFor annual sales **S**:\n\n- 15% on sales up to and including $100M. \n- 18% on the portion above $100M up to and including $150M. \n- 21% on the portion above $150M. \n- Plus 4% supply margin on net sales.\n\nExamples: \n- At $125M sales: royalty = 15% × $100M + 18% × $25M = $19.5M; supply margin = 4% × $125M = $5.0M; total = $24.5M. \n- At $160M sales: royalty = $15.0M + $9.0M + 21% × $10M = $26.1M; supply margin = $6.4M; total = $32.5M.\n\n#### Royalty / supply rPV by year\n\nAmounts below are scenario-weighted conditional cash flows assuming launch, then risk-adjusted by 26.6% launch probability.\n\n| Year | Base sales | Offer A scenario-weighted royalty + supply before launch probability | Offer B scenario-weighted royalty before launch probability | Offer A risk-adjusted PV | Offer B risk-adjusted PV |\n|---:|---:|---:|---:|---:|---:|\n| 2031 | $45 | $8.6 | $8.6 | $1.3 | $1.3 |\n| 2032 | $85 | $16.3 | $16.2 | $2.1 | $2.1 |\n| 2033 | $125 | $25.0 | $23.8 | $2.9 | $2.8 |\n| 2034 | $150 | $30.6 | $28.5 | $3.2 | $3.0 |\n| 2035 | $160 | $33.1 | $30.4 | $3.1 | $2.8 |\n| 2036 | $150 | $30.6 | $28.5 | $2.6 | $2.4 |\n| 2037 | $125 | $25.0 | $23.8 | $1.9 | $1.8 |\n| 2038 | $90 | $17.3 | $17.1 | $1.2 | $1.1 |\n| **Total rPV** | | | | **$18.2** | **$17.2** |\n\n---\n\n### E. Limitations of this screening analysis\n\nThis analysis intentionally simplifies several material items:\n\n1. **Taxes ignored.** After-tax value may be materially lower, and withholding taxes could differ by jurisdiction and structure. \n2. **Foreign exchange ignored.** European/UK revenues would likely be earned in EUR/GBP, while valuation is in USD. \n3. **COGS and operating costs ignored.** Offer A’s 4% supply margin is treated as net margin, but real manufacturing may require capex, working capital, QA/QC, and supply-chain investment. \n4. **Time value within milestone years ignored.** Q1 2027 payments are conservatively discounted to year-end; Q4 payments are roughly aligned. \n5. **No country-by-country reimbursement delay modeled.** Sales are treated as annual year-end cash flows, not phased by pricing and reimbursement timing. \n6. **No probability assigned to sublicensing proceeds.** Sublicense economics are assessed qualitatively because no sublicense probability or consideration forecast was provided. \n7. **No dilution or per-share valuation model.** Offer B’s equity is included as $20M cash proceeds only; per-share impact depends on VWAP, shares issued, and final securities terms. \n8. **No counterparty-specific execution adjustment.** Both parties are assumed equally capable until diligence proves otherwise.",
"cost": 0.80791,
"finishReason": "stop",
"reasoningContent": [
"**Calculating cash flows**\n\nI need to create a board memo with calculations regarding cash flows. The valuation date is September 30, 2026, and I need to discount annual cash flows at year-end. If signing occurs at that valuation date, it seems like there's likely no discount. Should I consider payments in 2027 discounted to year-end 2027? It looks like I should discount annual cash flows as if received at each year-end. I'll also determine milestones for each year, starting with the signing cash at date zero.",
"**Calculating screening analysis**\n\nI need to assess the screening at the end of each calendar year, possibly using t=1 for 2027. Since the valuation date is September 30, 2026, I should consider fractional years. I need to show discount factors while remembering to ignore time value within milestone years. For Q1 and Q4 2027, I’ll use year-end 2027. Signing is at t=0, and the 2028 Q4 milestone would approximately be 2.25 years. I’ll also calculate probabilities sequentially—advancing to filing at 35%, filing to approval at 80%, and commercial launch success at 95%.",
"**Applying sales probabilities**\n\nI need to calculate the probability of approval at 28% and the sales milestones or royalties at 26.6%. Now, I'm wondering if I should apply scenario weights based on the likelihood of the launch. It seems important to use the cumulative launch probability along with the scenario weights. This could help me estimate the most likely sales scenarios if the launch goes ahead. I want to ensure I’m accurately reflecting these conditions in my calculations.",
"**Calculating discount factors**\n\nI need to calculate royalties using a 12% annual discount rate. The formula uses the discount factor (DF) that I need to compute for each year, starting from September 30. For year-end cash flows, I note that the factors for 2027 to 2038 will be about 1.25 to 12.25, respectively. I’ve calculated DFs for each year, from 2026 to 2038, using the formula DF = 1/(1.12^t). I want to ensure I have these values accurate.",
"**Considering milestone adjustments**\n\nI see that if the alternative year index changes values by 2.9%, I should mention that. I also need to adjust the headlines to the nearest 0.1. So, it’s time to compute this. For Milestones Offer A, I have a signing value of 42.0, which is immediate. I’ll make sure to keep everything accurate and clear as I finalize these calculations and considerations. It’s important to get these details right!",
"**Evaluating Offers and Cash Flow**\n\nI’m thinking about the cash proceeds from the offers. For example, Offer B has an estimated rPV that’s $1.2M higher than Offer A when looking at licenses alone. But, including financing, B is $21.2M higher. However, I need to consider the dilution costs associated with the equity in Offer B. Offer A is non-dilutive with upfront cash differing significantly. By Q1 2027, B may showcase greater overall cash, but I have to think about the burn rate and runway.",
"**Evaluating strategic decisions**\n\nI’m considering the final authority of NordVale if execution is strong, while Asterion might not hold up if their infrastructure is weaker than the protections. I need to weigh the preferred economic outcome against the preferred risk-adjusted strategic outcome. The values are B cash plus rPV at 130.2 versus A at 109.0. B seems to offer more near-term cash and better contractual protection, making it a likely choice for the strategic outcome. But I’m pondering if pure non-dilutive license economics could be preferred.",
"**Weighing options for economic outcomes**\n\nI’m looking at A’s $42 non-dilutive upfront payment and supply. The “preferred economic outcome” might lean towards B when considering equity. If the difference for a \"license-only\" option is minimal, A could be better due to its non-dilutive upfront and manufacturing benefits. My recommendation is to pursue Offer B as the preferred risk-adjusted strategic outcome but negotiate for three must-haves. If improvements aren’t made, I’d sign with B unless Asterion’s execution is insufficient. Economic-wise, B is superior by about $21.2 million rPV and provides more certain cash. In terms of strategic advantages, B offers better control and lower manufacturing burdens.",
"**Formulating negotiation strategies**\n\nI’m proposing to focus on Offer B as my recommendation, while also keeping A as a fallback option. I need to identify three must-have changes, along with three that are negotiable, and a walk-away option. Since I'm advocating for B, I should direct the mandate towards Asterion, using A as my Best Alternative To a Negotiated Agreement (BATNA). \n\nFor the must-haves, I’m considering converting equity into a non-dilutive upfront payment or placing limits on ownership and ensuring no voting rights or standstill agreements. I wonder if this could be packaged as a change.",
"**Analyzing commercial PV components**\n\nI'm evaluating commercial PV components and looking at sales milestones and royalties. For Company A, total revenue from sales milestones and royalties seems to be around 25.1 at the launch price. Meanwhile, Company B shows a bit lower at 26.5. When considering total pre-commercial values, A comes in at 109.0 and B at around 130.227. I'm wondering how the differences between them might impact sales, especially with A potentially benefiting from higher sales in the supply tier.",
"**Evaluating sales sensitivity**\n\nI’m looking into how sensitivity to sales affects economic values. If equity has no value, sales scenarios could change outcomes significantly. I want to quantify sales sensitivity variations, maybe at ±20%, and see how that might affect projected values.\n\nI need to calculate sales projections based on different scenarios, including upside and downside. This also involves considering milestone timings and royalties. So, I’ll be comparing these metrics to ensure it's credible and relevant. I’ll dive into those calculations now.",
"**Calculating sales milestones**\n\nI have total sales milestones at 4.156. Now, I need to create a formula for the royalties plus supply conditional. For scenarios where sales are below 100, the total royalty is 19%. If sales reach 100, I can maintain that total. \n\nLooking at higher sales, for 120 and 128, I'll use the formula: royalty of 15 + 0.18(S-100) + supply 4S. It simplifies to 0.22S - 3. For sales at 120, the total is 23.4, and for 128, it’s 25.16.",
"**Analyzing royalty advantages**\n\nI'm considering the royalty advantages and how they play out under different sales scenarios. For sales above 150, I'm calculating cash flows as A = 0.25S - 7.5 and B = 0.19S, which gives a difference of A - B = 0.06S - 7.5. This shows a positive difference when sales exceed 125. Between 100 and 150, the difference is A - B = 0.03S - 3, remaining positive above 100. I'm curious how this affects sales milestones.",
"**Analyzing project success probabilities**\n\nI'm considering the probability of success in Phase 2, estimating it at around 35%. It's important to compare milestones for A and B, where B has larger milestones but may have lower probabilities. I notice that cash flow is significant for B, and without equity, A shows a better outcome. If the P filing is low, breakeven analysis becomes crucial. How do I ensure the right assumptions in this analysis?",
"**Calculating milestone valuations**\n\nI'm working on milestone valuation tables for a project with various scenarios concerning signing probabilities and financial projections. I’ll summarize expected payments and their present values (PV) based on different scenarios, like \"down,\" \"base,\" and \"up.\" I’m focusing on expected sales milestones and calculating PVs accordingly, aiming for clarity. It seems that I can derive total outcome values while considering weights and probabilities—like the 0.266 multiplier—across different years for more accurate assessments.",
"**Condensing royalties table**\n\nI'm considering a way to condense the royalties table, focusing on expected or conditional launch figures. I want to set up columns for each year, including base sales, weighted cash for scenarios A and B before the launch, along with discount factors (DF). Additionally, I’ll calculate the risk-adjusted present values (PV) for both A and B. This organization should help in analyzing potential outcomes more clearly and efficiently while retaining important details about revenue projections.",
"**Evaluating Offer B**\n\nI'm thinking about \"Offer B equity investment at a 25% premium.\" I should treat it as financing proceeds, where existing shareholders issue fewer shares than at the volume-weighted average price (VWAP). The premium might provide some economic benefit compared to the market value. However, it’s essential to note that there's no economic value above cash, which raises concerns about potential dilution for the shareholders. It seems like a complex situation to navigate!"
]
}reference-to-text
Vineyard Disease Scouting Report$0.0699~34sReasoning
**Analyzing leaf conditions**
I see that in the first image, one leaf shows signs of chlorosis and a white growth, likely due to lesions and possible sporulation on the underside. It's probably not powdery mildew, as it doesn’t match the descriptions. I need to consider factors like Botrytis or non-disease issues like nutrient problems. I should craft a table that lists downy mildew and powdery mildew, along with any non-disease causes. Overall, it looks like one leaf is definitely affected while four to six nearby leaves appear healthier. I should also note a small dark insect or debris closely related to the lesions.
**Clarifying observations and treatment**
I think I should include a confidence level and urgency in my assessment. My confidence is moderate to high regarding fungal mildew, especially downy mildew, but I need to confirm that before proceeding with any treatment. It’s crucial to differentiate between visible evidence and my interpretations. I'm planning to split Section 2 to emphasize these points more clearly. This way, everything will be organized and easy to follow for the user!## 1. Executive assessment
**Most likely issue:** Probable grapevine mildew disease, most consistent visually with **downy mildew-type infection**, but **not confirmed** from one photograph.
**Confidence:** **Moderate** — the combination of yellow leaf spots and white fungal growth is strongly suggestive, but the photo does not clearly prove which leaf surface is shown or show both sides of the same lesion.
**Urgency:** **High for scouting within 24 hours** because visible sporulation and multiple chlorotic spots suggest an active foliar issue that could spread if conditions are favorable.
---
## 2. Visible evidence
### Direct observations from the image
- **Affected leaf count:**
- **1 prominently affected grape leaf** in the center foreground.
- Approximately **4–6 surrounding leaves appear mostly green and comparatively healthy** in the visible frame, though some have minor edge blemishes or are partially obscured.
- **Symptom morphology on the main leaf:**
- Numerous **round to irregular yellow chlorotic spots**, mostly scattered across the blade.
- Spots vary in size from small pinpoints to larger rounded patches.
- A larger yellow area is visible near the lower-central portion of the leaf.
- **Fungal growth:**
- A dense **white, cottony to downy fungal-looking growth** is visible on the lower-central portion of the same leaf, concentrated around veins and extending across several lobes.
- **Color:**
- Yellow chlorosis on green tissue.
- White superficial growth.
- Brown necrotic/dried areas along parts of the lower leaf margin and near a damaged lobe.
- **Leaf surfaces involved:**
- Only the visible surface can be assessed from the photo. The opposite surface is not shown clearly.
- **Secondary damage:**
- Brown necrotic edge lesions and small damaged areas near the leaf margin.
- A small dark insect-like object or debris is visible on/near the white growth area, but identity cannot be determined from the image.
- Water droplets are present on nearby leaves.
### Interpretation
- The yellow spots plus white downy growth are most consistent with a **mildew-type disease**, especially **downy mildew**, but confirmation requires checking both leaf surfaces and lesion structure.
- The brown marginal tissue could be secondary necrosis associated with disease progression, physical injury, or unrelated damage.
---
## 3. Differential diagnosis
| Possible cause | Image evidence supporting it | Image evidence against / uncertainty |
|---|---|---|
| **Downy mildew** | Many yellow “oil-spot-like” chlorotic lesions; dense white downy growth associated with veins; visible moisture on foliage could be compatible with sporulation, though weather cannot be inferred. | Downy mildew typically shows yellow lesions on the upper surface with white sporulation on the underside; the photo does not clearly show both sides of the leaf, so surface relationship is uncertain. |
| **Powdery mildew** | White fungal growth is visible on the leaf surface; grape leaves can show chlorosis under mildew colonies. | The growth appears cottony/downy rather than fine powdery; the numerous bright yellow spots are more suggestive of downy mildew than typical powdery mildew. |
| **Non-disease injury or pest feeding, e.g., leafhopper/mites/chemical spotting with secondary saprophyte growth** | Multiple yellow spots could resemble stippling or phytotoxic spotting; small dark insect-like object/debris is visible; brown edge damage may be non-pathogenic. | The dense white fungal growth is not typical of simple feeding injury or chemical spotting. The pattern and fungal growth make a primary mildew disease more likely. |
---
## 4. Canopy pattern and likely progression
- **Visible distribution:** The issue is concentrated on **one foreground leaf**. Surrounding leaves in the frame appear mostly green, so this photo does **not** prove a widespread block-level outbreak.
- **Pattern on the affected leaf:** Yellow lesions are scattered over much of the blade, with heavier white fungal growth in the lower-central portion near veins.
- **Likely progression if mildew is active:** Additional lesions may appear on nearby leaves, and sporulation may increase on susceptible tissue. Necrotic areas may expand where tissue is already damaged.
- **Cannot be concluded from one photograph:**
- Whether the infection is isolated to one vine or present across the row/block.
- Whether clusters, shoots, or rachises are affected.
- Cultivar susceptibility, growth stage, recent weather, spray coverage, or treatment failure.
- Exact disease identity without examining both leaf surfaces and collecting samples.
---
## 5. Next 24-hour actions
1. **Prioritized scouting**
- Inspect the **same vine first**, then adjacent vines on both sides and across nearby rows.
- Check at least the **lower, interior, shaded canopy** and the **outer exposed canopy**, because mildew expression and sporulation can differ by zone.
- Look for additional yellow spots and white growth on:
- Young expanding leaves
- Mature leaves
- Leaf undersides and upper surfaces
- Shoot tips
- Petioles
- Tendrils
- Flower/fruit clusters and rachises, if present
2. **Mark and document**
- Flag or geotag the affected vine.
- Photograph both sides of affected leaves with close-ups of individual lesions.
- Record approximate number of symptomatic leaves per vine and whether symptoms are clustered or scattered.
3. **Limit spread during inspection**
- Avoid brushing wet foliage more than necessary.
- Scout clean-appearing areas before heavily symptomatic areas if moving through the block.
4. **Sample collection**
- Collect several symptomatic leaves showing:
- Yellow spots without white growth
- White fungal growth
- Brown necrotic margins
- Include a few apparently healthy leaves from the same vine for comparison.
- Place samples in a paper bag or breathable container; keep cool and deliver promptly for diagnosis.
---
## 6. Confirmation checklist before treatment decision
- Confirm **which leaf surface** has white sporulation.
- Examine lesions with a hand lens:
- Downy mildew: downy growth often associated with underside of yellow lesions.
- Powdery mildew: superficial powdery colonies often on either surface.
- Check whether yellow spots on one side align with fungal growth on the opposite side.
- Inspect clusters and rachises for any visible mildew growth or discoloration.
- Determine field distribution:
- Single vine?
- Row-end pattern?
- Low/interior canopy concentration?
- Scattered across block?
- Submit sample to a diagnostic lab or qualified plant pathologist if treatment implications are significant.
- Review recent scouting maps and disease history, but do not rely on the photo alone for a control decision.
---
## 7. Management note
Use an **integrated pest-management approach**. Treat this as a **probable visual diagnosis, not a confirmed diagnosis**. Base any intervention on confirmed disease identity, vineyard-wide scouting results, disease pressure, susceptible tissue present, canopy density, and local viticulture guidance.
At the strategy level:
- Improve detection by scouting both leaf surfaces and all canopy zones.
- Reduce canopy conditions favorable to mildew where appropriate through canopy management and airflow improvement.
- Remove or flag heavily affected tissue only if consistent with vineyard practice and diagnostic needs.
- Use disease-specific management only after confirmation; do not select products or rates from the image alone.Finish reason:
stopimport { createClient } from '@runware/sdk'
const client = await createClient({ apiKey: process.env.RUNWARE_API_KEY })
await client.connect()
const [result] = await client.run({
model: 'openai:gpt@5.5',
settings: {
thinkingLevel: 'medium',
maxTokens: 4096
},
inputs: {
images: [
'https://assets.runware.ai/assets/inputs/6dbe7f29-4efb-4a82-8aa7-007135c49bd4.jpg'
]
},
messages: [
{
role: 'user',
content: 'Act as a commercial viticulture scout. Analyze the attached vineyard photograph and prepare a concise field-ready scouting report for the vineyard manager. Base every observation on information actually visible in the image; do not invent weather, location, cultivar, acreage, growth stage, treatment history, or symptoms outside the frame.\n\nStructure the report with these sections:\n1. Executive assessment: the most likely issue, confidence level, and urgency.\n2. Visible evidence: specific symptom morphology, color, distribution, leaf surfaces involved, approximate number of visibly affected versus apparently healthy leaves, and any secondary damage. Clearly separate direct observations from interpretation.\n3. Differential diagnosis: compare the three most plausible causes in a table, listing image evidence for and against each. Include both disease and non-disease possibilities where credible.\n4. Canopy pattern and likely progression: explain what the visible distribution suggests, while explicitly identifying what cannot be concluded from one photograph.\n5. Next 24-hour actions: prioritized scouting, isolation, documentation, and sample-collection steps. Specify which additional plant parts and canopy zones should be inspected.\n6. Confirmation checklist: practical field or laboratory checks needed before making a treatment decision.\n7. Management note: give integrated pest-management guidance at the strategy level only. Do not prescribe pesticide products, rates, or legal compliance claims from the image alone.\n\nUse plain professional language, quantify only where the photograph supports it, flag uncertainty, and distinguish a probable visual diagnosis from a confirmed diagnosis.'
}
]
})import asyncio
import os
from runware import Runware
async def main():
async with Runware(api_key=os.environ["RUNWARE_API_KEY"]) as client:
results = await client.run({
"model": "openai:gpt@5.5",
"settings": {
"thinkingLevel": "medium",
"maxTokens": 4096
},
"inputs": {
"images": [
"https://assets.runware.ai/assets/inputs/6dbe7f29-4efb-4a82-8aa7-007135c49bd4.jpg"
]
},
"messages": [
{
"role": "user",
"content": "Act as a commercial viticulture scout. Analyze the attached vineyard photograph and prepare a concise field-ready scouting report for the vineyard manager. Base every observation on information actually visible in the image; do not invent weather, location, cultivar, acreage, growth stage, treatment history, or symptoms outside the frame.\n\nStructure the report with these sections:\n1. Executive assessment: the most likely issue, confidence level, and urgency.\n2. Visible evidence: specific symptom morphology, color, distribution, leaf surfaces involved, approximate number of visibly affected versus apparently healthy leaves, and any secondary damage. Clearly separate direct observations from interpretation.\n3. Differential diagnosis: compare the three most plausible causes in a table, listing image evidence for and against each. Include both disease and non-disease possibilities where credible.\n4. Canopy pattern and likely progression: explain what the visible distribution suggests, while explicitly identifying what cannot be concluded from one photograph.\n5. Next 24-hour actions: prioritized scouting, isolation, documentation, and sample-collection steps. Specify which additional plant parts and canopy zones should be inspected.\n6. Confirmation checklist: practical field or laboratory checks needed before making a treatment decision.\n7. Management note: give integrated pest-management guidance at the strategy level only. Do not prescribe pesticide products, rates, or legal compliance claims from the image alone.\n\nUse plain professional language, quantify only where the photograph supports it, flag uncertainty, and distinguish a probable visual diagnosis from a confirmed diagnosis."
}
]
})
asyncio.run(main())curl https://api.runware.ai/v1 \
-H "Authorization: Bearer $RUNWARE_API_KEY" \
-H "Content-Type: application/json" \
-d '[
{
"taskType": "textInference",
"taskUUID": "8e4574a8-46ef-4893-8eaa-767ee4e49bdb",
"model": "openai:gpt@5.5",
"settings": {
"thinkingLevel": "medium",
"maxTokens": 4096
},
"inputs": {
"images": [
"https://assets.runware.ai/assets/inputs/6dbe7f29-4efb-4a82-8aa7-007135c49bd4.jpg"
]
},
"messages": [
{
"role": "user",
"content": "Act as a commercial viticulture scout. Analyze the attached vineyard photograph and prepare a concise field-ready scouting report for the vineyard manager. Base every observation on information actually visible in the image; do not invent weather, location, cultivar, acreage, growth stage, treatment history, or symptoms outside the frame.\n\nStructure the report with these sections:\n1. Executive assessment: the most likely issue, confidence level, and urgency.\n2. Visible evidence: specific symptom morphology, color, distribution, leaf surfaces involved, approximate number of visibly affected versus apparently healthy leaves, and any secondary damage. Clearly separate direct observations from interpretation.\n3. Differential diagnosis: compare the three most plausible causes in a table, listing image evidence for and against each. Include both disease and non-disease possibilities where credible.\n4. Canopy pattern and likely progression: explain what the visible distribution suggests, while explicitly identifying what cannot be concluded from one photograph.\n5. Next 24-hour actions: prioritized scouting, isolation, documentation, and sample-collection steps. Specify which additional plant parts and canopy zones should be inspected.\n6. Confirmation checklist: practical field or laboratory checks needed before making a treatment decision.\n7. Management note: give integrated pest-management guidance at the strategy level only. Do not prescribe pesticide products, rates, or legal compliance claims from the image alone.\n\nUse plain professional language, quantify only where the photograph supports it, flag uncertainty, and distinguish a probable visual diagnosis from a confirmed diagnosis."
}
]
}
]'runware run openai:gpt@5.5 \
settings.thinkingLevel=medium \
settings.maxTokens=4096 \
inputs.images.0=https://assets.runware.ai/assets/inputs/6dbe7f29-4efb-4a82-8aa7-007135c49bd4.jpg \
messages.0.role=user \
messages.0.content="Act as a commercial viticulture scout. Analyze the attached vineyard photograph and prepare a concise field-ready scouting report for the vineyard manager. Base every observation on information actually visible in the image; do not invent weather, location, cultivar, acreage, growth stage, treatment history, or symptoms outside the frame.
Structure the report with these sections:
1. Executive assessment: the most likely issue, confidence level, and urgency.
2. Visible evidence: specific symptom morphology, color, distribution, leaf surfaces involved, approximate number of visibly affected versus apparently healthy leaves, and any secondary damage. Clearly separate direct observations from interpretation.
3. Differential diagnosis: compare the three most plausible causes in a table, listing image evidence for and against each. Include both disease and non-disease possibilities where credible.
4. Canopy pattern and likely progression: explain what the visible distribution suggests, while explicitly identifying what cannot be concluded from one photograph.
5. Next 24-hour actions: prioritized scouting, isolation, documentation, and sample-collection steps. Specify which additional plant parts and canopy zones should be inspected.
6. Confirmation checklist: practical field or laboratory checks needed before making a treatment decision.
7. Management note: give integrated pest-management guidance at the strategy level only. Do not prescribe pesticide products, rates, or legal compliance claims from the image alone.
Use plain professional language, quantify only where the photograph supports it, flag uncertainty, and distinguish a probable visual diagnosis from a confirmed diagnosis."{
"taskType": "textInference",
"taskUUID": "8e4574a8-46ef-4893-8eaa-767ee4e49bdb",
"model": "openai:gpt@5.5",
"settings": {
"thinkingLevel": "medium",
"maxTokens": 4096
},
"inputs": {
"images": [
"https://assets.runware.ai/assets/inputs/6dbe7f29-4efb-4a82-8aa7-007135c49bd4.jpg"
]
},
"messages": [
{
"role": "user",
"content": "Act as a commercial viticulture scout. Analyze the attached vineyard photograph and prepare a concise field-ready scouting report for the vineyard manager. Base every observation on information actually visible in the image; do not invent weather, location, cultivar, acreage, growth stage, treatment history, or symptoms outside the frame.\n\nStructure the report with these sections:\n1. Executive assessment: the most likely issue, confidence level, and urgency.\n2. Visible evidence: specific symptom morphology, color, distribution, leaf surfaces involved, approximate number of visibly affected versus apparently healthy leaves, and any secondary damage. Clearly separate direct observations from interpretation.\n3. Differential diagnosis: compare the three most plausible causes in a table, listing image evidence for and against each. Include both disease and non-disease possibilities where credible.\n4. Canopy pattern and likely progression: explain what the visible distribution suggests, while explicitly identifying what cannot be concluded from one photograph.\n5. Next 24-hour actions: prioritized scouting, isolation, documentation, and sample-collection steps. Specify which additional plant parts and canopy zones should be inspected.\n6. Confirmation checklist: practical field or laboratory checks needed before making a treatment decision.\n7. Management note: give integrated pest-management guidance at the strategy level only. Do not prescribe pesticide products, rates, or legal compliance claims from the image alone.\n\nUse plain professional language, quantify only where the photograph supports it, flag uncertainty, and distinguish a probable visual diagnosis from a confirmed diagnosis."
}
]
}Response
{
"taskType": "textInference",
"taskUUID": "8e4574a8-46ef-4893-8eaa-767ee4e49bdb",
"text": "## 1. Executive assessment\n\n**Most likely issue:** Probable grapevine mildew disease, most consistent visually with **downy mildew-type infection**, but **not confirmed** from one photograph. \n**Confidence:** **Moderate** — the combination of yellow leaf spots and white fungal growth is strongly suggestive, but the photo does not clearly prove which leaf surface is shown or show both sides of the same lesion. \n**Urgency:** **High for scouting within 24 hours** because visible sporulation and multiple chlorotic spots suggest an active foliar issue that could spread if conditions are favorable.\n\n---\n\n## 2. Visible evidence\n\n### Direct observations from the image\n- **Affected leaf count:** \n - **1 prominently affected grape leaf** in the center foreground. \n - Approximately **4–6 surrounding leaves appear mostly green and comparatively healthy** in the visible frame, though some have minor edge blemishes or are partially obscured.\n- **Symptom morphology on the main leaf:** \n - Numerous **round to irregular yellow chlorotic spots**, mostly scattered across the blade. \n - Spots vary in size from small pinpoints to larger rounded patches. \n - A larger yellow area is visible near the lower-central portion of the leaf.\n- **Fungal growth:** \n - A dense **white, cottony to downy fungal-looking growth** is visible on the lower-central portion of the same leaf, concentrated around veins and extending across several lobes.\n- **Color:** \n - Yellow chlorosis on green tissue. \n - White superficial growth. \n - Brown necrotic/dried areas along parts of the lower leaf margin and near a damaged lobe.\n- **Leaf surfaces involved:** \n - Only the visible surface can be assessed from the photo. The opposite surface is not shown clearly.\n- **Secondary damage:** \n - Brown necrotic edge lesions and small damaged areas near the leaf margin. \n - A small dark insect-like object or debris is visible on/near the white growth area, but identity cannot be determined from the image. \n - Water droplets are present on nearby leaves.\n\n### Interpretation\n- The yellow spots plus white downy growth are most consistent with a **mildew-type disease**, especially **downy mildew**, but confirmation requires checking both leaf surfaces and lesion structure.\n- The brown marginal tissue could be secondary necrosis associated with disease progression, physical injury, or unrelated damage.\n\n---\n\n## 3. Differential diagnosis\n\n| Possible cause | Image evidence supporting it | Image evidence against / uncertainty |\n|---|---|---|\n| **Downy mildew** | Many yellow “oil-spot-like” chlorotic lesions; dense white downy growth associated with veins; visible moisture on foliage could be compatible with sporulation, though weather cannot be inferred. | Downy mildew typically shows yellow lesions on the upper surface with white sporulation on the underside; the photo does not clearly show both sides of the leaf, so surface relationship is uncertain. |\n| **Powdery mildew** | White fungal growth is visible on the leaf surface; grape leaves can show chlorosis under mildew colonies. | The growth appears cottony/downy rather than fine powdery; the numerous bright yellow spots are more suggestive of downy mildew than typical powdery mildew. |\n| **Non-disease injury or pest feeding, e.g., leafhopper/mites/chemical spotting with secondary saprophyte growth** | Multiple yellow spots could resemble stippling or phytotoxic spotting; small dark insect-like object/debris is visible; brown edge damage may be non-pathogenic. | The dense white fungal growth is not typical of simple feeding injury or chemical spotting. The pattern and fungal growth make a primary mildew disease more likely. |\n\n---\n\n## 4. Canopy pattern and likely progression\n\n- **Visible distribution:** The issue is concentrated on **one foreground leaf**. Surrounding leaves in the frame appear mostly green, so this photo does **not** prove a widespread block-level outbreak.\n- **Pattern on the affected leaf:** Yellow lesions are scattered over much of the blade, with heavier white fungal growth in the lower-central portion near veins.\n- **Likely progression if mildew is active:** Additional lesions may appear on nearby leaves, and sporulation may increase on susceptible tissue. Necrotic areas may expand where tissue is already damaged.\n- **Cannot be concluded from one photograph:** \n - Whether the infection is isolated to one vine or present across the row/block. \n - Whether clusters, shoots, or rachises are affected. \n - Cultivar susceptibility, growth stage, recent weather, spray coverage, or treatment failure. \n - Exact disease identity without examining both leaf surfaces and collecting samples.\n\n---\n\n## 5. Next 24-hour actions\n\n1. **Prioritized scouting**\n - Inspect the **same vine first**, then adjacent vines on both sides and across nearby rows.\n - Check at least the **lower, interior, shaded canopy** and the **outer exposed canopy**, because mildew expression and sporulation can differ by zone.\n - Look for additional yellow spots and white growth on:\n - Young expanding leaves\n - Mature leaves\n - Leaf undersides and upper surfaces\n - Shoot tips\n - Petioles\n - Tendrils\n - Flower/fruit clusters and rachises, if present\n\n2. **Mark and document**\n - Flag or geotag the affected vine.\n - Photograph both sides of affected leaves with close-ups of individual lesions.\n - Record approximate number of symptomatic leaves per vine and whether symptoms are clustered or scattered.\n\n3. **Limit spread during inspection**\n - Avoid brushing wet foliage more than necessary.\n - Scout clean-appearing areas before heavily symptomatic areas if moving through the block.\n\n4. **Sample collection**\n - Collect several symptomatic leaves showing:\n - Yellow spots without white growth\n - White fungal growth\n - Brown necrotic margins\n - Include a few apparently healthy leaves from the same vine for comparison.\n - Place samples in a paper bag or breathable container; keep cool and deliver promptly for diagnosis.\n\n---\n\n## 6. Confirmation checklist before treatment decision\n\n- Confirm **which leaf surface** has white sporulation.\n- Examine lesions with a hand lens:\n - Downy mildew: downy growth often associated with underside of yellow lesions.\n - Powdery mildew: superficial powdery colonies often on either surface.\n- Check whether yellow spots on one side align with fungal growth on the opposite side.\n- Inspect clusters and rachises for any visible mildew growth or discoloration.\n- Determine field distribution:\n - Single vine?\n - Row-end pattern?\n - Low/interior canopy concentration?\n - Scattered across block?\n- Submit sample to a diagnostic lab or qualified plant pathologist if treatment implications are significant.\n- Review recent scouting maps and disease history, but do not rely on the photo alone for a control decision.\n\n---\n\n## 7. Management note\n\nUse an **integrated pest-management approach**. Treat this as a **probable visual diagnosis, not a confirmed diagnosis**. Base any intervention on confirmed disease identity, vineyard-wide scouting results, disease pressure, susceptible tissue present, canopy density, and local viticulture guidance.\n\nAt the strategy level:\n- Improve detection by scouting both leaf surfaces and all canopy zones.\n- Reduce canopy conditions favorable to mildew where appropriate through canopy management and airflow improvement.\n- Remove or flag heavily affected tissue only if consistent with vineyard practice and diagnostic needs.\n- Use disease-specific management only after confirmation; do not select products or rates from the image alone.",
"cost": 0.06992,
"finishReason": "stop",
"reasoningContent": [
"**Analyzing leaf conditions**\n\nI see that in the first image, one leaf shows signs of chlorosis and a white growth, likely due to lesions and possible sporulation on the underside. It's probably not powdery mildew, as it doesn’t match the descriptions. I need to consider factors like Botrytis or non-disease issues like nutrient problems. I should craft a table that lists downy mildew and powdery mildew, along with any non-disease causes. Overall, it looks like one leaf is definitely affected while four to six nearby leaves appear healthier. I should also note a small dark insect or debris closely related to the lesions.",
"**Clarifying observations and treatment**\n\nI think I should include a confidence level and urgency in my assessment. My confidence is moderate to high regarding fungal mildew, especially downy mildew, but I need to confirm that before proceeding with any treatment. It’s crucial to differentiate between visible evidence and my interpretations. I'm planning to split Section 2 to emphasize these points more clearly. This way, everything will be organized and easy to follow for the user!"
]
}tool-calling
Location Shoot Weather Tool Handoff$0.00128~2s{
"taskType": "textInference",
"taskUUID": "8b2b5460-7317-4ff1-b61c-6fa06292d0d4",
"cost": 0.001275,
"finishReason": "tools",
"tools": [
{
"id": "call_wQr8l3hJpa7etMz0iWUxfby7",
"name": "get_weather",
"input": {
"location": "Jökulsárlón Glacier Lagoon, Iceland",
"unit": "celsius"
}
}
]
}Finish reason:
toolsimport { createClient } from '@runware/sdk'
const client = await createClient({ apiKey: process.env.RUNWARE_API_KEY })
await client.connect()
const [result] = await client.run({
model: 'openai:gpt@5.5',
settings: {
thinkingLevel: 'medium',
maxTokens: 4096
},
messages: [
{
role: 'user',
content: 'What is the current weather at Jökulsárlón Glacier Lagoon in Iceland? Please use Celsius so I can assess conditions for today’s exterior shoot.'
}
],
tools: [
{
type: 'function',
name: 'get_weather',
description: 'Retrieve current weather conditions for a requested location.',
schema: {
type: 'object'
}
}
],
toolChoice: {
type: 'tool',
name: 'get_weather'
}
})import asyncio
import os
from runware import Runware
async def main():
async with Runware(api_key=os.environ["RUNWARE_API_KEY"]) as client:
results = await client.run({
"model": "openai:gpt@5.5",
"settings": {
"thinkingLevel": "medium",
"maxTokens": 4096
},
"messages": [
{
"role": "user",
"content": "What is the current weather at Jökulsárlón Glacier Lagoon in Iceland? Please use Celsius so I can assess conditions for today’s exterior shoot."
}
],
"tools": [
{
"type": "function",
"name": "get_weather",
"description": "Retrieve current weather conditions for a requested location.",
"schema": {
"type": "object"
}
}
],
"toolChoice": {
"type": "tool",
"name": "get_weather"
}
})
asyncio.run(main())curl https://api.runware.ai/v1 \
-H "Authorization: Bearer $RUNWARE_API_KEY" \
-H "Content-Type: application/json" \
-d '[
{
"taskType": "textInference",
"taskUUID": "8b2b5460-7317-4ff1-b61c-6fa06292d0d4",
"model": "openai:gpt@5.5",
"settings": {
"thinkingLevel": "medium",
"maxTokens": 4096
},
"messages": [
{
"role": "user",
"content": "What is the current weather at Jökulsárlón Glacier Lagoon in Iceland? Please use Celsius so I can assess conditions for today’s exterior shoot."
}
],
"tools": [
{
"type": "function",
"name": "get_weather",
"description": "Retrieve current weather conditions for a requested location.",
"schema": {
"type": "object"
}
}
],
"toolChoice": {
"type": "tool",
"name": "get_weather"
}
}
]'runware run openai:gpt@5.5 \
settings.thinkingLevel=medium \
settings.maxTokens=4096 \
messages.0.role=user \
messages.0.content="What is the current weather at Jökulsárlón Glacier Lagoon in Iceland? Please use Celsius so I can assess conditions for today’s exterior shoot." \
tools.0.type=function \
tools.0.name=get_weather \
tools.0.description="Retrieve current weather conditions for a requested location." \
tools.0.schema.type=object \
toolChoice.type=tool \
toolChoice.name=get_weather{
"taskType": "textInference",
"taskUUID": "8b2b5460-7317-4ff1-b61c-6fa06292d0d4",
"model": "openai:gpt@5.5",
"settings": {
"thinkingLevel": "medium",
"maxTokens": 4096
},
"messages": [
{
"role": "user",
"content": "What is the current weather at Jökulsárlón Glacier Lagoon in Iceland? Please use Celsius so I can assess conditions for today’s exterior shoot."
}
],
"tools": [
{
"type": "function",
"name": "get_weather",
"description": "Retrieve current weather conditions for a requested location.",
"schema": {
"type": "object"
}
}
],
"toolChoice": {
"type": "tool",
"name": "get_weather"
}
}Response
{
"taskType": "textInference",
"taskUUID": "8b2b5460-7317-4ff1-b61c-6fa06292d0d4",
"cost": 0.001275,
"finishReason": "tools",
"tools": [
{
"id": "call_wQr8l3hJpa7etMz0iWUxfby7",
"name": "get_weather",
"input": {
"location": "Jökulsárlón Glacier Lagoon, Iceland",
"unit": "celsius"
}
}
]
}